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Abstract 
 
Motor proteins drive the movement of organelles and other types of cargo inside 
every eukaryotic cell type. These motors include myosins, kinesins and dyneins. 
Myosin-5a, a ubiquitous motor protein, has been intensively studied and its 
enzymatic properties and cellular functions have been described in great detail. This 
dimeric molecule walks processively along actin filaments, enabling it to transport a 
variety of cargos including mRNA, pigment granules, organelles such as the 
endoplasmic reticulum and endocytic vesicles. Cargos bind to the C-terminal 
globular tail domain of the molecule, while the N-terminal motor domain hydrolyses 
ATP to take regular steps on the actin filament. 
The structure and enzymatic properties of myosin-5 moving processively along actin 
under unloaded conditions have already been well characterised. However, while 
pulling a cargo through the viscoelastic cytoplasm, the molecule will experience 
variable forces. Therefore it is important to study how these forces alter the structure 
and kinetic behaviour of myosin-5. 
The purpose of this study was to design myosin-5 constructs that could be tethered, 
in a controlled manner, to actin via sequences introduced into the tail region of the 
molecule. The tethered motor protein is expected to ’stall’ while moving along the 
actin filament. In this way, the effects of strain on the myosin-5 structure and kinetics 
could then be investigated. This would simulate a case where inside the cell 
myosin-5 stalls due to strain, for example, whilst trying to move its cargo through 
spatially restricted areas of the actin cytoskeleton. 
To find a new way to attach the tail of myosin-5 to actin, small, artificial actin-binding 
proteins named Adhirons were raised with phage display assay and their properties 
were explored. They bind to actin with high affinity and they are also useful for 
staining actin in cells or for attaching actin to coverslips in various motility assays. 
Multiple myosin-5 constructs were explored, that had either an Avi-tag or an actin-
binding Adhiron at their C-terminal ends. A construct that contained the full predicted 
coiled-coil motif of myosin-5, could not be attached to the same actin filament via its 
tail as the motors were bound to. Two further constructs that have an artificial long 
coiled-coil tail, were cloned and expression trials are currently in progress.  
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1. Introduction 
1.1 Myosins 
Every eukaryotic cell utilises motor proteins in order to move and position their 
organelles and other types of cargo. Molecular motors, which include myosins, 
kinesins and dyneins, use the energy of ATP hydrolysis for cargo transport. 
In eukaryotes the cytoskeleton is comprised of the interconnected network of actin 
filaments and microtubules. Molecular motors in the cell use these filaments as 
tracks for transporting and anchoring cargos. Kinesins and dyneins move along 
microtubules, while myosins move along actin filaments, reviewed by (Hartman and 
Spudich, 2012). The superfamily of myosins consists of at least 35 classes and 
members of the superfamily participate in numerous cellular processes reviewed by 
(Odronitz and Kollmar, 2007; Bloemink and Geeves, 2011). 
Muscle myosin-2, responsible for muscle contraction, was the first myosin 
discovered in 1864 by Willy Kühne. The first non-muscle myosin was discovered in 
1973 (Pollard and Korn, 1973) and later on other non-muscle myosins were also 
found with various functions (Figure 1.1). Initially these other myosins were called 
unconventional in order to distinguish them from the muscle myosin that had been 
the sole myosin studied up to that point. Nowadays, these other myosins are the 
subject of many studies, so the term unconventional is rarely used. 
 
1.1.1 Basic structure of myosins 
Members of the myosin superfamily contain a conserved motor domain that includes 
the actin and ATP binding sites (Figure 1.2). This is typically followed by a lever that 
binds calmodulin or calmodulin-like light chains to its IQ motifs. IQ motifs are ~24 
residues long motifs usually starting with an isoleucine, invariably followed by a 
glutamine. In some myosins the lever also contains a stable single-alpha helical 
domain (SAH) which allows extension of the lever without the need for binding light 
chains (Yang et al., 2009; Knight et al., 2005; Spink et al., 2008). Rotation of this 
lever about a pivot point near the base of the motor domain is the major 
conformational change which underlies myosin based motility. The lever is followed 
by a tail that has widely varying functions across the myosin superfamily. These 
functions include oligomerisation, regulation of enzymatic activity, subcellular 
targeting and cargo binding. 
2 
 
 
Figure 1.1. Family tree of 12 classes of human myosin heavy chains, according to 
Uniprot. Labels such as MYO5A are the names of the human genes. Differential 
splicing of these genes produces more different myosins. The heavy chains can also 
bind various light chains that leads to even more diversity. Right panel legend 
describes additional bound molecules, domains and structural parts present in 
various human myosins. Figure is taken from (Peckham, 2011). 
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Figure 1.2. Crystal structure of the muscle myosin-2 head with bound light chains 
and without bound nucleotide (PDB ID: 2MYS (Rayment et al., 1993), the presented 
crystal structure, that contains coordinates of all atoms of the light chains, was 
received from Prof. Ivan Rayment). Nucleotide and actin binding sites are shown in 
the motor domain. Protein is shown as cartoon representation. 
 
Historically, fragments of muscle myosin-2 were prepared by treating the myosin 
sample with proteases. The full length myosin-2 molecule consists of a pair of heavy 
chains which are dimerised through a long coiled-coil tail. Cleavage of this full length 
protein by trypsin (Lowey and Cohen, 1962) or by α-chymotrypsin (Weeds and 
Taylor, 1975) yields an HMM (heavy meromyosin) and an LMM (light meromyosin) 
fragment (Figure 1.3). The HMM comprises the heads and the first part of the coiled-
coil. Further cleaving the HMM at the lever–coiled-coil junction by papain 
(Szent-Györgyi et al., 1973) or by α-chymotrypsin (Weeds and Taylor, 1975) yields 
the S1 and S2 subfragments: S1 is a monomeric subfragment that contains the head 
and retains ATPase activity, whereas S2 is a coiled-coil subfragment. For simplicity, 
the terms HMM and S1 have been retained for use when describing fragments of 
other myosins. The term HMM therefore describes a dimeric molecule which 
contains two motor domains, the subsequent levers and the coiled-coil dimerisation 
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region. The term S1 describes a molecule truncated prior to the coiled-coil that 
therefore remains monomeric. These terms can be used for proteolytic fragments of 
myosin or, as is more common today, for molecules produced via recombinant 
protein expression. 
 
 
Figure 1.3. Schematic representation of the muscle myosin-2 fragments prepared by 
proteolytic cleavage. 
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1.1.2 Actomyosin ATPase cycle 
The energy that drives myosin based motility is derived from the hydrolysis of ATP. 
Importantly, this ATPase activity is coupled to actin binding, as actin activates 
ATPase activity of myosin. This allows myosin to efficiently convert the chemical 
energy of ATPase hydrolysis into mechanical work when myosin is bound to actin. 
The specific enzymatic and mechanical properties of a given myosin are determined 
by the specific parameters of its ATPase cycle. A general scheme for this ATPase 
cycle is shown in Figure 1.4.  
The starting point of the cycle can be defined as myosin strongly bound to actin in 
the absence of ATP (Lymn and Taylor, 1971). ATP binding to actomyosin (step 1, 
Figure 1.4) induces a conformational change in the myosin motor domain. This 
results in weakened actin binding affinity of the myosin motor, thus detachment from 
actin (step 2, Figure 1.4). Whilst unbound from actin, hydrolysis of ATP to ADP and 
Pi takes place along with a conformational change that rotates the lever and is 
termed the recovery stroke (step 3, Figure 1.4). The ADP–Pi bound myosin motor 
rebinds to actin (step 4, Figure 1.4) and then Pi release takes place along with the 
force-generating powerstroke (step 5, Figure 1.4). ADP dissociates (step 6, 
Figure 1.4) and the cycle is thus complete. Force results from a conformational 
change within the head, containing four subdomains connected by three flexible 
linkers, which occurs when the Pi leaves the active site. Little relative movement of 
three subdomains causes the lever to make a large, concerted movement, which is 
associated with the powerstroke. 
As can be seen in Figure 1.4, the cycle consists of a number of states in which 
myosin is strongly bound to actin and a number of states in which the motor is 
detached. The fraction of time which myosin spends in the strong actin binding 
states with respect to the whole cycle is termed the duty ratio. Low duty ratio motors 
therefore spend a majority of the cycle detached from actin whilst high duty ratio 
motors spend a majority of the cycle attached to actin. Myosins where Pi release is 
rate limiting, tend to be low duty ratio motors whilst myosins where ADP release is 
rate limiting, tend to have a higher duty ratio (De La Cruz et al., 1999; El Mezgueldi 
et al., 2002).  
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Figure 1.4. Schematic representation of the actomyosin ATPase cycle showing 
strong and weak actin binding states of myosin. Figure is taken from (De La Cruz 
and Ostap, 2004). 
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1.1.3 Myosin superfamily 
Members of the myosin superfamily participate in a wide variety of cellular processes 
(Figure 1.1). Myosin-5, which is one of the most studied myosins (Nyitrai and 
Geeves, 2004; Sellers and Veigel, 2006; Trybus, 2008; Veigel and Schmidt, 2011), is 
involved in cargo transport, reviewed by (Hammer  3rd and Sellers, 2012). Besides 
myosin-5, members of myosin classes 1, 2, 6 and 7 are also involved in cargo 
transport in animal cells, reviewed by (Syamaladevi et al., 2012). In plants myosin-8 
and myosin-11 are responsible for long-range movement of organelles (Sparkes, 
2010). Myosin-19 transports mitochondria in human cells (Quintero et al., 2009), 
while myosin-11 transports them in plants (Wang and Pesacreta, 2004). 
One of the functions of non-muscle myosin-2 is to help to separate daughter cells 
during cytokinesis (Vicente-Manzanares et al., 2009). Myosin-6 participates in 
vesicular membrane trafficking (Arden et al., 2007), and myosin-10 stimulates 
filopodia formation (Sousa and Cheney, 2005). 
Many myosins localise to membrane extensions such as stereocilia in hair cells 
(Hasson et al., 1997; Belyantseva et al., 2003; Schneider et al., 2006) or microvilli in 
the intestines or in the kidney (Heintzelman et al., 1994; Benesh et al., 2010). Some 
myosins are associated with endosomes (Raposo et al., 1999; Hasson, 2003; Wang 
et al., 2008) or with phagosomes (Tuxworth et al., 2001; Cox et al., 2002). Most 
myosins are restricted to the cytoplasm, however some were found in the nucleus as 
well (Woolner and Bement, 2009). 
As myosins are responsible for a wealth of different cellular processes, mutations in 
the myosin genes can lead to various diseases. Some examples are myosin-2, 
myosin-5a and myosin-7a. Mutations in myosin-7a can lead to deafness (Kremer et 
al., 2006), mutant myosin-5a can cause defects in pigmentation and neuronal 
malfunction (Van Gele et al., 2009), and defects in cardiac myosin-2 are responsible 
for cardiomyopathies (Walsh et al., 2010). 
Non-muscle myosins interact with cargos through their C-terminal cargo binding 
domain. The tail region of different myosins is highly divergent, unlike their 
conserved motor domains, enabling them to interact with various cargos through 
association with adaptors and other binding proteins (Thompson and Langford, 
2002). However, some myosins bind directly to lipids instead of interacting with 
adaptor proteins (McConnell and Tyska, 2010). 
8 
 
1.2 Actin 
Actin is a 42 kDa globular protein (G-actin) with four subdomains (Figure 1.5A) that 
polymerises into filaments (F-actin) spontaneously under physiological salt 
conditions. The structure of the resulting filament (Figure 1.5B) can be viewed as 
either i) the right-handed double helix made up from strands of actin subunits that 
has a crossover length of 13 subunits, the rise per strand is 5.5 nm and the offset of 
subunits between the two helices is half a subunit. (Figure 1.5C left side) or as ii) the 
left-handed single helix with a pitch of 5.9 nm and a repeat period of 26 subunits and 
a 2.75 nm rise per subunit (Figure 1.5C right side). Since the actin filament is a 
polymer produced from asymmetric monomers, the actin filament is also polar. 
The filament is often defined as having a pointed end and a barbed end, like an 
arrowhead, due to the appearance of the filament when myosin heads are bound in 
the absence of nucleotide (Huxley, 1963; Pollard, 2016) (Figure 1.5D). 
Nucleotide (ATP or ADP) can bind in the cleft between subdomains II and IV. 
The β- and γ-phosphate of ATP (or solely the β-phosphate of ADP) bind either Ca2+ 
or Mg2+ stabilizing the interaction between the nucleotide and the protein (Kabsch et 
al., 1990). Mg2+ and monovalent cations promote polymerisation of actin monomers 
as they enhance interaction between the subunits in the filament (Kang et al., 2013).  
Upon polymerisation a conformational change takes place in subdomains I and III 
(Fujii et al., 2010), that increases the rate of ATP hydrolysis (Blanchoin and Pollard, 
2002). Actin polymerisation from monomers starts with a slow lag phase as the 
formation of dimers and trimers are very slow, however the subsequent elongation is 
faster and polymers are much more stable (Sept and McCammon, 2001). Although 
actin filaments can elongate at both ends, the critical concentration (which is defined 
as the concentration above which there is net polymerisation and below which there 
is net depolymerisation) is not the same at both ends of the filament. The end of the 
filament that polymerises more rapidly is known as the plus end (equivalent to the 
barbed end described above) and the opposite end is known as the minus end 
(equivalent to the pointed end described above).  
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Figure 1.5. Structures of actin. A) Crystal structure of G-actin complexed with ADP 
(PDB ID: 1J6Z (Otterbein et al., 2001)). Protein is shown as cartoon representation, 
secondary structure is colour coded (red: α-helix, yellow: β sheet, green: loop). ADP 
is denoted by sticks with atomic colouring. B) Cryo electron microscopy structure of 
F-actin (PDB ID: 3LUE (Galkin et al., 2010)). Protein is shown as both cartoon 
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representation with colour coded subunits and as surface representation with 
transparent grey colour. CH1 domain of α-actinin is bound to F-actin in the structure, 
however that is omitted for clarity. C) Schematic representation of F-actin shows 
subunits as spheres. Lines on the left side show double helix interpretation of 
F-actin. Sinusoidal curve on the right side shows single helix interpretation of F-actin. 
D) Negative stain electron microscope image of F-actin decorated in part with 
myosin heads that show pointed and barbed end of an arrowhead structure. Image is 
taken from (Pollard, 2016). 
 
Actin is essential in all eukaryotes. In muscle cells it makes up the thin filaments and 
along with muscle myosin-2, which makes up the thick filaments, is responsible for 
muscle contraction. In non-muscle cells actin has a wide range of functions as actin 
filaments are major component of the cytoskeleton and are responsible for 
maintaining cell structure and dynamics. During cytokinesis actin takes part in the 
contractile ring formation (Pelham and Chang, 2002). Actin dynamics in lamellipodia 
and filopodia plays a major role in cell migration. Actin is also found in focal 
adhesions and stress fibers that are involved in cell adhesion (Le Clainche and 
Carlier, 2008). Actin also provides track for cargo transport inside the cell. To carry 
out these various functions, a wide range of actin-binding proteins bind to the 
filaments. These protein often bind to the groove between actin subdomains I and III 
(Dominguez, 2004). 
Actin is one of the most conserved proteins in eukaryotes (Gunning et al., 2015). 
Prokaryotes also encode actin homologue proteins, called MreB, FtsA and ParM that 
are responsible for distinct cellular processes, reviewed by (Pollard, 2016). Most 
eukaryotes utilise distinct actin isoforms for distinct cellular processes: α-actin in 
muscle cells, β- and one type of γ-actin in nonmuscle cells and another type of 
γ-actin in smooth muscle cells (Herman, 1993).  
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1.3 Myosin-5 
1.3.1 Structure of myosin-5 
The myosin-5 molecule contains two heavy chains that form a dimer. The dimer 
takes several 36 nm steps, before falling off actin, which makes it a processive 
molecular motor. It consists of a head and a tail domain (Cheney et al., 1993). 
The N-terminal head comprises the motor domain which binds actin and hydrolyses 
ATP and the α-helical lever, which has 6 IQ motifs, binding 6 calmodulin-like light 
chain molecules. The tail domain contains coiled-coil forming sequences, which are 
required for dimerisation. This is followed by sequences that are predicted to form 
coiled-coil and are interrupted by two loops, a proximal and a distal loop. 
The C-terminal region of the molecule is the cargo binding domain or globular tail 
domain (GTD) (Figure 1.6, 1.7). Alternative splicing yields the two isoforms of 
myosin-5a, found in melanocytes and brain cells containing exons A, C, D, E, F and 
A, B, C, E, respectively (Seperack et al., 1995). All exons are located at the tail 
domain, importantly exons B and D are located at the distal loop and exon F is 
located downstream compared to them (Figure 1.8) (Seperack et al., 1995; X. Wu et 
al., 2002). 
Myosin-5a was first identified in mammalian brain tissue (Larson et al., 1988), then 
later on in yeast (Johnston et al., 1991) and also in mammalian melanocytes (Mercer 
et al., 1991). It was first purified from chicken brain tissue (Espreafico et al., 1992). 
Cheney et al. found that besides calmodulin two additional proteins co-purify with 
myosin-5a (Cheney et al., 1993), that were identified as L17 and L23 myosin-2 
essential light chains, that are 17 and 23 kDa, respectively (Espindola et al., 2000). 
However these light chains were not found in myosin-5a purified from mouse brain 
(Wang, Chen, et al., 2000). A further 10 kDa light chain was found to bind both 
chicken and mouse brain myosin-5a (Espindola et al., 2000; Wang, Chen, et al., 
2000). This light chain was identified to be the same that binds to cytoplasmic and 
axonemal dynein (King et al., 1996), thus its name, DLC8 dynein light chain, was 
retained. Exon B that is located on the distal loop in the tail domain of brain isoform 
myosin-5a was found to be responsible for dynein light chain binding and thus this 
molecules only binds to the brain isoform (Hodi et al., 2006; Wagner et al., 2006). 
Myosin-5a was imaged with rotary shadowing electron microscopy, in which two 
heads, a tail and cargo binding domains were clearly visible (Figure 1.6) (Cheney et 
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al., 1993). The head is approximately 31 nm in size that consists of the motor 
domain (~10 nm) and of the lever with 6 IQ motifs (~21 nm) (Cheney et al., 1993). 
The size of the motor domain corresponds to that observed for muscle myosin-2 
(~9 nm) using crystallography (Figure 1.2) (Rayment et al., 1993). A myosin-5 
construct, which comprises only the motor domain and the lever with 6 IQ motifs is 
usually considered an S1 fragment. That is followed by a coiled-coil that is ~30 nm in 
chicken myosin-5a (Cheney et al., 1993). However in mouse myosin-5a the coiled-
coil is ~26 nm as it is made up from 175 residues (Baboolal et al., 2009). The first 
part of the coiled-coil is followed by the proximal loop that contains a PEST site, 
which is rich in proline, glutamic acid, serine and threonine and is prone to cleavage 
by proteases. The HMM construct of myosin-5 comprises the head and the tail up to 
this point. The proximal loop is followed by another predicted coiled-coil segment 
that is ~13 nm in both chicken (Cheney et al., 1993) and mouse myosin-5a. This is 
followed by the distal loop, which encodes exon B that is 3 amino acids long (DDK) 
(Hodi et al., 2006; Wagner et al., 2006). The final, predicted coiled-coil segment just 
preceding the globular tail domain is ~13 nm in chicken (Cheney et al., 1993) and 
~15 nm in mouse myosin-5a considering that it is ~100 residue-long and the length 
of a coiled-coil was measured to be 0.15 nm rise per amino acid (Chothia et al., 
1981). C-terminal of the protein is the globular tail domain that is responsible for 
cargo binding. 
Myosin-5a was first imaged bound to actin by negative stain electron microscopy 
(Figure 1.7A) (Walker et al., 2000). The two heads of the molecule were usually 
bound 13 actin subunits apart, that is 36 nm distance. However some molecules 
were bound 11 or 15 actin subunits apart (30 and 41 nm, respectively), suggesting 
that flexibility in the myosin heads enables it to vary the angle and distance it is 
attached to actin. The lead head was found to be curved, whereas the trail head is 
straighter. The short tail of the HMM construct that was used in this study was 
usually found to be angled in the direction of the trail head (arrow on Figure 1.7A). 
The trailing lever was found to be angled at 40º to the filament, whereas the leading 
lever angled at the average of 115º (values ranging from 90º to 150º) to the filament, 
resembling post- and pre-powerstroke conformations, respectively (Walker et al., 
2000). 
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Figure 1.6. Electron micrograph and schematic figure of myosin-5. Panel A) shows 
shadowing electron micrograph of myosin-5 with heads and tail domains. Scale bar 
is 50 nm. Panel B) shows schematic representation of myosin-5 observed in panel A. 
Calmodulins bound to the lever of myosin are represented black. Adapted from 
(Cheney et al., 1993). 
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Figure 1.7. Electron micrograph and schematic figure of myosin-5a bound to actin. 
Panel A) shows negative stain electron micrograph of myosin-5a bound to F-actin. 
Arrow points to the coiled-coil tail. Scale bar is 50 nm. Figure is taken from (Walker 
et al., 2000). Panel B) shows schematic representation of myosin-5a carrying cargo 
on an actin track. GTD stands for globular tail domain. The two myosin heads bind to 
actin 36 nm apart from each other spanning the helical pitch of the actin filament. 
There are 6 light chains bound to the 6 IQ motifs of the lever. The coiled-coil tail of 
myosin-5 is interrupted by loops. Adapted from a figure by Dr. James Sellers. 
 
 
Figure 1.8. Schematic figure of the two isoforms of myosin-5a. Exon B, D and F are 
denoted with blue, green and red colouring, respectively. Adapted from (X. Wu et al., 
2002). 
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1.3.2 Myosin-5a motor activity 
Myosin-5a undergoes multiple enzymatic cycles without the molecule detaching from 
actin, which allows the processive movement of myosin along the actin track 
(Sakamoto et al., 2008; Nelson et al., 2009; Andrecka et al., 2015). This is required 
for the in-vivo function of myosin-5a, which is transporting various cargos, reviewed 
by (Hammer  3rd and Sellers, 2012). 
Myosin-5 moves in a hand-over-hand fashion, where the two heads alternate 
position in every step (Walker et al., 2000; Yildiz et al., 2003; Warshaw et al., 2005; 
Sakamoto et al., 2008; Andrecka et al., 2015). Starting from the waiting state in the 
enzymatic cycle (A in Figure 1.9), myosin is attached to actin with bound ADP in both 
heads (Sakamoto et al., 2008). The intramolecular strain exerted on the trail head by 
the lead head accelerates the release of ADP from the trail head by two fold and 
inversely, the intramolecular strain exerted on the lead head by the trail head slows 
ADP release on the lead head by 50 fold (Rosenfeld and Sweeney, 2004; Veigel et 
al., 2005). This is then quickly followed by the binding of ATP and detachment of the 
trail head (B in Figure 1.9). The bound head then undergoes the powerstroke and 
the free head hydrolyses ATP (C in Figure 1.9). The free head then rebinds to actin 
(D in Figure 1.9) to become the new leading head and it releases Pi (E in Figure 1.9). 
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Figure 1.9. Enzymatic cycle of myosin-5 processive motion. A) Waiting state, where 
both heads of myosin-5 is bound to actin and contain ADP. ADP dissociates from the 
trail head with a rate constant of 12 s-1. B) ATP binds to the trail head with a rate 
constant of 0.9 µM-1 s-1. C) The trail head lets go of actin, hydrolyses ATP and the 
lead head undergoes the powerstroke. The red arrow shows the displacement of the 
trail head and lever. D) The trail head binds to actin becoming the new lead head. 
E) Pi dissociates from the new lead head. Figure is taken from (Vale, 2003). 
 
Electron microscopy and X-ray crystallography revealed the two conformations of the 
lever being 60° apart from each other representing the two ends of the powerstroke 
(Walker et al., 2000; Coureux et al., 2003; Coureux et al., 2004). Burgess et al. 
compared the observed electron micrographs of the lead and trail heads with crystal 
structures of scallop myosin-2 docked onto actin (Figure 1.10). They demonstrated 
that the lead and the trail heads have their converter domains and thus their lever in 
different positions. The detached head undergoes the recovery stroke before binding 
again to actin (Burgess et al., 2002). 
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Figure 1.10. The lead and the trail heads have their lever in different positions. 
Figure is taken from (Burgess et al., 2002) A) Superimposition of average lead and 
trail heads of myosin-5 considering that the molecule moves towards the pointed end 
(left) of the actin filament. B-C) Superimposition of apo and ADP.VO4 containing 
scallop myosin-2 crystal structures docked onto the atomic model of the actin 
filament (Lorenz et al., 1993). B) Image has been filtered to 2 nm resolution. C) Actin 
filament is grey, myosin-2 heavy chain is blue, motor domains are light blue, green, 
magenta, converter region is black, light chains are yellow. 
 
A single molecule fluorescence study demonstrated the tight coupling between the 
ATPase cycle and the stepping motion of myosin-5 (Sakamoto et al., 2008). 
Sakamoto et al. used a fluorescent analogue of ATP (deac-aminoATP) and 
fluorescently labelled calmodulins bound to the lever of myosin-5. They 
simultaneously followed the two fluorescent signals and found that they move in the 
same direction with the same speed, however, myosin-5 was moving in 36 nm steps, 
whereas the nucleotide signal was moving in 18 nm steps. One step of the 
nucleotide signal happened together with the myosin-5 signal and the other step in 
the dwell time of myosin-5. Figure 1.11 shows the model built from the observations. 
In step 1, where both heads contain deac-aminoADP, the fluorescent nucleotide 
signal coincides with the myosin-5 signal. Then the trail head releases ADP (step 2), 
so the signal moves 18 nm, as it is now only coming from the lead head 
deac-aminoADP. In step 3 the trail head binds deac-aminoATP and dissociates from 
actin, the powerstroke happens in the leading head and the trail head becomes the 
lead head. Even though the ATP binding is partially rate limiting in this experiment as 
they used low concentrations of ATP, still the binding of nucleotide and the 
concomitant powerstroke is more rapid than the sampling rate in the experiments, 
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therefore no backwards stepping of the nucleotide signal was observed. Thus, in 
step 4 both the myosin-5 and the nucleotide signal move and coincide again. 
This study showed that the gating between the two heads is very strong, as the 
fluorescence signal coming from the nucleotide does not take a backward step, 
meaning that no nucleotide is released from the lead head as long as the trail head 
is attached. 
 
 
Figure 1.11. ATPase mechanism and stepping motion of myosin-5. Step 1: Both 
myosin heads contain ADP, therefore the fluorescent signal coming from the myosin 
(red arrow) and nucleotides (blue arrow) coincide. Step 2: ADP dissociates from the 
trail head, thus the nucleotide signal moves 18 nm forward. Step 3: ATP binds to the 
trail head, which lets go of actin. This step is faster than the sampling rate of the 
experiment, therefore no movement of the signals is observed. Step 4: The trail head 
becomes the new lead head with bound ADP, so the myosin signal moved 36 nm, 
while the nucleotide signal 18 nm, and they coincide again. Figure is taken from 
(Sakamoto et al., 2008). 
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Veigel et al. found that the working stroke of both single-headed recombinant 
myosin-5 and dimeric myosin-5 are 21–25 nm, however the stepping of the dimeric 
myosin-5 was found to be 36 nm, which is 13 actin subunits apart from the previous 
binding site (Veigel et al., 2002). They proposed that a forward-biased thermally 
driven diffusive movement adds the remaining 11 nm movement. According to the 
model, after the working stroke happens the new lead head has to go under a 
movement of 11 nm to bind preferentially 36 nm away from the trail head. In this 
conformation both heads can bind to actin with little or no twist compared to the actin 
filament axis. However, the heads can rotate at the head-tail junction to enable 
attachment to actin, thus attachment of 11 and 15 subunits apart was also found in 
the 13% and 10% of the observed molecules, respectively (Oke et al., 2010). Since 
the actin subunits in the filament have a helical path with crossover points every 
36 nm (Figure 1.5C), this size of stepping, which is determined by the length of the 
lever and the angle through which it moves, enables myosin to linearly transport 
cargo along the actin filaments. It also facilitates myosin-5 to walk along bundles of 
actin, where following a helical track would not be possible. 
Processive runs can be established via strain-dependent kinetic gating. Being a high 
duty ratio motor, a single-headed myosin-5 spends approximately 70% of its ATPase 
enzymatic cycle bound to actin at low actin and ADP concentrations (De La Cruz et 
al., 1999). The strain exerted on the lead head by the trail head dramatically slows 
the rate of ADP release from the lead head (Rosenfeld and Sweeney, 2004; Veigel 
et al., 2005; Sakamoto et al., 2008). This interhead strain facilitates that the trail 
head detaches before the lead head, and then it quickly rebinds to become the new 
leading head, however the two heads work independently in the absence of actin 
(Forgacs et al., 2008). This mechanism can ensure that myosin-5 does not detach 
from actin before transporting the vesicle to its target place (Forgacs et al., 2008). 
The kinetics of myosin-5 is also regulated by the external load, so that pulling and 
pushing forces increase and reduce the average lifetime of myosin-5 bound to actin, 
respectively (Veigel et al., 2005) and pulling forces can reduce the rate of the 
diffusive search of the new leading head (Clemen et al., 2005). A range of pulling 
forces does not affect the length of the step (Veigel et al., 2005). However, mutant 
molecules containing 4 or 8 IQ motifs in the lever, thus being 2 IQ shorter or longer 
than the wild type, walk in shorter or longer steps, respectively, leading to a helical 
path (Sakamoto et al., 2003; Sakamoto et al., 2005; Oke et al., 2010). 
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The IQ motifs present in the lever of myosin-5 can be substituted by single alpha 
helical (SAH) domains, and this structural motif can also act as a lever in myosin-6 
and myosin-10. Baboolal et al found that the SAH domain containing myosin-5 
chimera takes similar processive steps along actin as the wild-type, however no 
gating was found for the ADP release from the lead head. This observation 
questions if kinetic gating is required for the processivity of myosin-5 (Baboolal et al., 
2009). 
 
1.3.3 Myosin-5 tail and the organelle transport 
In higher eukaryotic cells, organelles are usually being transported from the centre of 
the cell to the periphery by kinesins, while dyneins participate in retrograde transport 
directed towards the cell centre. Kinesins walk along microtubules from the minus 
end at the centrosome towards the plus end. When reaching the periphery of the 
cell, the cargo is switched to actin-based transport (Woolner and Bement, 2009). 
Myosin-5 is then involved in the local movement of the cargo. 
Myosin-5 moves mRNA, pigment granules, neuronal vesicles, endoplasmic reticulum 
and other vesicles in the cells. Myosin-5a moves melanosomes in melanocytes and 
endoplasmic reticulum in Purkinje neurons, while myosin-5b carries endosomes in 
hippocampal neurons, reviewed by (Hammer  3rd and Sellers, 2012). Myo4 that is a 
myosin-5 homologue in budding yeast Saccharomyces cerevisiae moves mRNA into 
the bud tips (Shepard et al., 2003). 
Mouse myosin-5a was found to transport melanosomes at 0.14 µm/sec speed in 
melanocytes (Wu et al., 1998) and to transport endoplasmic reticulum at 
0.45 µm/sec speed in Purkinje neurons (Wagner et al., 2011). Since in vitro the 
number of the observed processive steps is between 20 and 60 (Veigel et al., 2002; 
Baker et al., 2004), myosin should transport its cargo over micrometre distances. 
It is also capable of switching between actin tracks to transport the cargo for long 
distances (Ali et al., 2007; Bao et al., 2013). It is currently not known how many 
myosins attach to one cargo to enable its transport inside the cell, however it has 
been estimated that more than 100 myosin-5 molecules are attached to a vesicle of 
a radius of 100 nm (Miller and Sheetz, 2000). 
The C-terminal GTD is responsible for binding the cargo, however the cargo may 
also bind to the loops interrupting the coiled-coil domain (X.S. Wu et al., 2002). 
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Adaptor proteins are also involved in this process, which makes myosin-5 capable of 
binding different cargos and also different isoforms of myosin-5 bind different cargos. 
Exon F located at the tail domain of melanocyte isoform myosin-5 was found to be 
indispensable for myosin-5 localisation to melanosomes, as a mutant protein lacking 
this exon or the brain isoform of myosin-5 did not co-localise with melanosomes 
(X. Wu et al., 2002). Dynein light chain bound to exon B, present in the brain isoform 
of myosin-5 tail domain, is thought to be involved in cargo binding (Naisbitt et al., 
2000; Navarro et al., 2004). When there is no cargo present, the globular tail domain 
tends to bind the motor domains and the molecule folds into a triangular 
conformation (Thirumurugan et al., 2006; Liu et al., 2006). In this conformation 
ATPase activity is inhibited, but increased level of Ca2+ can reactivate the molecule 
in vitro (Krementsov et al., 2004; Wang et al., 2004). However, the physiological 
activator of myosin-5 is presumably binding of an adaptor protein like melanophilin 
(Wu et al., 2006; Li et al., 2005; Sckolnick et al., 2013), since increased Ca2+ level 
would make calmodulins dissociate from the lever inhibiting myosin-5 stepping 
(Nguyen and Higuchi, 2005; Wu et al., 2006; Shen et al., 2016). 
 
1.3.4 Properties enabling myosin-5 to transport cargo 
To be able to transport cargo inside the cell, the physical properties of myosin-5 
have to overcome the following issues. i) The size of the cargo transported along the 
actin filaments is ranging from 50 nm to 1 µm (Tabb et al., 1998), and therefore it 
might get stuck in the meshwork of cytoskeletal filaments and membranes within the 
cell. ii) The cytosol exhibits time-dependent deformation when stress is applied, as it 
is a viscoelastic medium (Canetta et al., 2005; Luby-Phelps, 2013; Goychuk et al., 
2014), meaning that it has the properties of both viscous and elastic materials. 
The viscosity of the cell is in the range of 102 Pa.sec (Bausch et al., 1999), which is 
approximately five orders of magnitude higher than the viscosity of water. Moving of 
a relatively large cargo in a viscous medium would generate drag force on the 
myosin-cargo complex. iii) Given that the cell is a ‘crowded environment’ 
(Luby-Phelps, 2013) and a wide range of molecules can bind to actin, this can often 
mean that myosin-5 encounters obstacles while moving on actin filaments. 
In cells, the behaviour of organelles trafficked by molecular motors is affected by the 
crowded environment. It has been shown that high densities of free kinesins can 
cause a ‘traffic jam’ on microtubules and hinder forward transport of cargo in vitro 
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(Conway et al., 2012). Results also suggested that cargos bind multiple kinesins that 
increase run length (Beeg et al., 2008), moreover cargos can also acquire new 
motors along the way enabling them to overcome obstacles or traffic jams (Conway 
et al., 2012). The transport of early endosomes by dynein was studied with live cell 
imaging and it was found that two-thirds of the early endosomes exhibited a confined 
motion, caged by the actin cytoskeleton (Zajac et al., 2013; Trybus, 2013). 
The motile subpopulation of the cargos showed directed movement with longer, 
diffusive pauses (Zajac et al., 2013). The site of the pauses co-localised with high 
density of microtubules, endoplasmic reticulum and other early endosomes, 
suggesting that these can regulate transport (Zajac et al., 2013; Trybus, 2013). 
It has been previously proposed that if the tail region of myosin-5 is elastic, myosin-5 
would step more regularly while moving cargo through a viscoelastic cytoplasm 
(Schilstra and Martin, 2006). The idea is that the motor could continue moving while 
the cargo is being squeezed through the meshwork, which can only be possible if the 
tail is able to extend over the force range that the cargo exerts on the motor. The 
coiled-coil tail of skeletal muscle myosin-2 (Schwaiger et al., 2002; Root et al., 2006) 
and that of mouse myosin-5 (Nagy et al., 2009) were studied using force 
spectroscopy and it was found that the tail domain of myosin-5 is much more elastic 
compared to the skeletal muscle myosin-2, most probably because various loops 
interrupt the coiled-coil segment (Nagy et al., 2009; Hammer  3rd and Sellers, 2012). 
The coiled-coil motif of myosin-2 is mechanically stable and relatively stiff compared 
to the loops. However, the coiled-coil motif is able to extend too and unfolds at forces 
of 25-40 pN (Schwaiger et al., 2002; Root et al., 2006). This force is much higher 
than the stall force of myosin-5, that is ~3 pN (Mehta et al., 1999; Uemura et al., 
2004; Schilstra and Martin, 2006). Therefore the coiled-coil would not allow much 
movement of the heads in front of the cargo, thus if myosin-5 tail would only consist 
of coiled-coil segment, it would not be able to efficiently transport cargo along actin 
tracks. Force spectroscopy experiments revealed that first a low-force unfolding of 
the loops occurs and then the relative stiff coiled-coil structure extends while 
stretching the molecule (Nagy et al., 2009). Complete unfolding of the tail domain is 
not likely to occur in vivo, however the loops can extend even at low forces. This can 
be evidenced by the finding that the tail domain can be significantly longer (75 nm) 
than the sum of the coiled-coil domains (56 nm) as observed for chicken brain 
myosin-5a (Cheney et al., 1993). Presumably the loop motifs interrupting the coiled-
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coil (Figures 1.6 and 1.7) enable the tail domain to extend elastically and absorb the 
force generated when the cargo is being stuck. 
The potential ‘backward’ force applied to the cargo, combined with the forward 
movement bias of the motor is likely to result in an applied load on the motor 
(Schilstra and Martin, 2006). Imaging of molecular motors in vitro tends to use 
conditions where there is no load (Walker et al., 2000). Since the role of myosin-5 is 
to move cargo within the cell, it is of utmost importance to study the protein in 
circumstances mimicking load. Therefore the aim of this study was to investigate the 
effect of strain on the biophysical properties of myosin-5.  
The challenge was to devise a methodology by which strain is introduced on 
myosin-5 in vitro as it walks along actin. To do this, I have generated recombinant 
myosins in which the tail of myosin-5 was modified so that it would strongly attach to 
the actin filament. When the tail engages with the actin filament as the myosin walks 
along it, it would be expected to exert a load on the motor. As the motor continues to 
walk along the filament, the load will increase until eventually the motor will stall at 
~3 pN.  
 
1.3.5 Tethering the tail using the biotin-avidin interaction 
The initial approach I used to attach the tail to the actin filament exploited the 
avidin-biotin interaction. Biotin, also known as vitamin B7 or vitamin H, is a carboxylic 
acid that serves as a coenzyme for carboxyl transferase enzymes (György et al., 
1940). Avidin is a homotetrameric glycoprotein that is found in the egg white of birds 
(Eakin et al., 1940). Each subunit of avidin binds biotin with an approximate 
dissociation constant of 10-15 M (Green, 1963), which makes the avidin-biotin 
interaction the strongest known protein-ligand interaction. NeutrAvidin, a 
non-glycosylated and neutral derivative of avidin, has since been isolated (Hiller et 
al., 1987). The molecular weight of a NeutrAvidin subunit is 15 kDa and its β-barrel 
structure is made up from 8 antiparallel β-strands (Livnah et al., 1993). The biotin 
binding site is inside the β-barrel, positioned close to one end (Figure 1.12). 
The NeutrAvidin tetramer is a globular, 60 kDa molecule that has a diameter of 
~5.8 nm, which is close to that of actin (5.5 nm). NeutrAvidin retains the binding 
properties of the native avidin glycoprotein, but has a reduced non-specific binding 
due to nonglycosylation, and a lack of positively charged residues (Hiller et al., 1987; 
Marttila et al., 2000). NeutrAvidin binding to surface-immobilised biotin has a 
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dissociation constant of approximately 2 pM and a binding rate constant of 
2*108 M-1 s-1 (Wayment and Harris, 2009). 
 
 
Figure 1.12. Crystal structure of the deglycosylated avidin tetramer with bound biotin 
(PDB ID: 2AVI (Livnah et al., 1993)). Protein is shown as cartoon representation with 
colour coded monomers. Red arrows point to biotin that is shown with stick 
representation and atomic colouring with black carbons. The structure on the right 
side has been rotated 90º right around the vertical axis with respect to the structure 
on the left side. 
 
A biotinylation tag at the N-terminus of myosin-5a HMM has previously been used to 
attach quantum dots via streptavidin to myosin-5a (Hodges et al., 2007; Nelson et 
al., 2009; Andrecka et al., 2015). The 15 amino acid Avi-tag on purified myosin-5a 
was specifically biotinylated by the purified E. coli biotin ligase (BirA) enzyme in vitro 
(Beckett et al., 1999). In our experiments, the Avi-tag was introduced at the 
C-terminal end of a myosin-5a construct (Figure 1.13). The aim was to biotinylate the 
purified myosin, mix it with biotinylated F-actin, in which 5-10% of the actin 
monomers are biotinylated, and then add avidin to crosslink the biotinylated myosin 
tail to the actin filament. By tethering the tail to the actin filament in this way, this was 
expected to apply a load to the motor as it walks along the actin filament away from 
the site of tail attachment, and thus enable us to visualise any effects on the coiled-
coil tail and on the motor domains (Figure 1.13). 
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The extent of the coiled-coil domain was assessed using the COILS webserver 
(http://embnet.vital-it.ch/software/COILS_form.html), which predicts the probability of 
coiled-coil formation (Lupas et al., 1991). The prediction suggests that residues 
900 to 1100, 1150 to 1240 and 1310 to 1430 form coiled-coil (Figure 1.14), whereas 
residues 1100 to 1150 and 1240 to 1310 form loops. This agrees with earlier 
published predictions (Cheney et al., 1993). Previously, HMM constructs of mouse 
myosin-5a have been studied. This construct is 1,091 residues long (Wang, Chen, et 
al., 2000) and contains a ~26 nm long coiled-coil (e.g. the first region of coiled-coil 
predicted to exist in the tail) (Baboolal et al., 2009). The present construct is 
350 amino acids longer than the HMM construct, and additionally contains the loops 
and both of the predicted distal coiled-coil motifs. 
The C-terminal cargo binding globular tail domain (GTD) of myosin-5a is not included 
in this construct, as the main focus of this study was the investigation of the coiled-
coil tail. Including the GTD in the construct would have increased its size by an 
additional 44 kDa, making the construct more difficult to express. Moreover, a full 
length construct containing the GTD tends to adopt an auto inhibitory conformation 
without the cargo being present (Thirumurugan et al., 2006), and this may have 
interfered with achieving the aims of this study. 
The myosin-5a Avi-tag construct contains an N-terminal GFP followed by the first 
1,440 amino acids of the mouse myosin-5a brain isoform, which includes the motor 
domain and coiled-coil motifs, but excludes the cargo binding domain. This is 
followed by an Avi-tag sequence (15 amino acids long (GLNDIFEAQKIEWHE)) 
(Beckett et al., 1999) and a Flag tag for affinity purification. The heavy chain of the 
construct is 1,721 residues long (Figure 1.16). The predicted molecular weight is 
200 kDa and it is expected to bind six calmodulin molecules per heavy chain. 
For simplicity, this construct is called Myo5-Avi.  
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Figure 1.13. Schematic representation shows how the biotin-actin interaction is 
planned to be applied to attach the tail of myosin-5 to actin. 
 
 
Figure 1.14. Result of the coiled-coil prediction by COILS webserver, using a 
scanning window of 28 amino acids. Probability of coiled-coil formation is shown as a 
function of the residue numbers of the brain isoform of mouse myosin-5a. Panel A) 
shows all residues of mouse myosin-5a. Panel B) shows only the coiled-coil region 
for easier assessment. 
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1.3.6 Making the coiled-coil tail longer 
Attaching the tail of the previously described Myosin-5-Avi construct to actin might 
not work well if the tail is not long enough or not flexible enough to attach to the 
same actin filament as the myosin motors are walking on. To overcome this possible 
issue, the tail was designed to be longer in a second, Myosin-5-cc construct 
compared to the Myosin-5-Avi construct.  
The myosin-5a HMM construct contains the first region of coiled-coil, equating to 
189 amino acids, that makes the tail of this molecule 28 nm long (0.15 nm rise per 
amino acid (Chothia et al., 1981; Baboolal et al., 2009)). A second construct was 
engineered in which this region of coiled-coil was almost doubled. This is achieved 
by adding an additional 175 residues of coiled-coil sequence from the first region of 
coiled-coil. This is expected to increase the length of the coiled-coil by 26 nm. 
The planned construct was also assessed by the COILS webserver and prediction 
suggested that this doubled region still forms coiled-coil (Figure 1.15). The inserted 
region of coiled-coil is then followed by the remaining 350 amino acids of the tail, 
Avi-tag and Flag tag sequences as in the Myo5-Avi construct. This construct is 1,896 
residues long (Figure 1.16). The predicted molecular weight is 220 kDa and it binds 
six calmodulin molecules per heavy chain. For simplicity, this construct is named 
Myo5-cc. 
 
 
Figure 1.15. Result of the coiled-coil prediction of Myo5-cc by COILS webserver, 
using a scanning window of 28 amino acids. Probability of coiled-coil formation is 
shown as a function of the residue numbers. 
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1.3.7 Use of an Adhiron to tether myosin-5a to actin via its tail 
A further myosin-5a construct was also designed using Myo5-cc, in which the 
sequence for the Avi-tag at the end of the tail, was replaced by the sequence for 
Adhiron14. As shown in  chapter 3, Adhiron14 binds to F-actin with a high affinity, 
and therefore its inclusion at the end of the myosin-5a tail should enable the binding 
of the tail to F-actin without any need to modify the protein. This construct contains 
an N-terminal Avi-tag that could potentially be used to label this construct with a 
Q-dot. GFP is also included in this construct downstream of the sequence for 
Adhiron14, to monitor expression of this protein in Sf9 cells, and for use as a 
fluorescent reporter of the isolated protein in in-vitro studies. The whole construct is 
1,993 residues long and the predicted molecular weight is 232 kDa (Figure 1.16). 
This construct is also expected to bind six calmodulin light chains per heavy chain. 
For simplicity, this construct is called Myo5-Ad. 
 
 
Figure 1.16. Schematic representation of the full length wild type myosin-5a and of 
the designed constructs. Labelling is the following. Motor: motor domain of 
myosin-5a; IQ: lever with the 6 IQ motifs; CC: 175 amino acids long coiled-coil; 
CC & loops: 350 amino acids long tail domain that contains predicted coiled-coil and 
loops; GTD: globular tail domain; GFP: enhanced GFP; Ad: Adhiron14. 
 
1.3.8 Use of chaperones to improve folding and expression of myosin-5a 
constructs 
Co-expression of specific chaperones has recently been shown to increase the yield 
of recombinant myosin motor constructs (Bird et al., 2014; Bookwalter et al., 2014). 
These chaperones are normally associated with proper folding of the motor domain 
(Barral et al., 2002; Liu et al., 2008). In particular, heat shock protein chaperones 
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(Hsc70 and Hsp90) and their co-chaperone (Unc45b) are required for proper folding 
of striated muscle myosin motor domain (Barral et al., 2002; Liu et al., 2008). Hsc70 
and Hsp90 are general chaperones, while members of the Unc45 family are myosin 
specific co-chaperones. Unc45b is only expressed in skeletal and cardiac tissues, 
whereas Unc45a can be found in every vertebrate tissue (Price et al., 2002). 
The N-terminal tetratricopeptide repeat (TPR) motif of Unc45 proteins is responsible 
for the protein-protein interaction of Unc45 with Hsp90, while the C-terminal UCS 
domain interacts with the myosin motor (Srikakulam et al., 2008). The UCS domain 
is named after the proteins that were found to contain this domain: Unc45 from 
Caenorhabditis elegans, Cro1 from Podospora anserina and She4p from 
Saccharomyces cerevisiae (Barral et al., 2002). These chaperones are required to 
express soluble and active myosin-14 (Bookwalter et al., 2014) and myosin-15 
(Bird et al., 2014) in Sf9 cells. Co-expression of both Hsp90 and Unc45b increased 
the yield of soluble myosin-15 in Sf9 cells, even though there is some endogenous 
expression of Hsp90 in these cells (Bird et al., 2014). 
The myosin-5a constructs used here are larger than the usual HMM constructs that 
were designed and expressed previously (Andrecka et al., 2015; Zimmermann et al., 
2015). I therefore wanted to test if their co-expression with chaperones might 
increase protein expression levels to obtain high yields for the downstream 
biochemical and in-vitro studies. 
 
1.4 Actin binding molecules 
1.4.1 Phalloidin 
Phalloidin, which is the toxin of death cap mushroom (Amanita phalloides), is a cyclic 
peptide that causes severe liver damage in humans (Wieland and Faulstich, 1978). 
It binds tightly with a 1:1 stoichiometry in the proximity of the nucleotide binding site 
of actin (Barden et al., 1987) with a dissociation constant of 22 nM (Cooper, 1987). 
Phalloidin decreases the rate of actin filament depolymerisation (Estes et al., 1981) 
by blocking the nucleotide exchange in actin subunits (Barden et al., 1987). Binding 
of phalloidin to actin decreases the critical concentration of filament formation as it 
shifts the equilibrium between actin monomers and filaments towards the 
filamentous state (Estes et al., 1981). The cell membrane is impermeable for 
phalloidin, thus it was microinjected into live cells and results showed that phalloidin 
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perturbs actin dynamics and cell growth (Wehland et al., 1977). Therefore 
fluorescent derivatives of phalloidin have only been applied to stain actin in fixed 
cells a long since (Wulf et al., 1979). As phalloidin binds inbetween the actin subunits 
(Steinmetz et al., 1998), it usually does not interfere with actin-binding proteins. 
However, exemptions include nebulin that competes with phalloidin for the same 
binding site (Ao and Lehrer, 1995) and both cofilin and gelsolin, that change the actin 
organisation, so that phalloidin is unable to bind (Nishida et al., 1987; Allen and 
Janmey, 1994). The interaction between the motor domain of some non-muscle 
myosin-2 isoforms and actin can also be perturbed in the presence of phalloidin that 
should be considered in the experimental design of in-vitro experiments (Diensthuber 
et al., 2011). 
 
1.4.2 Actin-binding proteins and their use in imaging actin 
A plethora of actin-binding proteins exist in the cell, that regulate actin assembly by 
various processes like nucleating actin for polymerisation, elongating, severing, 
capping, crosslinking and bundling actin filaments, reviewed by (Pollard, 2016). 
Crystallographic studies showed that some actin-binding proteins, including gelsolin, 
cofilin, the WH2 (Wiskott-Aldrich syndrome homology region 2) motif containing 
proteins, profilin and FH2 (formin homology) motif bind to the hydrophobic pocket in 
subdomain I (Figure 1.5A) (Dominguez, 2004; Ferron et al., 2007; Park et al., 2015). 
This hydrophobic pocket is at the barbed end groove, which is still accessible when 
actin is polymerised into filaments. The actin-binding motif that is responsible for 
binding to the hydrophobic pocket was found to contain an α-helix with hydrophobic 
residues, but without consensus sequence similarity (Dominguez, 2004). 
The interaction and the binding site between the myosin motor and F-actin have 
been recently explored in detail by a high resolution cryo electron microscopy study 
(von der Ecken et al., 2016). The motor domain was found to interact with 
subdomains I and II of one actin subunit and also with the loop of subdomain II of the 
adjacent actin subunit. 
The spectrin superfamily that includes fimbrin, α-actinin, utrophin and dystrophin 
actin-binding proteins, bind with a calponin homology (CH) domain to actin. Cryo 
electron microscopy studies suggested that the tandem CH repeat domains interact 
with subdomains I and II in an actin subunit (Galkin et al., 2002; Galkin et al., 2010). 
Utrophin and dystrophin are homologue proteins, the latter was identified as the 
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defective protein in Duchenne and Becker muscular dystrophies (Monaco et al., 
1986). 
 
As actin is involved in various fundamental processes inside the cell including 
cytokinesis, migration and adhesion, there has always been a need to image actin 
structures and dynamics in living cells. As it was described above (in section 1.4.1), 
phalloidin was one of the first compounds used to study actin labelling in live cells. 
However, it is usually not applied anymore in living cells as i) it stabilises actin 
filaments and thus perturbs actin dynamics, ii) it requires microinjection which may 
have adverse effects on the behaviour of the cell. Another approach was to express 
or microinject fluorescent G-actin into cells (Kreis et al., 1982). However, expression 
of fluorescent G-actin altered actin assembly (Aizawa et al., 1997) and it was found 
to be excluded from formin-bound F-actin structures (Kovar et al., 2006; Chen et al., 
2012). 
One of the most widely used probes for staining actin in cells is Lifeact (Riedl et al., 
2008), a fluorescently-tagged 17 residues long peptide from the N-terminus of the 
yeast actin-binding protein Abp140. It exhibits tight binding to both F-actin and 
G-actin, while it does not interfere with actin severing, nucleation, elongation or with 
the binding of myosin or α-actinin (Riedl et al., 2008). However Lifeact molecules 
rapidly exchange on F-actin (Riedl et al., 2008) and it was reported that Lifeact does 
not bind to stress induced cofilin-bound actin rods (Munsie et al., 2009). 
Another widely used probe is F-tractin, the N-terminal, alpha-helical 66 amino acids 
of Inositol 1,4,5-Trisphosphate 3-Kinase A fused to a fluorophore (Schell et al., 
2001). It was found to bind tightly to F-actin with a similar Kd (~2 µM) compared to 
Lifeact (Schell et al., 2001; Riedl et al., 2008). However it was also reported to 
dimerise and bundle actin filaments in vitro (Johnson and Schell, 2009) and modify 
F-actin structure in vivo (Schell et al., 2001; Johnson and Schell, 2009). 
The CH domain of utrophin, that is the N-terminal 261 amino acids of the full length 
molecule, that binds to actin with a Kd of ~18 µM (Rybakova and Ervasti, 2005). 
Fluorescently-tagged version of this domain was found to label actin in variety of cell 
types without disturbing actin assembly (Burkel et al., 2007). 
Recent studies compared the available fluorescent actin-binding probes in their 
localisation to different actin structures (Belin et al., 2014; Lemieux et al., 2014; 
Spracklen et al., 2014). The CH domain of either utrophin or filamin appeared to 
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have limited distribution (Belin et al., 2014; Lemieux et al., 2014), and do not 
recognise lamellipodial actin networks of spreading cells (Belin et al., 2014). Lifeact 
also failed to recognise lamellipodial structures and additionally is excluded from 
formin-bound actin filaments (Belin et al., 2014). The CH domain of utrophin and 
Lifeact were expressed in the Drosophila germline and found to cause sterility and 
severe actin defects (Spracklen et al., 2014). In contrast, F-tractin was found to label 
actin structures well, while not causing sterility or actin defects, when expressed in 
the Drosophila germline (Spracklen et al., 2014). The distribution of F-tractin 
resembled the distribution observed by phalloidin staining (Belin et al., 2014). 
However, it was also found that the choice of the fluorescent protein fused to the 
actin-binding probe and also the peptide linker between the probe and the 
fluorescent protein can alter the subset of F-actin labelled by the probe in the cells 
(Lemieux et al., 2014). 
 
1.4.3 Single molecule motility assay setup 
The motility of single molecules of motor proteins can be studied in a 
fluorescence-based in-vitro assay using TIRF (total internal reflection fluorescence) 
microscope. In this assay actin filaments are attached to the surface of a coverslip, 
then myosin is added and the translocation of single fluorescently labelled myosin 
molecules can be tracked. 
Even though actin binds loosely to the surface of the coverslip, this does not attach 
actin properly as in this case the filaments were observed to move. Proper 
attachment of actin to the surface is crucial, so it does not interfere with myosin 
walking, especially since some myosins have been shown to follow a helical path 
around actin (Ali et al., 2002; Sun et al., 2007). Therefore it is best to have the actin 
filament tethered to the surface via an attachment protein only at certain intervals. 
Traditionally, actin is attached to the surface of the coverslip in these assays using 
either one of two possible techniques. In the first, biotinylated BSA is applied to the 
surface of the coverslip, streptavidin or NeutrAvidin is then bound to this, and then 
biotinylated F-actin is added, which binds to the avidin (Toepfer and Sellers, 2014). 
The biotinylated actin filaments are formed using approximately 10-20% of 
biotinylated actin monomers, that are polymerised with unmodified G-actin. However 
some experiments use biotinylated myosins with streptavidin attached Q-dot 
(Warshaw et al., 2005) or beads. In these experiments biotinylated myosin can 
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potentially attach to NeutrAvidin that was used to attach actin to the surface. 
Moreover, streptavidin Q-dots can potentially attach to the biotinylated actin 
subunits. In the second technique, NEM-treated skeletal muscle myosin-2 HMM is 
applied to the surface and then actin is added (Warshaw et al., 1990; Guilford et al., 
1997; Warshaw et al., 2005). N-ethyl-maleimide (NEM) treatment of myosin 
chemically inactivates the myosin’s ATPase activity, however its strong actin binding 
affinity is retained. In fact, the NEM treatment produces a variety of myosin 
molecules considering their activity. This leads to a group of molecules, where some 
myosin molecules are still active and moving actin, while being attached to the 
surface; some myosin molecules are inactivated and attach actin to the surface; and 
some myosin molecules are inactivated to lose even their actin binding affinity. 
In other words there is a fine line between inactivating the myosin’s ATPase activity 
and still retaining strong actin binding activity (Warshaw et al., 1990). Moreover, 
during storage by freezing, the strong, ATP-insensitive actin binding of NEM-treated 
myosin declines with time. However, this method still provides a way for label-free 
actin tethering to the coverslip, enabling the use of biotinylation for myosin labelling. 
 
1.4.4 Adhirons 
As an alternative to actin-binding domains, we wanted to explore the possibility of 
raising Adhirons against actin that we could use to tether myosin-5 to actin. Adhirons 
are small, artificial, non-antibody binding proteins, that were developed by the groups 
of Dr. Tomlinson and Prof. McPherson at the University of Leeds (Tiede et al., 2014). 
The core of this scaffold protein is based on a consensus phytocystatin, a plant 
cysteine inhibitor, sequence that was derived by aligning 57 sequences. Consensus 
proteins are often exploited as the scaffold of artificial binding proteins (Devi et al., 
2004; Main et al., 2003), due to their enhanced structural stability. The Adhiron 
scaffold was found to be extremely stable with a Tm of 101 ºC, and is the most stable 
artificial binding protein scaffold to date (Tiede et al., 2014). Crystallisation and 
structure determination of the Adhiron core shows that the scaffold is made up from 
four β-strands and an α-helix (Figure 1.17). Two variable, 9 amino acids long loops 
are present in this scaffold, loop1 is inserted between the 1st and 2nd β-sheet and 
loop2 between the 3rd and 4th β-sheet. A large phage display library was developed, 
comprising more than 3*1010 clones that are expected to only differ in the amino acid 
composition of their two loops. Screening of random clones showed that 86% of 
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them were full length and that the prevalence rate of each amino acid (except Cys) 
are similar, indicating that the library is of high quality. Cysteine was not included in 
the library to prevent Adhirons from disulphide bond induced dimerisation. These 
proteins are 12 kDa and easy to express in E. coli with reasonably high yields of 
50-100 mg/l. All these properties of the Adhirons make them as an artificial 
alternative to antibodies, but they are easier to express and have much higher 
thermal stability compared to antibodies. 
 
 
Figure 1.17. Crystal structure of the Adhiron scaffold at 1.75 Å resolution (PDB ID: 
4N6T (Tiede et al., 2014)) is shown as cartoon representation. Secondary structure 
is colour coded (red: α-helix, yellow: β-sheet, green: loop), termini and insertion sites 
are shown on the figure. Note that this Adhiron scaffold only has the insertion sites 
(3 and 4 residues loop, respectively), whereas the loops of the binders are 9 
residues long. There are 4 residues at the N-terminal, that are disordered and 6 at 
the C-terminal, followed by the single Cys residue and the His-tag.  
 
Using phage display assay, Adhirons can be raised against any protein (Tiede et al., 
2014). The phage display technique applies phage that displays a protein on the 
outside of their packing. A phage library is required, that contains numerous clones 
that differ in the sequence of the displayed protein. In our case Adhirons are 
displayed on the outer protein shell of the virus, and are thus available to bind to 
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proteins of interest, that is fixed to a surface. Non-binders are washed off, binders 
are eluted and further amplified. Usually three selection rounds are performed 
yielding specific binders. 
Actin-binding Adhirons were raised by Dr. Christian Tiede using biotinylated rabbit 
skeletal muscle G-actin (Cytoskeleton) that was bound to streptavidin-coated wells of 
a 24-well plate. As the screening is performed in PBS, it is likely that the actin used 
in the screen polymerises to F-actin, even though there was no Mg2+ or ATP present 
(Pollard, 2016).  
Once Adhirons have been isolated that show potential binding to the protein of 
interest, the coding sequence for the Adhiron is subcloned into a bacterial 
expression plasmid which codes for a C-terminal His-tag, to facilitate Ni-resin 
purification. The protein is then expressed using E. coli, and the purified Adhiron 
characterised for its ability to bind the protein of interest. Adhirons have been raised 
against yeast Small Ubiquitin-like Modifier (SUMO), growth factor FGF1, receptor 
CD31, SH2 domain of Grb2 (Tiede et al., 2014), fibrinogen (King et al., 2015) and 
against hypoxia-inducible transcription factor (HIF-1α) (Kyle et al., 2015) so far. 
Typically, they have 7–140 nM binding affinities to their binding partners and have 
87–95 ºC Tm (Tiede et al., 2014; Kyle et al., 2015). In addition, a single cysteine 
residue can be added to the C-terminal of the Adhiron sequence that can be used for 
biotinylation or other types of labelling. Fluorescent streptavidin can be added to 
biotinylated Adhirons for use in fluorescent studies such as staining of fixed cells 
(e.g. in a similar way to antibodies). The DNA sequence of the Adhirons can also be 
subcloned into a GFP expression vector and cells can be transfected with this 
plasmid. Expression of GFP-tagged Adhirons raised against a given protein in live 
cells enables studying the localisation of the target protein in vivo. 
Therefore, we isolated Adhirons to actin, and tested their properties in a variety of 
assays to determine if they are suitable for tethering myosin-5 to actin by its tail. 
We measured the binding affinities of the Adhirons to actin, determined their ability to 
recognise and bind to actin in fixed cells, and tested the ability of Adhirons fused to 
GFP to bind to actin in live mammalian cells. We also tested if Adhirons are able to 
attach actin filaments to microscopy slides used in TIRF microscopy single molecule 
motility assays. 
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2. General Materials and Methods 
2.1 Materials 
Molecular biology reagents were from Thermo Fisher Scientific. Restriction enzymes 
and buffers were from New England BioLabs®. Buffers and reagents for cell culture 
work were from Gibco® Life Technologies™. All other reagents and chemicals were 
from Sigma-Aldrich® if not stated otherwise. Stock concentrations of reagents used 
to make up buffers are listed in Table 2.1. 1 M HCl and 1 M NaOH stock solutions 
and their dilutions were used to adjust pH of buffers. Deionised water was used to 
make buffers and for other procedures. Composition of PBS buffer used for 
non-sterile applications was 154 mM NaCl, 5.6 mM Na2HPO4,1.06 mM KH2PO4, 
pH 7.4. 
 
Reagent Stock concentration 
Na2ATP 100 mM pH 7.0 
CaCl2 2 M 
EDTA 100 mM pH 8.0 
EGTA 100 mM pH 7.2 
KCl 2 M 
MgCl2 1 M 
MOPS 1 M pH 7.0 
NaCl 5 M 
NaN3 1 M 
PMSF 100 mM in anhydrous ethanol 
Table 2.1. Stock concentration of the reagents used to make up buffers. 
 
2.2 Molecular biology techniques 
2.2.1 PCR 
Appropriate DNA was amplified using Pfx DNA polymerase and gene-specific 
primers. The reagents for the PCR reaction (Table 2.2) were mixed in 100 µl final 
volume. Pfx DNA polymerase was used as it has 3’ to 5’ proofreading exonuclease 
activity, high specificity and sensitivity (Cline et al., 1996). The DNA polymerase was 
activated by a ‘hot start’ (3 minutes at 94 ºC), which denatured the Platinum® 
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antibody specifically binding to and inhibiting the polymerase (Sharkey et al., 1994). 
Following this, 35 cycles of i) 94 ºC for 1 minute (to denature the DNA) ii) 1 minute at 
55 ºC (to anneal the primers) and iii) x minutes at 68 ºC (for extension) were used to 
amplify the DNA. Pfx DNA polymerase extends 1 kb DNA per minute, and thus x 
was calculated to cover the full length of the PCR product. Following the 35 cycles, 
there was a final extension step of 10 minutes. Details of the PCR cycle are shown in 
Table 2.3. 
 
Reagent Final concentration 
Pfu Amplification 
buffer 
20 mM Tris-HCl pH 8.8, 2 mM MgSO4, 
10 mM KCl, 10 mM (NH4)2SO4, 0.1% v/v 
Triton™ X-100, 0.1 mg/ml nuclease-free BSA 
dNTP mix 0.2 mM each 
MgSO4 1 mM 
Forward primer 1 µM 
Reverse primer 1 µM 
Template DNA 1 µg/ml 
Platinum® Pfx 
DNA polymerase 
10 unit/ml 
Table 2.2. Concentration of the reagents used in the PCR reactions. 
 
94 ºC 3 min 94 ºC 1 min  68 ºC 5 min 
  55 ºC 1 min 35x   
  68 ºC x min    
Table 2.3. Temperatures and times used in the PCR amplification. Pfx DNA 
polymerase extends 1 kb DNA per minute, and thus x was calculated to cover the full 
length of the PCR product. 
 
2.2.2 Restriction digest 
DNA was digested using restriction enzyme in a total volume of 50 µl for 1 hour at 
37 ºC. The mixture contained 20 µg/ml DNA and 200 unit/ml restriction enzyme in 
CutSmart® buffer (20 mM Tris acetate pH 7.9, 50 mM Potassium acetate, 10 mM 
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Magnesium acetate, 100 µg/ml BSA). If double digest was performed the 
concentration of both restriction enzymes was 200 unit/ml. 
 
2.2.3 Agarose gel electrophoresis 
After PCR or restriction digest DNA samples were separated on an agarose gel 
according to size. 1% w/v agarose gel was made by adding agarose (Bioline) to TAE 
buffer (40 mM Tris base, 20 mM acetic acid and 1 mM EDTA). Mixture was 
microwaved for 1–2 minutes to get agarose dissolved in the solution. Then the 
mixture was left to cool down to ~40 ºC and ethidium bromide was added to a final 
concentration of 0.7 µg/ml. Solution was poured into casts and was left to solidify. 
DNA loading dye was added to the samples to have a final concentration of 1.7 mM 
Tris-HCl pH 7.6, 10 mM EDTA, 0.005% w/v bromophenol blue, 0.005% w/v xylene 
cyanol FF and 10% v/v glycerol. Samples were loaded in the wells and 
electrophoresis was run at 100 V for 30 minutes. GeneRuler 1 kb DNA ladder 
(Thermo Fisher Scientific) was used for size estimation. Ethidium bromide facilitates 
visualization by intercalating into DNA and fluorescing in UV light. Images were 
taken by Kodak Image Station or by UVIdoc Gel Documentation System (UVItec). 
 
2.2.4 DNA purification 
To purify DNA from solution after PCR or restriction digest NucleoSpin® Gel and 
PCR Clean-up kit (Mackerey-Nagel) was used. Alternatively DNA was run on an 
agarose gel and appropriate sized band was excised and DNA was recovered using 
QIAquick® Gel Extraction Kit (QIAGEN®) or NucleoSpin® Gel and PCR Clean-up 
Kit (Mackerey-Nagel), following the manufacturer’s instructions. The concentration of 
the purified DNA was measured using a NanoDrop® Spectrophotometer set to a 
wavelength of 260 nm. 
 
2.2.5 Transformation after cloning 
The ligation mixture was transformed into Stellar™ Competent Cells (Clontech 
Laboratories). 1 µl of the mixture containing the ligated plasmid was added to 50 µl 
of cells and incubated on ice for 30 minutes. Then cells were heat shocked at 42 ºC 
for 45 s to facilitate DNA entry into the cells. The mixture was then incubated on ice 
for 3 minutes, before adding 150 µl room temperature SOC medium (Invitrogen™). 
The cells were then incubated at 37 ºC for 1 hour while shaking at 230 rpm. 100 µl of 
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the cells were plated onto LB agar plates containing selective antibiotics to select for 
cells containing the ligated vector. Plates were incubated at 37 °C for 16–18 hours. 
Individual colonies were picked from the plates and used to inoculate 5 ml LB 
cultures, containing antibiotics, and grown overnight with shaking at 37 °C. Plasmids 
were purified from these cultures using the QIAprep® Spin Miniprep Kit (QIAGEN®), 
following the manufacturer’s instructions. The construct sequence was verified by 
DNA sequencing at Eurofins Genomics. 
 
2.2.6 Protein concentration measurement 
Protein concentration was measured by UV absorbance at 280 nm wavelength using 
a NanoDrop® or a Cary Spectrophotometer. The extinction coefficient of the different 
constructs was calculated using the ProtParam tool webserver 
(http://web.expasy.org/protparam) (Wilkins et al., 1999). Protein concentration was 
calculated according to the Beer-Lambert law: 
𝐴 = 𝜀𝜀𝜀 
where A is the absorbance, ε is the extinction coefficient, c is the concentration of the 
protein and l is the path length of the solution. 
 
2.2.7 SDS-PAGE 
To perform SDS gel electrophoresis, self-made 12% or 15% w/v acrylamide or 
commercial 4-12% gradient NuPAGE® Bis-Tris pre-cast gels (Novex®) were used 
and also two different buffer systems were applied accordingly. The first was the 
standard ‘Tris’ buffer, containing 25 mM Tris base, 192 mM glycine pH 8.0, 0.1% w/v 
SDS. The second was an MES buffer, containing 50 mM MES 
(2-(N-Morpholino)ethanesulfonic acid), 50 mM Tris base pH 7.3, 0.1% w/v SDS, and 
1 mM EDTA, which is optimised for resolving small proteins on the pre-cast gels. 
Protein samples were diluted in Laemlli buffer (50 mM Tris pH 6.8, 2% w/v SDS, 
10% v/v glycerol, 5% v/v β-mercaptoethanol, 0.005% w/v bromophenol blue) and 
incubated at 98 ºC for 5 minutes to ensure proteins become denatured through the 
binding of SDS. 
Mini gels (8 cm x 8 cm) were run at 180 V for 30-40 minutes in Bio-Rad Mini-
PROTEAN® gel tank. To estimate approximate molecular masses of proteins in the 
samples, protein ladders were used. These included: PageRuler Plus, BenchMark™, 
unstained BenchMark™ or SeeBlue Plus2. All protein ladders were from Thermo 
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Fisher Scientific. After running the gels, they were submerged in stain solution 
(0.25% w/v Coomassie Brilliant Blue R-250, 10% v/v acetic acid, 50% v/v methanol) 
for 1-2 hours, while rocking, to stain the proteins. Then gels were washed with 
destain solution (7.5% v/v acetic acid, 27.5% v/v methanol for 12 hours). Destained 
gels were imaged with Odyssey® Imaging System (LI-COR Biosciences) at 700 nm 
wavelength. 
 
During the course of my experiments, I discovered that proteins of similar molecular 
mass in the BenchMark pre-stained protein ladder and PageRuler Plus ladders run 
at different positions on NuPAGE® Bis-Tris pre-cast gels. In particular, proteins in 
the BenchMark ladder run faster on the gel than the PageRuler Plus ladders. 
To directly compare the two, both PageRuler Plus and BenchMark ladders were run 
on the same NuPAGE® Bis-Tris pre-cast gel (Figure 2.1A). Migration of a protein 
band on an SDS gel is inversely proportional to the logarithm of its molecular weight 
in gels that have fixed acrylamide content. However, here gradient gels were used 
that have a complex correlation between molecular weight and migration, especially 
because exact acrylamide content at a distinct point in the gel is indefinable. 
Therefore the results were treated as if they were obtained from a gel with fixed 
acrylamide content and the logarithmical correlation was applied as follows. 
The migration of each protein was measured from the top of the gel using ImageJ. 
Then the logarithm of the molecular mass was plotted as a function of the migration 
(Figure 2.1B) for the PageRuler Plus ladder. The data points were fitted with a linear 
function that had the equation of y = 5.48 – 0.24x, where x is the migration and y is 
the logarithm of the molecular weight. Putting the migration values of BenchMark 
ladder into this equation gave the apparent molecular weight of the bands. These 
corrected values will be showed throughout the Results. 
Note that the linear equation that was fitted to the data points of PageRuler Plus do 
not fully fit the dataset, which is most probably due to the neglect of the properties of 
the gradient gel. This leads to contrary, e.g. the 77 kDa band of BenchMark still runs 
faster than the 70 kDa band of PageRuler Plus. However, as in this study the ladders 
serve to estimate size and not to determine exact molecular weight, keeping this in 
mind, the ladders can still be used with caution. 
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Figure 2.1. Calibration of BenchMark pre-stained protein ladder in 4-12% gradient 
NuPAGE® Bis-Tris pre-cast gels. A) Coomassie-stained SDS-PAGE gel showing 
both BenchMark and PageRuler Plus pre-stained ladders. Numbers in brackets 
show the nominal molecular weight in kDa of the BenchMark protein bands. 
Numbers on the right side of the lanes show actual molecular weight in kDa. 
B) Logarithm of molecular weight of the bands of PageRuler Plus from panel A as a 
function of their migration. Equation y = 5.48 – 0.24x was fitted to the data points. 
 
2.2.8 Western blot 
Western blotting using specific antibodies was performed to identify proteins. 
To perform a Western blot, proteins were transferred from the SDS gel to either a 
PVDF or nitrocellulose membrane. For the PVDF membrane, the iBlot® Dry Blotting 
System (Invitrogen™) was used on program P2 (23 V) for 7 minutes (iBlot® Gel 
Transfer Stacks PVDF Mini from Novex®). For the nitrocellulose membrane, proteins 
were blotted onto Amersham™ Hybond™-ECL nitrocellulose membrane 
(GE Healthcare) at 250 mA for 2 hours in Transfer Buffer (Pierce™) using Mini 
Trans-Blot® cell apparatus (Bio Rad Laboratories). After transferring the proteins 
onto the membrane, the membrane was blocked with PBS containing 0.05% v/v 
Triton™ X-100 (PBST) and 3% w/v skimmed milk powder or BSA. Membranes were 
either blocked at room temperature for 1 hour or at 4 ºC for 16-18 hours. After 
blocking, the membrane was washed with PBST, 3 times, for 3 minutes each at 
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room temperature, and then incubated with primary antibody (for dilutions, see Table 
2.4), diluted into blocking solution either for 1 hour at room temperature, or at 4 ºC 
for 16-18 hours. Primary antibody was then removed by washing with PBST, 3 times, 
for 3 minutes each at room temperature. The membrane was then incubated with 
secondary antibody, diluted into blocking buffer for 1 hour at room temperature. 
Finally, the blot was washed with PBST, 3 times, for 3 minutes each at room 
temperature. 
To detect the binding of the primary antibody, either horseradish peroxidase (HRP) 
linked or IRDye® linked secondary antibodies were used. For HRP-linked antibodies, 
the membrane was developed using the Pierce™ ECL Western Blotting kit (Thermo 
Fisher Scientific), following the manufacturer’s instructions. Chemiluminescence was 
detected by exposing the membrane to Kodak X-Ray film and the film was 
processed using a Xograph Compact X2 instrument. When IRDye® linked 
secondary antibodies were used, the incubation was performed in a case protected 
from light as this dye is light-sensitive. After incubation the membrane was scanned 
with Odyssey® Imaging System (LI-COR Biosciences) at 700 nm wavelength. 
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Primary antibody Secondary antibody 
Mouse anti-calmodulin (clone 6D4, 
Sigma-Aldrich®) in 1:2,000 dilution 
Goat anti-mouse HRP-linked (Thermo 
Fisher Scientific) in 1:5,000 dilution 
Mouse anti-GFP (clone 9F9.F9, 
Abcam) in 1:3,000 dilution 
Goat anti-mouse IRDye® 680-linked 
(LI-COR®) in 1:50,000 dilution 
Rabbit anti-Myo5a (clone H-90, 
Santa Cruz Biotechnology®) in 
1:100 dilution 
Goat anti-rabbit IRDye® 680-linked 
(LI-COR®) in 1:50,000 dilution 
Mouse anti-Flag (clone M2, Sigma-
Aldrich®) in 1:1,000 dilution 
Goat anti-mouse IRDye® 680-linked 
(LI-COR®) in 1:50,000 dilution 
Mouse anti-biotin (clone Z021, 
Invitrogen™) in 1:1,000 dilution 
Goat anti-mouse IRDye® 680-linked 
(LI-COR®) in 1:50,000 dilution 
Rabbit anti-GFP (polyclonal, 
Millipore) in 1:2,000 dilution 
Goat anti-rabbit HRP-linked (Thermo 
Fisher Scientific) in 1:5,000 dilution 
Rabbit anti-Myo5a (clone H-90, 
Santa Cruz Biotechnology®) in 
1:200 dilution 
Goat anti-rabbit HRP-linked (Thermo 
Fisher Scientific) in 1:5,000 dilution 
Mouse anti-Flag (clone M2, Sigma-
Aldrich®) in 1:2,000 dilution 
Goat anti-mouse HRP-linked (Sigma-
Aldrich®) in 1:5,000 dilution 
Table 2.4. Pairs of primary and secondary antibodies that were used in Western 
blots. 
 
2.3 Actin techniques 
2.3.1 Preparation of acetone-dried muscle powder 
Preparation of acetone-dried powder was performed according to (Pardee and 
Spudich, 1982) using approximately 400 grams of fresh rabbit skeletal muscle. 
All procedures were carried out at 4 °C. The muscle was minced, and then added to 
1.5 litres of 0.1 M KCl, 0.15 M potassium phosphate pH 6.5, and stirred for 
10 minutes. The solution was filtered through sterile gauze, and the mince added to 
3 litres of 0.05 M NaHCO3, stirred for 10 minutes, and then filtered again. The mince 
was then added to 1.5 litres of 1 mM EDTA pH 7.0, stirred for 10 minutes and 
filtered. A further two extractions were then performed with 2 litres of H2O, stirring for 
5 minutes each time, then filtered. The mince was then added to 1 litre of acetone, 
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and stirred for 10 minutes, before filtering. This was repeated 4 more times. All the 
steps with acetone were performed in the fume hood on ice. This procedure removes 
all the water from the extract. The resulting acetone-dried powder was allowed to dry 
in the fume hood for 16-18 hours and then stored at -20 °C. 
 
2.3.2 Isolation of actin 
Isolation of actin from acetone-dried powder was performed according to (Spudich 
and Watt, 1971). To extract actin and depolymerise it, 8 grams of acetone-dried 
powder made from rabbit muscle was dissolved in 160 ml Buffer A (2 mM Tris base 
pH 8.0, 0.2 mM CaCl2, 1 mM DTT, 0.5 mM NaN3, 0.2 mM ATP) at 0 °C and stirred 
for 30 minutes. After sedimentation at 31,500 g for 45 minutes, the supernatant was 
filtered through a 0.22 µm pore size filter. Then a final concentration of 5 mM 
Tris-HCl, 50 mM KCl, 2 mM MgCl2 and 1 mM ATP were added to the solution and 
actin was allowed to polymerise for 2 hours at room temperature. To dissociate 
contaminant tropomyosin and troponin from actin, a high salt step was performed, by 
increasing the salt concentration to 800 mM KCl, and stirring for 30 minutes at room 
temperature. After sedimentation at 111,000 g for 2 hours, the pellet was 
resuspended in 10 ml Buffer A. The solution was then dialysed to depolymerise 
actin. First it was dialysed against 700 ml Buffer A at 4°C for 5 hours, then a fresh 
1.5 litres Buffer A was used for 16-18 hours at 4°C. Before freezing, another 
sedimentation step was carried out at 67,000 g for 1 hour to get rid of contaminants. 
Supernatant was kept and concentration was measured. The resulting G-actin was 
drop frozen in liquid nitrogen, the frozen drops transferred to a cryo-tube, which was 
then stored in liquid nitrogen. Effectiveness of the preparation and purification steps 
was checked with SDS-PAGE. 
 
2.3.3 Measurement of actin concentration 
G-actin concentration was measured according to (Houk  Jr. and Ue, 1974) using a 
Cary Spectrophotometer. Absorbance at 290 nm was corrected for scattering by 
subtracting the absorbance at 320 nm. Protein concentration was calculated from the 
corrected absorbance with an extinction coefficient of 0.63 ml mg-1 cm-1 (Houk  Jr. 
and Ue, 1974). 
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F-actin concentration was calculated by measuring absorbance at 280 nm with the 
NanoDrop® Spectrophotometer and using extinction coefficient of 45,840 M-1 cm-1 
as described in section 2.2.6. 
 
2.3.4 Polymerisation of actin 
Actin polymerisation was carried out as described by (Burgess et al., 2002) using 
exchange and polymerisation buffers (Table 2.5). 1 µl of exchange buffer was added 
to 10 µl of G-actin stock (50-80 µM), and the solution was left on ice for 5 minutes. 
Then 1 µl of polymerisation buffer was added and the mixture incubated on ice for 
1 hour. To generate biotin labelled F-actin, biotin labelled rabbit skeletal muscle 
G-actin (Cytoskeleton) was mixed with non-labelled G-actin before polymerisation, 
so that 5-20% of the actin monomers were biotinylated. 
Final concentration of the buffer F-actin was in is the following: 10 mM MOPS, 
25 mM KCl, 1.25 mM MgCl2, 1 mM EGTA, 1.67 mM Tris, 0.17 mM CaCl2, 0.83 mM 
DTT, 0.42 mM NaN3, 0.17 mM ATP. 
 
Exchange buffer 3 mM MgCl2, 11 mM EGTA pH 7.0 
Polymerisation 
buffer 
300 mM KCl, 12 mM MgCl2, 
1 mM EGTA, 120 mM MOPS pH 7.0 
Table 2.5. Buffers used for actin polymerisation. 
 
2.4 Myosin techniques 
2.4.1 Cloning of the Myosin-5-Avi construct 
The recombinant Myosin-5-Avi construct in pFastBac™ vector (Invitrogen™) was 
made using an In-Fusion® cloning protocol (Clontech Laboratories) following the 
manufacturer’s recommendations (Figure 2.2). First a linearised vector was created 
by cleaving the donor pFastBac plasmid at the multiple cloning site (MCS) with a 
restriction endonuclease. The appropriate DNA insert was amplified by PCR using 
primers which have at least 15 bp 5’ extension complementary to the linearised 
donor vector ends. After purification the PCR product was cloned into the vector 
using In-Fusion® HD EcoDry™ recombinase. The mixture was incubated, then 
transformed into competent cells and colonies were selected on plates containing 
ampicillin (Figure 2.2). 
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Figure 2.2. Generalised In-Fusion® cloning protocol. Figure is taken from 
In-Fusion® HD EcoDry™ Cloning Kit User Manual. 
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The resulting Myo5-Avi construct contains the coding sequence for the first 
1,440 amino acids of the mouse myosin-5a, with a C-terminal Avi-tag™. The forward 
primer contained sequence that matched that of the vector at the EcoR I/Stu I sites 
and the first 16 bases of the coding sequence for myosin-5a (Figure 2.3). 
The reverse primer contained sequence that matched that of the vector at the 
Stu I /Sal I sites, the Avi-tag sequence, and the coding sequence for residues 
1335 to 1440 (i.e. 18 bases; Figure 2.3). The pFastBac plasmid already contained 
eGFP cloned into the BssH II site and Flag tag sequence (DYKDDDDK) cloned into 
the Not I site by Dr. Attila Nagy (Dr. Sellers’ laboratory at NIH, NHLBI). Enhanced 
GFP (eGFP) is a point mutant of GFP that exhibits much higher fluorescent intensity 
compared to GFP (Cormack et al., 1996). The GFP tag at the N-terminus of 
myosin-5 enables monitoring protein expression by Sf9 cells and is required for 
fluorescence microscopy studies. The C-terminal Flag tag is required for Flag affinity 
purification of the protein. The source of the myosin-5 cDNA was the brain isoform of 
mouse (Mus musculus) myosin-5a (NCBI Reference Sequence: XM_006510832.3). 
Both the source and the donor plasmids were kind gifts from Dr. Attila Nagy 
(Dr. Sellers’ laboratory at NIH, NHLBI). 
To generate the construct, the coding sequence for the first 1,440 amino acids of the 
mouse myosin-5a was PCR-amplified from the source plasmid using the primers 
described (Figure 2.3), applying an extension time of 5 minutes. This is a suitable 
length of time to fully amplify the insert DNA (total length of 4.3 kb DNA). Both 
primers were designed according to the In-Fusion® cloning protocol. PCR was 
performed as described in section 2.2.1. 
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Figure 2.3. Cloning strategy, primer sequences and the resulting DNA and amino 
acid sequence of the Myosin-5-Avi construct with numbering. Restriction sites are 
shown where GFP, the myosin sequence, Avi-tag and Flag tag were cloned into the 
multiple cloning site of the pFastBac vector. Motor, IQ and CC stand for the DNA 
sequence coding for the myosin-5 motor domain, the lever with the 6 IQ motifs, and 
the predicted coiled-coil tail with the loops, respectively. Nucleic acid and amino acid 
sequences are shown with single letter code. 
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After amplification, the PCR reaction was run on a 1% w/v agarose gel, and the 
amplified cDNA was gel purified as described (sections 2.2.3 and 2.2.4). 
The pFastBac vector was digested with Stu I restriction enzyme, and purified as 
described (sections 2.2.2 through 2.2.4). The concentrations of both insert and 
vector were measured, and the In-Fusion® reaction set up using the amount of 
100 ng for both the vector and the insert in a total volume of 10 µl to the lyophilised 
pellet of the recombinase. The mixture was incubated for 15 minutes at 37 ºC, 
followed by 15 minutes at 50 ºC and then transformed as described (section 2.2.5). 
Cells were plated on LB agar plates containing 100 µg/ml ampicillin (KD Medical) to 
select for cells containing the pFastBac vector.  
Colonies were picked and plasmid was purified as described (section 2.2.5). 
Plasmids were screened by running them on an agarose gel as described (section 
2.2.3) and checking for an increased size of 4.3 kb in plasmids that contained an 
insert. The pFastBac vector containing the eGFP sequence is 5.5 kb and the size of 
the insert is 4.3 kb. Colonies containing a DNA insert were sequenced (Eurofins 
Genomics) to confirm the identity and fidelity of the inserted sequence (Figure 2.3). 
Ten different primers (Table 2.6) were used for sequencing to cover the entire 
sequence of the construct, and a Myo5-Avi construct was obtained in which the 
sequence was that expected (full length sequence of this construct is provided in the 
supplementary materials (S2)). 
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Primer name Primer sequence Location (bp) 
pFBfor TCCGGATTATTCATACCGTCCC  
FOR1 ACTACCAGCAGAACACCCCC 545 
FOR2 CGCAGTAGCTGAAGAGGCTT 1158 
FOR3 CATCTCGGGATTCAGACAGC 1760 
FOR4 CCGCATGTCAAACAAAGC 2361 
FOR5 CAAGGATAAATACCAGTTTGGTAAGA 2949 
FOR6 GACTACAAATGCCTCATGGAGA 3562 
FOR7 ACCAAGAACAGAGGAGCCAA 4149 
FOR8 GGGGAGATCCAGAGCCTAAA 4762 
pFBrev CCTCTACAAATGTGGTATGGCTG  
Table 2.6. Primers used for sequencing of Myosin-5-Avi construct. pFBrev to For8 
primers are forward primers and pFBrev is a reverse primer annealing to the 
backbone of the pFastBac plasmid. Numbers in the Location column show the start 
of each primer in bp considering the Myo5-Avi sequence. 
 
2.4.2 Re-cloning of the Myosin-5-Avi construct 
Expression trials for the initial Myo5-Avi construct were unsuccessful (see section 
4.1.3). As this was likely due to the backbone vector used, I subcloned the entire 
coding region for Myo5-Avi, including the N-terminal eGFP and the C-terminal 
Flag tag, into the EcoR I and Xho I sites of an unmodified pFastBac™ vector 
(Invitrogen™) (Figure 2.4) using In-Fusion® cloning (as described above in section 
2.4.1). The pFastBac vector was digested with EcoR I and Xho I (section 2.2.2), and 
the reaction was stopped by incubating it at 65 ºC for 20 minutes. The insert was 
amplified using the primers shown (Figure 2.4) applying the same conditions as 
described above (section 2.4.1). The resulting constructs were sequenced (Eurofins 
Genomics). The pFastBac vector was a kind gift from Dr. Jonathan Bird 
(Dr. Friedman’s laboratory at NIH, NIDCD). Sequence of this Myo5-Avi construct is 
identical to the original construct presented in section 2.4.1. 
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Figure 2.4. Cloning strategy and primer sequences used to amplify the myosin-5 
construct for re-cloning into a new pFastBac vector. Restriction sites are shown 
where the construct was cloned into the multiple cloning site of the pFastBac vector. 
Motor, IQ and CC stand for the DNA sequence coding for the myosin-5 motor 
domain, the lever with the 6 IQ motifs, and the predicted coiled-coil tail with the 
loops, respectively. 
 
  
52 
 
2.4.3 Cloning of the Myosin-5-cc construct 
The recombinant Myosin-5-cc construct in pFastBac™ vector (Invitrogen™) was 
made using the GeneArt® Seamless cloning protocol (Invitrogen™) following the 
manufacturer’s recommendations. First a linearised vector was created by cleaving 
the donor pFastBac plasmid with restriction endonuclease. Then the appropriate 
DNA insert was amplified by PCR using primers which have at least 15 bp 
5’ extension complementary to the linearised donor vector ends. After purification the 
PCR product was cloned into the vector using the GeneArt® Seamless enzyme. 
The mixture was incubated, then transformed into competent cells and colonies were 
selected on plates containing ampicillin. 
The pFastBac vector containing the Myosin-5-Avi construct in between the EcoR I 
and Xho I restriction sites, which was created during the re-cloning of the 
Myosin-5-Avi construct, was used as a donor vector. This plasmid was linearised 
using Afe I restriction enzyme that cuts the plasmid at the AGCGCT sequence 
coding for Arg1337 according to Myosin-5-Avi numbering (Arg1091 according to wild 
type mouse myosin-5a numbering). This residue is the last amino acid of the 
proximal part of coiled-coil and also the last residue of the HMM construct. 
The coding sequence for 175 amino acids of the mouse myosin-5a coiled-coil 
starting with Arg917 and ending with Arg1091 according to the wild type myosin-5a 
numbering was PCR-amplified from the source plasmid using the primers described 
(Figure 2.5), applying an extension time of 30 seconds. This is a suitable length of 
time to fully amplify the insert DNA (total length of 0.5 kb DNA). Both primers were 
designed according to the GeneArt® Seamless cloning protocol. PCR was 
performed as described in section 2.2.1. The source plasmid was the brain isoform 
of mouse (Mus musculus) myosin-5a (NCBI Reference Sequence: 
XM_006510832.3). 
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Figure 2.5. Cloning strategy and primer sequences used to amplify the coding 
sequence of the 175 amino acid coiled-coil section. Afe I restriction site is shown 
where the insert was cloned into the Myosin-5-Avi sequence. Motor, IQ and CC 
stand for the DNA sequence coding for the myosin-5 motor domain, the lever with 
the 6 IQ motifs, and the predicted coiled-coil tail with the loops, respectively. 
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The PCR product and the digestion product were run on a 1% w/v agarose gel, and 
the DNA was gel purified as described (sections 2.2.3 and 2.2.4). The concentrations 
of both insert and vector were measured, and the GeneArt® Seamless reaction set 
up using the amount of 50 ng for both the vector and the insert in a total volume of 
20 µl. The final mixture also contained 4 µl enzyme buffer (from a 5x stock, provided 
in the cloning kit) and 2 µl enzyme mix (from a 10x stock, provided in the cloning kit). 
The mixture was incubated for 30 minutes at room temperature, and then 
transformed as described in section 2.2.5. Cells were plated on LB agar plates 
containing 100 µg/ml ampicillin to select for cells containing the pFastBac vector. 
Colonies were picked and colony PCR was performed as described in section 2.2.1. 
The colonies were touched with the tip of the pipette tip and the cell suspension 
attached to the tip was then transferred to the PCR mixture tube. The first, hot start 
step of the PCR (3 minutes at 94 ºC) enables the DNA to be released from the cells. 
For5 and Rev7 primers (Table 2.7) were used for the amplification, which yields a 
PCR product of 1,300 bp for the negative control and 1,800 bp if the colony contains 
the insert. After the amplification, the PCR products were run on an agarose gel as 
described in section 2.2.3, checking for a possible size difference of 500 bp. 
Colonies containing the insert were sequenced (Eurofins Genomics) to confirm the 
identity and fidelity of the inserted sequence (Figure 2.5). The sequencing primers 
listed in Table 2.6 and Table 2.7 were used for sequencing to cover the entire 
sequence of the construct. The amino acid sequence of the whole construct is in the 
supplementary materials (S3). 
The resulting construct contains the coding sequence for an eGFP and then the first 
1,091 amino acids of the mouse myosin-5a that would be a regular HMM. This is 
followed by 175 amino acids of coiled-coil that was doubled from the HMM and then 
the remaining 350 amino acids of the coiled-coil tail that is predicted to form both 
loops and coiled-coil. The sequence ends with a C-terminal Avi-tag™ (Avidity) 
(GLNDIFEAQKIEWHE), followed by a Flag tag sequence (DYKDDDDK). Enhanced 
GFP (eGFP) is a point mutant of GFP that exhibits much higher fluorescent intensity 
compared to GFP (Cormack et al., 1996). The GFP tag at the N-terminus of 
myosin-5 enables monitoring protein expression by Sf9 cells and is required for 
fluorescence microscopy studies. The C-terminal Flag tag is required for Flag affinity 
purification of the protein. The source of the myosin-5 cDNA was the brain isoform of 
mouse (Mus musculus) myosin-5a (NCBI Reference Sequence: XM_006510832.3), 
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that was a kind gift from Dr. Attila Nagy (Dr. Sellers’ laboratory at NIH, NHLBI). 
This construct is 1,896 residues long and the molecular weight is 220 kDa. 
Like Myosin-5-Avi, this construct also binds six calmodulin light chains per heavy 
chain. 
 
Primer name Primer sequence Location (bp) 
FOR5 CAAGGATAAATACCAGTTTGGTAAGA 2949 
FOR5.5 CCTTCAGTGCTGCTTCCGGCG 3411 
REV7 AGCTGCTTCTCCTGTTCCAG 4777 
Table 2.7. Primers used for colony PCR and sequencing of the Myosin-5-cc 
construct. For5 and Rev7 were used for colony PCR. All primers along with primers 
in Table 2.6 were used for sequencing. Numbers in the Location column show the 
start of each primer in bp considering the Myo5-cc sequence. 
 
2.4.4 Cloning of the Myosin-5-Ad construct 
The recombinant Myosin-5-Ad construct was cloned into the EcoR I and Xho I sites 
of the multiple cloning site of pFastBac plasmid by GenScript®. DNA sequence was 
codon optimised for expression in insect cells by GenScript, therefore DNA 
sequence differs from NCBI Reference Sequence XM_006510832.3. The construct 
contains an N-terminal Avi-tag for potential labelling with a Q-dot. This is followed by 
a mouse myosin-5a HMM molecule, that comprises the motor domain, the lever with 
6 IQ motifs and 175 amino acids of the coiled-coil. These 175 amino acids are then 
doubled to lengthen the tail of the molecule. This is followed by the remaining parts 
of the tail comprising the coiled-coil and loop motifs, but excluding the globular tail 
domain as in the previous Myosin-5-cc construct. Then the sequence continues with 
a GFP to monitor expression and also to use the molecule later on in fluorescent 
studies, and then with the sequence of the actin-binding Adhiron14. For potential 
removal of the actin-binding Adhiron14, a PreScission protease site (GE Healthcare, 
LEVLFQGP) is inserted between the GFP and the Adhiron14 sequence. 
The sequence ends with a C-terminal Flag tag that allows purification of the 
molecule on a Flag affinity resin. The whole construct is 1,993 residues long and the 
molecular weight is 232 kDa (Figure 1.16). Like Myosin-5-Avi, this construct also 
binds six calmodulin light chains per heavy chain. Sequence of the construct in 
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pFastBac plasmid was verified by GenScript and can be found in the Supplementary 
Materials (S4). 
 
2.4.5 Bacmid DNA generation 
Generation of recombinant baculovirus was carried out according to the Bac-to-Bac® 
Baculovirus Expression Systems protocol (Invitrogen™). The recombinant donor 
pFastBac™ plasmid was transformed into DH10Bac™ competent cells 
(Invitrogen™) as follows. 50 ng plasmid was added to 100 µl of freshly thawed cells 
on ice and incubated on ice for 30 minutes. The tube was transferred to a water 
bath, set to a temperature of 42 ºC, for 45 s to facilitate the DNA entering the cells, 
then transferred back to ice for 3 minutes. 900 µl SOC medium was added, and the 
tube was transferred to the incubator at 37 ºC for 4 hour with shaking at 230 rpm 
before plating the cells onto bacmid plates.  
Bacmid plates were prepared using LB medium + 1.5% w/v Agar (KD Medical), 
supplemented with 50 µg/ml kanamycin (Gibco® Life Technologies™), 7 µg/ml 
gentamicin (Gibco® Life Technologies™), 10 µg/ml tetracycline (Sigma-Aldrich®), 
100 µg/ml Bluo-gal (Invitrogen™, stock solution dissolved in DMSO) and 40 µg/ml 
IPTG (Sigma-Aldrich®). 100 µl of the bacterial cells were plated onto the bacmid 
plates and the plates were incubated at 37 ºC for 48 hours. Cells, in which the DNA 
from the pFastBac plasmid was transposed into the bacmid, appeared white on 
these selective plates. Other cells, in which the lacZ gene was not disrupted by the 
transposition, express β-galactosidase which cleaves Bluo-gal producing a blue 
product turning these colonies blue. As these colonies are small and often hard to 
distinguish if they are blue or white, multiple colonies were picked and restreaked 
onto a fresh bacmid plate and incubated at 37 ºC for 16-18 hours, to enable clear 
blue/white selection. 
Multiple white colonies and one blue colony as a negative control were picked from 
the plates, used to inoculate 5 ml LB containing 50 µg/ml kanamycin, 7 µg/ml 
gentamicin and 10 µg/ml tetracycline and incubated at 37 ºC for 24 hours, while 
shaking at 230 rpm. Bacmid purification was then performed according to the 
Bac-to-Bac® bacmid purification protocol as follows, using solutions P1, P2 and N3 
from the QIAprep® Spin Miniprep Kit (QIAGEN®). The cell culture was centrifuged at 
3,800 g and the pellet resuspended in 300 µl of solution P1. 300 µl of solution P2 
was added, and the mixture incubated at room temperature for 5 minutes. 300 µl of 
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solution N3 was then added and the mixture was incubated on ice for 10 minutes. 
The mixture was then centrifuged at 16,000 g for 10 minutes and the supernatant 
transferred to fresh tube containing 800 µl isopropanol. The tube was incubated on 
ice for 10 minutes, then centrifuged again at 16,000 g for 15 minutes. After removing 
the supernatant the pellet was washed with 500 µl 70% v/v ethanol and centrifuged 
at 16,000 g for 5 minutes. After air drying the pellet for 15 minutes 40 µl H2O was 
added and bacmid stored at 4 ºC. 
 
2.4.6 Verification of transposition 
The large size of the bacmid DNA (>135 kb) makes it difficult to verify that 
transposition has occurred simply based on its size on an agarose gel. Instead, PCR 
using M13 primers (Table 2.8) were used, following the protocol described above 
(section 2.2.1) with an extension time of 8 minutes. These primers anneal to either 
side of the specific site within the lacZ gene where the transposition is expected to 
occur. A negative control PCR amplification was also performed using the bacmid 
from a blue colony, in which no transposition should have occurred. Using these 
primers, the PCR product is expected to be the size of the gene of interest plus an 
additional 2.3 kb if the transposition occurred, or 2.3 kb if not. 
 
Forward 5'-CCCAGTCACGACGTTGTAAAACG-3' 
Reverse 5'- AGCGGATAACAATTTCACACAGG-3' 
Table 2.8. M13 primers used to verify transposition of the construct into the bacmid. 
 
2.4.7 Culturing Sf9 cells 
Previously prepared and frozen Sf9 (Spodoptera frugiperda) cells (Invitrogen™) are 
kept in the liquid nitrogen. A cryovial containing 1 ml Sf9 cells (usually 
~8x106 cells/ml) was thawed by hand. Then 9 ml room temperature Sf-900 II SFM 
medium (Invitrogen™) supplemented with 2.5% v/v heat inactivated FBS and 1x 
GlutaMAX™ (both from Gibco® Life Technologies™) was added to the cells and it 
was centrifuged at 180 g for 10 minutes. Pellet was resuspended in 2 ml fresh 
medium to eliminate the 10% v/v DMSO that is used as a cryoprotectant, when 
freezing the cells. Cells were counted using Trypan blue stain and a 
haemocytometer, and diluted to 0.5x106 cells/ml density. Suspension cultures were 
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grown while shaking with 120 rpm at 27 ºC. Cells usually double every 24 hours, 
therefore they were usually passaged every 2-3 days, when cell density reached 
~6x106 cells/ml, then cells were diluted to ~1x106 cells/ml. Cells were usually left 
growing and adapting to culture conditions for a week before using them for virus 
amplification or protein expression. After cells recovered, some of them were frozen 
down as follows. Cells were centrifuged and resuspended in the above described 
medium containing also 10% v/v DMSO, to a density of ~8x106 cells/ml. 1 ml of cells 
were transferred to cryovials, that were placed in the -80 ºC freezer and after 3 days 
were transferred into the liquid nitrogen storage. 
 
2.4.8 Myosin-5 baculovirus generation 
Baculovirus generation and virus amplification were first carried out according to the 
Bac-to-Bac® Baculovirus Expression System protocol. Sf9 cells were transfected 
with the bacmid DNA using Cellfectin® reagent. Prior to transfection, 105 Sf9 cells 
were seeded into a single well of a 6-well plate in 2 ml of Sf-900 II SFM medium 
containing 50 units/ml penicillin and 50 µg/ml streptomycin (PenStrep from Gibco® 
Life Technologies™) and left at 27 ºC for 1 hour to attach. 5 µl of bacmid DNA was 
mixed with 6 µl of Cellfectin® reagent (Invitrogen™) in 200 µl of the same medium 
without antibiotics and incubated at room temperature for 30 minutes. After washing 
the cells with 2 ml of medium without antibiotics, the DNA mixture, diluted to 1 ml 
with Sf-900 II SFM medium, was pipetted onto the cells and the cells incubated at 27 
°C for 5 hours. The cells were then washed with medium containing antibiotics, 2 ml 
of medium with antibiotics was added, and the cells were then incubated at 27 °C. 
After 72 hours of incubation, the medium and the cells were centrifuged, and the 
supernatant containing the P1 virus was harvested. However, this method only 
provides 2 ml of P1 virus, all of which has to be used to amplify the virus further. 
To obtain high enough titre, this meant performing 4 or 5 rounds of amplification, and 
this did not provide good results in expression trials. Therefore, I switched to a 
different approach. 
In an improved approach to generating virus (Bird et al., 2014), 25 µg bacmid DNA 
was added to 300 µl sterile PBS (Gibco® Life Technologies™). In a separate tube, 
300 µl of polyethyleneimine (PEI from Polysciences, stock concentration: 1 mg/ml) 
was added to 300 µl PBS. Then the bacmid solution was mixed with the PEI solution 
and incubated at room temperature for 10 minutes. 100 ml of 105 Sf9 cells/ml grown 
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in suspension in Sf-900 II SFM medium supplemented with 2.5% v/v heat inactivated 
FBS and 1x GlutaMAX™ were then transfected using this bacmid mixture. 
The culture was incubated at 27 °C while shaking at 120 rpm, and virus replication 
followed by fluorescence microscopy, as the construct contains eGFP. Virus was 
harvested when ~80% of the cells were eGFP positive, usually after 4-5 days. 
This method provided 100 ml of high titer P1 virus, which required only one further 
amplification to have enough virus for expression. 
 
2.4.9 Calmodulin baculovirus generation 
Since myosin-5a needs to be co-expressed with a calmodulin (CaM) expressing 
virus, to ensure that there is enough CaM to bind to the myosin lever, a fresh 
baculovirus for CaM was also generated. The original plasmid (pVL1392) which 
contains the Xenopus laevis CaM (Uniprot: P62155) was used. The sequence of 
Xenopus CaM is identical to that of mouse. In this case, the bacmid DNA is 
co-transfected with the plasmid, and the transposition takes place in the Sf9 cells. 
This approach uses the BaculoGold™ Transfection Kit (BD Biosciences), which 
includes the bacmid DNA. The plasmid was a kind gift from Dr. Attila Nagy 
(Dr. Sellers’ laboratory at NIH, NHLBI). 
2x106 Sf9 cells were seeded into a single well of 6-well plate, in 2 ml of 
Sf-900 II SFM medium, and incubated at 27 ºC for 15 minutes to allow the cells to 
attach. The medium was then removed and 1 ml of Transfection Buffer A added to 
the cells. 0.5 µg BD BaculoGold™ Baculovirus DNA was mixed with 2 µg of the 
pVL1392 plasmid containing the CaM gene, and incubated at room temperature for 
5 minutes, before adding 1 ml of Transfection Buffer B. This mixture was then added 
dropwise to the cells, while gently rocking the plate. The cells were then incubated at 
27 °C for 4 hours, before removing the transfection solution from the cells and 
adding 3 ml Sf-900 II SFM medium. The cells were incubated at 27 °C and P1 virus 
was harvested after 4-5 days. 
 
2.4.10 Virus harvesting and storage 
To harvest the virus, the cells were centrifuged at 400 g for 15 minutes. 
The supernatant was filtered through a sterile filter with a 0.22 µm pore size 
(Millipore). Filtered virus were kept at 4 ºC, protected from light as they are 
light-sensitive. 
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2.4.11 Virus titre determination 
The titre is a measure of how many infective particles there are per volume unit, and 
is used to add the appropriate amount of virus to Sf9 cells for expression (using MOI: 
multiplicity of infection). The titre was measured using an end-point assay (Hopkins 
and Esposito, 2009), which uses a novel cell line named Sf9 Easy Titer (Sf9-ET). 
This cell line has an eGFP gene under the control of the baculovirus polyhedrin 
promoter. Thus, if these cells are infected with baculovirus, they will turn green. 
The medium used to grow the Sf9-ET cells must contain Geneticin® (G418 from 
Gibco® Life Technologies™) to select for cells that contain the eGFP plasmid. 
The Sf9-ET cell line was a kind gift from Dr. Dominic Esposito (NIH, NCI). 
Using a 96-well plate, 100 µl of Sf-900 II SFM medium containing 0.1 mg/ml G418, 
2.5% v/v FBS and 1x GlutaMAX™ was pipetted into wells A2 through H10 (i.e. in all 
wells from column 2 to column 10). The viral stock was diluted 1:500 into medium 
containing G418 and 125 µl of this mixture was added into wells A1–H1. 25 µl of the 
solution in A1-H1 was removed and added to wells A2–H2, resulting in a 1:5 dilution. 
This was then repeated for each subsequent set of wells (A3–H3 and so on), 
resulting in a dilution of 1:5 each time. After adding 25 µl to the wells in column 
A9–H9 and mixing, 25 µl was removed, to ensure that each well had the same 
volume (100 µl). Virus was not added to the wells in the final column (A10–H10), 
to provide a negative control. Finally, 100 µl of Sf9-ET cells at a density of 
7.4x105 cells/ml, in medium containing G418, were pipetted into each well. 
This approach provides 8 parallel serial dilutions, each of which can be assessed to 
calculate the titre. The plate was incubated at 27 °C and the number of eGFP 
positive wells in every column was counted after 4-5 days. The data was transferred 
to an Excel spreadsheet to calculate the titre as described (Reed and Muench, 
1938). A titre of 1-5x108 infective particles/ml is considered to be good for 
subsequent experiments. 
 
2.4.12 Baculovirus amplification 
To generate a high titre virus stock, the virus has to be further amplified after its first 
round of amplification (P1). To amplify the virus 1.5–2x106 Sf9 cells/ml growing 
suspension in medium supplemented with 2.5% v/v FBS and 1x GlutaMAX™, were 
infected with the appropriate virus using an MOI (multiplicity of infection) of 0.1. 
An MOI of 0.1 indicates that there should be one infective virus particle for every 10 
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Sf9 cells. After infection, the cells were incubated at 27 °C, shaking at 120 rpm, and 
the eGFP fluorescence monitored by fluorescence microscopy each day. The virus 
was harvested when ~80% of the cells were eGFP positive, usually after 3 days. 
The virus titre was then determined. In most cases the viruses were only amplified 
once (to P2) or twice (to P3). Further amplification of the viruses can lead to 
fragmentation of DNA incorporated into the viral particles and/or the acquisition of 
mutations. 
 
2.4.13 Cell extraction for calmodulin Western blot 
Calmodulin expression of Sf9 cells was checked by Western blotting. Sf9 cells that 
were either non-infected or infected with calmodulin baculovirus at MOI of 5, were 
incubated for 2 days while shaking (as described in section 2.4.12). 500 µl of the 
cells were centrifuged at 400 g for 15 minutes. The cell pellet was resuspended in 
500 µl extraction buffer comprising 150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 1% v/v Triton™ X-100 and 1x Halt™ Protease Inhibitor Cocktail (Thermo 
Fisher Scientific). The mixture was incubated on ice for 30 minutes, then centrifuged 
at 16,000 g for 20 minutes at 4 °C. Supernatant was mixed with Laemlli buffer 
(as described in section 2.2.7), 15 µl loaded and run on an SDS-PAGE gel and 
Western blotting was performed (as described in section 2.2.8). 
 
2.4.14 Myosin expression 
To express the myosin-5 constructs, 1.5 litres of 1.5-2x106 Sf9 cells/ml in a medium 
supplemented with 2.5% v/v FBS and 1x GlutaMAX™ were co-infected with both 
myosin-5 and CaM baculoviruses at MOI of 5. The infected culture was shaken at 
27 °C at 90 rpm until ~70% of the cells were eGFP positive as followed by 
fluorescence microscopy (usually 2 days). The cell culture was then centrifuged at 
400 g for 15 minutes, and the pellet flash frozen in liquid nitrogen. 
In some cases, chaperones were additionally co-expressed with the myosin-5 
constructs, to help improving expression. P2 virus of Unc45b/Hsp90 was provided as 
a kind gift from Dr. Jonathan Bird (Dr. Friedman’s laboratory at NIH, NIDCD). Both 
chaperones, (UNC45 and HSP90; Mus musculus), were cloned into the same 
pFastBac™ Dual vector (Bird et al., 2014) and P1 virus had been generated as 
described (section 2.4.8). The P2 virus was amplified further (to P3 as described in 
2.4.12) to provide enough virus for co-expression at an MOI of 5. 
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2.4.15 Cell extraction for Myosin-5-Ad Western blot 
Myosin-5-Ad expression in Sf9 cells was checked by Western blotting. 200 ml of Sf9 
cells that were infected with Myosin-5-Ad, calmodulin and Unc45b baculoviruses, all 
at MOI of 5, were incubated for 3 days while shaking (as described in section 
2.4.14). 1 ml sample was taken 1, 2 and 3 days after the infection and these were 
centrifuged at 400 g for 15 minutes. The cell pellet was resuspended in 100 µl boiling 
1x Laemlli buffer. 10 µl from that mixture was loaded and run on an SDS-PAGE gel 
(as described in section 2.2.7). Western blotting was performed using anti-Flag and 
anti-Myo5a antibodies (as described in section 2.2.8). 
 
2.4.16 Myosin purification 
Proteins were purified as described previously (Wang, Harvey, et al., 2000; Nagy et 
al., 2013) using the same protocol. Each step was performed on ice or in the cold 
room at 4 °C. Frozen cell pellets from 1.5 litres of cell culture were extracted in 
300 ml extraction buffer (Table 2.9) using a manual glass homogeniser. The cell 
lysate was sonicated using a microtip on a Misonix Sonicator Controller XL2020. 
Sonication was performed in ~150 ml volume for 3 minutes using 1 s cycles of 
sonication/no sonication. This 3 minute cycle was applied 2-3 times, then the lysate 
was centrifuged at 48,000 g for 15 minutes.  
Myosin-5a constructs were purified from the supernatant using Flag affinity 
chromatography, applying a resin in which Flag antibodies are attached to M2 
agarose beads (Sigma-Aldrich®). 2 ml Flag resin was added to ~300 ml supernatant 
and incubated for 3 hours, while rocking. The mixture was then centrifuged at 200 g 
for 4 minutes and the pelleted resin was washed 3 times with 50 ml Mary’s buffer 
(Table 2.9), then once with 50 ml HMM buffer (Table 2.9) as follows. Supernatant 
was pipetted off from the resin carefully not to lose any resin, and then buffer was 
mixed with the resin and the mixture was centrifuged at 200 g for 4 minutes. The 
resin was transferred into a 10 ml chromatography column (Bio-Rad Laboratories) 
and myosin-5a constructs eluted with elution buffer (Table 2.9). 1 ml elution fractions 
were collected, and analysed using SDS-PAGE. The fractions that had high 
concentration of myosin-5a constructs were dialysed, by placing the fractions into 
Spectra/Por® dialysis tubing (cut-off: 20,000 Da) and dialysing against 2 litres 
dialysis buffer (Table 2.9) for 16-18 hours. The dialysis buffer was exchanged for 
fresh dialysis buffer, and dialysis continued for an additional 3-4 hours. Protein was 
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concentrated 5-10 fold using Amicon® Ultra filter tubes (cut-off: 30,000 Da). 
The tubes were first centrifuged with dialysis buffer alone to activate the filter and 
prevent protein sticking to it, and then the protein sample was added. The tubes 
were centrifuged at 3,800 g for 20-40 minutes using a swing out rotor. Purified 
myosin-5a constructs were flash frozen in liquid nitrogen, by adding 20 µl drops of 
the purified protein to liquid nitrogen. The frozen beads were transferred to a 
cryo-tube on dry ice, and then stored at -80 °C. 
 
Extraction 
buffer 
10 mM MOPS pH 7.3, 200 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 
3 mM NaN3, 0.1 mM DTT, 0.1 mM PMSF, 2 mM ATP, 1 mg/l leupeptin, 
protease inhibitor mixture comprising 2 mg/l chymostatin, 1 mg/l 
pepstatin, 1 mg/l Nα-Tosyl-L-lysine-chloromethylketone-HCl, 1 mg/l N-p-
Tosyl-L-phenylalanine chloromethylketone 
Mary's 
buffer 
10 mM MOPS pH 7.2, 500 mM NaCl, 0.1 mM EGTA, 
3 mM NaN3, 0.1 mM DTT, 0.1 mM PMSF, 
1 mg/l leupeptin, 1 mM ATP, 5 mM MgCl2 
HMM 
buffer 
10 mM MOPS pH 7.2, 0.1 mM EGTA, 3 mM NaN3, 
0.1 mM DTT, 0.1 mM PMSF, 1 mg/l leupeptin 
Elution 
buffer 
10 mM MOPS pH 7.2, 100 mM KCl, 0.1 mM EGTA, 3 mM NaN3, 
0.1 mM DTT, 0.1 mM PMSF, 1 mg/l leupeptin, 0.3 mg/ml Flag peptide 
Dialysis 
buffer 
10 mM MOPS pH 7.2, 100 mM KCl, 0.1 mM EGTA, 
3 mM NaN3, 1 mM DTT 
Table 2.9. Buffers used in myosin purification. 
 
2.4.17 Measurement of Myo5 constructs concentration 
The extinction coefficient of the myosin constructs with 6 calmodulin molecules 
(Table 2.10) obtained from ProtParam was used for calculating protein concentration 
as described (section 2.2.6). Protein concentration is given as concentration of 
heads. 
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Construct 
name 
Extinction 
coefficient 
Myo5-Avi 186,575 M-1 cm-1 
Myo5-cc 192,650 M-1 cm-1 
Myo5-Ad 219,120 M-1 cm-1 
Table 2.10. Extinction coefficients of the Myo5-constructs with 6 calmodulins bound, 
obtained by ProtParam. 
 
2.4.18 Biotinylation of Myo5-Avi 
Biotinylation of the recombinant Myosin-5-Avi construct was carried out using the 
Biotinylation kit from Avidity. Usually 10 µl of 2 µM recombinant myosin-5 was mixed 
with 1.25 µl of Biomix-A buffer (10x stock concentration: 0.5 M bicine buffer pH 8.3) 
and 1.25 µl of Biomix-B buffer (10x stock concentration: 100 mM ATP, 100 mM 
Mg oxaloacetate, 500 µM d-biotin) and 0.2 µl of BirA biotin ligase enzyme (stock 
concentration: 3 mg/ml). All solutions and the enzyme were included in the kit from 
Avidity. The mixture was incubated at 30 °C for 45 minutes or on ice for 16-18 hours. 
As the biotinylation reaction by BirA is specific to Avi-tag sequences 
(GLNDIFEAQKIEWHE), the reaction is expected to stop when all the available 
Avi-tag sequences are biotinylated. Biotinylation was checked by Western blotting 
using an anti-biotin antibody (section 2.2.8) and also by mass spectrometry as 
described below (section 2.4.19). Biotinylated myosin-5 construct was either used in 
experiments after biotinylation or stored at -80 °C as described (section 2.4.16). 
 
2.4.19 Mass spectrometry of Myo5-Avi and actin 
Biotinylated and non-biotinylated myosin-5a constructs and actin samples were 
analysed with reverse phase HPLC linked to a mass spectrometer as described 
(Taggart et al., 2000; Liu et al., 2014). 2-3 µl of a ~1 mg/ml protein was introduced 
into the HPLC. The initial solvent was 0.05% trifluoroacetic acid with gradient elution 
by acetonitrile, 0.05% trifluoroacetic acid increasing at 2% v/v per minute with a flow 
rate of 0.2 ml/min. The fractionated protein samples were then introduced into the 
mass spectrometer. Positive-ion electrospray ionisation mass spectra of the samples 
were obtained with an Agilent 6224 mass spectrometer equipped with an ion 
electrospray ionisation interface and a time-of-flight mass detector. Mass spectra 
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were analyzed and deconvolved using the MassHunter software (Agilent). 
The non-biotinylated and biotinylated actin samples contained only one peak 
analysed by HPLC. The non-biotinylated and biotinylated myosin samples contained 
more peaks analysed by the HPLC, but only one of those contained the full length 
myosin construct. Mass spectrometry and data analysis were carried out with the 
help of Dr. Duck-Yeon Lee (director of Biochemistry Core NHLBI, NIH). 
 
2.5 Adhiron techniques 
2.5.1 Phage ELISA 
Phage ELISA was performed by Dr. Christian Tiede as described (Tiede et al., 2014) 
to check if there were any potential binders. Streptavidin-coated plates were first 
blocked with casein blocking buffer (Sigma-Aldrich®), and then biotinylated actin was 
bound to the wells. After that growth medium, containing cells, helper phage and 
Adhiron phage, were added to the wells. After washing, bound phage was detected 
using an HRP-linked anti-phage antibody (Seramun). The antibodies, and thus the 
phage bound to actin, were visualised by adding 3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate to the wells and absorbance was measured at 620 nm after 
2 minutes of incubation. Phage which binds to actin will not be washed away during 
the washing step and therefore will be recognised by the antibody and thus, by the 
absorbance of the TMB substrate. Controls were also performed in a similar way as 
described, but without adding biotinylated actin to check if there is any non-specific 
binding of the phage in this experimental setup. 
 
2.5.2 Cloning of Adhirons 
The screen resulted in the isolation of four potential actin-binding Adhirons, and the 
DNA encoding these Adhirons was provided to us in a phagemid vector between the 
Nhe I and Pst I restriction sites (Figure 2.6) by Dr. Christian Tiede. These were 
named Adhiron2, Adhiron6, Adhiron14 and Adhiron24 according to their location on 
the 24-well plate. 
First, the cDNA sequence for each Adhiron was subcloned from the phagemid into a 
pET11a vector (provided by Dr Christian Tiede) using the Nhe I and Not I restriction 
sites. This introduces a C-terminal His-tag to allow Ni-NTA resin affinity purification 
of the expressed protein. In addition, another subcloning step was performed for all 
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four Adhirons to generate a second expression construct for each one, in which 
there was a Cys at the end of the Adhiron sequence. This single Cys residue can be 
used for biotinylation or other kinds of labelling, and is at the C-terminus preceding 
the His-tag. 
 
 
Figure 2.6. pBSTG1 phagemid vector containing the coding region for Adhiron. 
Figure was taken from (Tiede et al., 2014). 
 
To achieve this, the pET11a plasmid was digested with Nhe I and Not I enzymes 
(section 2.2.2). After digestion, Antarctic Phosphatase (to a final concentration of 
50 unit/ml) was added to the digested pET11a DNA in Antarctic Phosphatase 
Reaction Buffer (final concentration: 50 mM Bis-Tris-Propane-HCl pH 6, 1 mM 
MgCl2, 0.1 mM ZnCl2) and the mixture incubated at 37 ºC for 15 minutes. This 
removes 5’ phosphate from the digested linear DNA to prevent self-ligation 
(Sambrook et al., 1989). The reaction was then heat inactivated at 65 ºC for 
5 minutes. The DNA of the plasmid (pET11a) was purified as described (section 
2.2.4). 
Adhiron sequences were PCR amplified (primers in Table 2.11 and PCR as 
described in section 2.2.1). To generate Adhirons with a C-terminal cysteine residue, 
the reverse primer named Cys-Reverse (Table 2.11) was used, to introduce the 
codon for the cysteine residue. An extension time of only 30 s was used, as the 
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coding sequences for the Adhirons are only ~300 bp. The amplified DNA was 
purified, double digested with Nhe I and Not I, and then re-purified. The purified 
vector and insert (Adhiron sequences) were used in a ligation reaction in a total 
volume of 20 µl as shown (Table 2.12). The ligation reaction was incubated at room 
temperature for 16-18 hours, before transforming the ligation mixture into E. coli, 
isolating colonies, and purifying the resulting plasmid DNA, as described (section 
2.2.4). The DNA sequence of the constructs was verified by Sanger sequencing 
(Source BioScience). 
 
Forward 5'-ATGGCTAGCAACTCCCTGGAAATCGAAG-3' 
Reverse 5'-TACCCTAGTGGTGATGATGGTGATGC-3' 
Cys-Reverse 5'-TTACTAATGCGGCCGCACAAGCGTCACCAACCGGTTTG-3' 
Table 2.11. Primers used to amplify the Adhiron constructs. Forward and reverse 
primers were used for non Cys-Adhirons. Forward and Cys-Reverse primers were 
used for Cys-Adhirons. Colour coded background indicates the sequence and the 
restriction sites (Green: Nhe I site, grey: stop codon, magenta: His-tag, light blue: 
Not I site, yellow: Cys). 
 
Reagent Final concentration 
T4 DNA ligase 
buffer 
50 mM Tris-HCl pH 7.5, 10 mM 
MgCl2, 1 mM ATP, 10 mM DTT 
Donor vector 3.75 ng/µl 
Insert 1.25 ng/µl 
T4 DNA ligase 20 unit/µl 
Table 2.12. Concentration of the reagents used in the ligation reaction. 
 
2.5.3 Transformation for Adhiron expression 
After confirming the correct sequence, 100 ng of the plasmids was transformed into 
50 µl BL21-CodonPlus(DE3)-RP E. coli competent cells (Agilent Technologies) for 
expression as described above (section 2.2.5), and colonies grown on LB agar 
plates containing 100 µg/ml ampicillin (KD Medical) to select for cells containing the 
pET11a vector. 
 
68 
 
2.5.4 Expression of Adhirons 
For each Adhiron, a single colony was picked from the agar plate and inoculated into 
5 ml sterile 2YT medium (16 g/l Bacto™ tryptone, 10 g/l Bacto™ yeast extract, 5 g/l 
NaCl, pH 7.0) supplemented with 1% w/v glucose and 100 µg/ml ampicillin. 
The culture was incubated at 37 °C for 16–18 hours while shaking at 230 rpm. Then 
250 ml LB medium (KD Medical) containing also 100 µg/ml ampicillin was inoculated 
with the overnight culture and incubated at 37 °C while shaking at 230 rpm. 
The optical density of the culture at 600 nm wavelength was monitored (to estimate 
cell density) and when it reached 0.7, usually after 2.5–3 hours, the culture was 
induced with a final concentration of 0.1 mM IPTG. Then cells were incubated at 
25 °C for 16–18 hours while shaking at 150 rpm. Cells were harvested using 
centrifugation for 15 minutes at 3500 g and cell pellets were kept at -80 °C until the 
protein purification step. 
 
2.5.5 Adhiron purification 
Cell pellets were resuspended in a 5 ml solution comprising 4.5 ml lysis buffer 
(Table 2.13), 500 µl 10x BugBuster (Novagen) and 5 µl Benzonase (25 unit/µl stock 
concentration, Novagen). Resuspended cells were then incubated at room 
temperature for 30 minutes while shaking. To heat denature the low stability E. coli 
proteins, the samples were incubated at 50 °C for 20 minutes. Adhirons are not 
affected by this step, as they are stable at 50 °C. Then the suspension was 
centrifuged for 20 minutes at 4 °C with 3,000 g and the rest of the purification was 
carried out at room temperature. The supernatant was loaded onto 1–1.5 ml Ni-NTA 
resin in 10 ml chromatography column (Bio-Rad Laboratories), which was already 
equilibrated with wash buffer (Table 2.13). The mixture was incubated for 1 hour with 
occasional shaking and mixing to ensure the resin binds all the Adhiron molecules. 
Then the flow through was collected and the resin was washed with 10–15 ml wash 
buffer, and again the flow through was collected. The resin was incubated for 
15 minutes first with 10 ml elution buffer (Table 2.13), and then the protein was 
eluted, collecting 1 ml fractions. The elute was monitored for its protein content using 
Bradford reagent and usually it showed that there is still protein in the last elution 
fraction, therefore additional 5 ml elution buffer was added to the resin, incubated 
and then eluted. Samples of the supernatant, pellet from centrifugation, flow through 
and wash fraction, along with the elution fractions were run and analyzed by SDS gel 
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electrophoresis. The elution fractions that contained most of the Adhiron, and the 
least contamination with other proteins, were combined. These fractions, usually 
10–13 ml, were then dialyzed using 7 kDa cut-off dialysis cassettes (Thermo 
Scientific) against 3–4 litres buffer comprising PBS (Quality Biological™) pH 7.4 and 
1 mM DTT for 16–18 hours at 4 °C. Typical concentration of Adhirons and yield of 
the expression varied between 10–170 µM (2–120 mg Adhirons/litre of E. coli cells). 
Purified Adhirons were flash frozen in liquid nitrogen and stored at -80 °C. 
 
Lysis buffer 
50 mM NaH2PO4, 300 mM NaCl, 20 
mM imidazole, 10% glycerol, pH 7.4 
Wash buffer 
50mM NaH2PO4, 500 mM NaCl, 20 
mM imidazole, 10% glycerol, pH 7.4 
Elution buffer 
50mM NaH2PO4, 500 mM NaCl, 300 
mM imidazole, 10% glycerol, pH 7.4 
Table 2.13. Buffers used in Adhiron purification. pH was adjusted to 7.4 by adding 
drops of 1 M HCl solution to the buffer containing all ingredients except glycerol. 
 
2.5.6 Adhiron concentration 
Protein concentration was calculated from the UV absorbance at 280 nm wavelength 
(see section 2.2.6), using the calculated extinction coefficients (Table 2.14). 
Cys-Adhirons have the same extinction coefficient as Cys-free ones. 
 
Adhiron2 18,450 M-1 cm-1 
Adhiron6 26,470 M-1 cm-1 
Adhiron14 26,470 M-1 cm-1 
Adhiron24 18,450 M-1 cm-1 
Table 2.14. Extinction coefficients of Adhirons. 
 
2.5.7 Biotinylation of Adhirons 
Cys-Adhirons can be covalently biotinylated at their cysteine residue using biotin 
maleimide. As this solvent-exposed Cys residue is highly reactive, first any cystine 
was reduced to cysteine, using a tris(2-carboxyethyl)phosphine (TCEP) disulphide 
reducing gel (Thermo Scientific), which was washed twice with equal volume of PBS 
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and centrifuged at 1,000 g for 2 minutes before adding to the Adhirons. Equal 
volumes of TCEP resin and Adhirons (still in elution buffer) were mixed and 
incubated at room temperature for 1 hour while rocking. The mixture was then 
centrifuged at 1,000 g for 2 minutes and the supernatant was mixed with 0.5 mM 
biotin-maleimide (50 mM stock concentration, dissolved in DMSO) and incubated on 
ice for 4 hours. Biotinylated Adhirons were then dialysed as described (section 
2.5.5). Biotinylation of the Adhirons were done by Dr. Christian Tiede. 
 
2.5.8 Actin spin down assay 
Various actin spin down assays were performed with Adhirons to study their binding 
affinities and possible binding sites on F-actin. To determine the dissociation 
constant of the Adhirons to F-actin, stock F-actin (prepared as described in section 
2.3.4) and Adhiron solutions were mixed and adjusted to a final volume of 200 µl, 
that contained 2.5 µM actin and 1-10 µM Adhiron in a buffer comprising 25 mM 
MOPS pH 7.0, 50 mM KCl, 2 mM MgCl2, and 1 mM DTT. After mixing the 
components, the mixture was incubated at room temperature for 30 minutes, and 
then centrifuged at 4 ºC for 1 hour at 110,000 g using a TLA100 fixed angle rotor. 
Samples from both the supernatant and the pellet were mixed with Laemlli buffer 
(as described in section 2.2.7). 50 µl supernatant was mixed with 50 µl 2x Laemlli 
buffer. The pellet was dissolved in 200 µl boiling hot 1x Laemlli buffer. 50 µl of this 
solution was further mixed with 50 µl 1x Laemlli buffer. Equal volumes of the 
supernatant and the pellet were loaded into separate wells of two, 10-well 4-12% 
gradient NuPAGE® Bis-Tris pre-cast SDS PAGE gels, and subjected to gel 
electrophoresis together in the same tank. Three independent sets of binding assays 
were run for each Adhiron and average of the three measurements with the standard 
deviation were plotted against the concentration. 
 
Additional experiments were performed to determine if Adhirons bind to the same 
binding site (Adhiron competition assay), or to the same binding site as the motor of 
myosin (myosin competition assay) on actin. In the Adhiron competition assay, stock 
F-actin, AdhironA and AdhironB were mixed to have a final concentration of 2.5 µM 
for all. All Adhirons have the same molecular weight, thus they are indistinguishable 
on an SDS gel. By using equimolar F-actin and Adhirons at concentrations well 
above the Kd, the sites on F-actin for each Adhiron will be nearly saturated. 
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In mixtures containing pairs of Adhirons, if the Adhirons do not compete, almost all 
the added Adhirons will pellet with the F-actin, with little in the supernatant. If they do 
compete, the amount in the pellet will be very similar to as with one Adhiron, and the 
rest will be in the supernatant. 
 
In the myosin competition assay, stock F-actin, Adhiron and Mus musculus 
myosin-5a subfragment 1 (S1) were mixed to have a final concentration of 2.5 µM 
F-actin, 2.5 µM Adhiron and 0.2-2.5 µM S1. The S1 prep, which consists of the 
motor domain and the 6 IQ motif lever, was made previously in Dr. Sellers’ 
laboratory (Wang, Chen, et al., 2000) and the extinction coefficient of S1 with 
6 calmodulin molecules (141,420 M-1 cm-1) was used for calculating protein 
concentration. After mixing, the samples were centrifuged as described for the 
Adhiron-actin binding assay. 
 
To determine binding, the gel was stained and imaged as described (section 2.2.7). 
When two gels were used to analyse all data points, the images were combined and 
the intensity of the bands were determined using ImageJ. Boxes were drawn around 
the band of interest so that the whole band fits in it and the additional intensity of the 
band compared to the background was calculated. F-actin and everything that is 
bound to it, pellet during the centrifugation. As the pellet is transparent and only 
approximately 2 mm in size on the bottom of the 200 µl tube, it is challenging to fully 
recover it. Therefore samples loaded into the wells of the SDS gel will vary in the 
amount of actin they have, even though actin amount was kept equal in all assays. 
To account for the variation in recovery of the pellet, Adhiron band intensities were 
normalised according to the variation in the actin band intensities. Intensities of actin 
in the pellet were determined and lower intensities were multiplied to have equal 
intensity for all lanes. The same multiplication was performed for Adhiron (and S1) 
pellet intensities. The intensities in the supernatant were not affected. Adhiron 
(and S1) band intensity was determined in the pellet and in the supernatant and the 
bound Adhiron (and S1) concentration was calculated for each data point using the 
following equation: 
 
𝐵𝐵𝐵𝐵𝐵 𝐴𝐵ℎ𝑖𝑖𝐵𝐵 = 𝑇𝐵𝑇𝑇𝜀 𝐴𝐵ℎ𝑖𝑖𝐵𝐵 ∗ 𝑃𝑃𝜀𝜀𝑃𝑇 𝑖𝐵𝑇𝑃𝐵𝑖𝑖𝑇𝑖(𝑃𝑃𝜀𝜀𝑃𝑇 𝑖𝐵𝑇𝑃𝐵𝑖𝑖𝑇𝑖 + 𝑆𝐵𝑆𝑃𝑖𝐵𝑇𝑇𝑇𝐵𝑇 𝑖𝐵𝑇𝑃𝐵𝑖𝑖𝑇𝑖) 
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Bound Adhiron concentrations were plotted as a function of the total Adhiron 
concentration and the following quadratic equation (Pollard, 2010) was fitted to the 
data points to determine the dissociation constant: 
 
𝑖 = (𝜀 + 𝑥 + 𝐾) − �(𝜀 + 𝑥 + 𝐾)2 − 4𝜀𝑥 2  
where x is the total Adhiron concentration, and y is the bound Adhiron concentration, 
c is the total F-actin concentration and K is the dissociation constant (Kd). 
Parameters c and K were allowed to float during the fitting. 
 
2.5.9 Generation of GFP-tagged Adhirons 
The Adhiron sequences were subcloned into the pEGFP-C1 mammalian expression 
vector (Clontech) using the method described (section 2.5.2). Using PCR, the 
Adhiron sequences were amplified without the His-tag and Cys using the primers 
shown (Table 2.15). The cDNA were inserted into the EcoR I and BamH I restriction 
sites, placing the sequence downstream of that for eGFP (Figure 2.7). After ligation, 
the mixture was transformed as described (section 2.2.5), and cells plated onto LB 
agar plates containing 30 µg/ml kanamycin (KD Medical) to select for cells containing 
the pEGFP-C1 vector. The sequence of the constructs was verified by DNA 
sequencing at Eurofins Genomics (see S1 supplementary materials). 
Plasmids with the correct sequences in the pEGFP-C1 vector were amplified and 
purified to provide a high enough concentration and quality DNA for transfection of 
mammalian cells, using the Plasmid Maxiprep Kit (QIAGEN®) according to the 
manufacturer’s protocol. 
 
Forward 5'- GAATTCTGCTAGCAACTCCCTGGAAATCGAAG -3' 
Reverse 5'- GGATCCCGCAGCGTCACCAACCGG -3' 
Table 2.15. Primers used to amplify the Adhiron constructs to subclone them into 
pEGFP-C1 vector. Colour coded background indicates the restriction sites (Yellow: 
EcoR I site, green: BamH I site). 
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Figure 2.7. Map and restriction sites of pEGFP-C1 plasmid. The DNA coding for the 
Adhiron was cloned between the EcoR I and BamH I restriction sites in the multiple 
cloning site (MCS) of the vector. Details of the restriction sites of the MCS are also 
shown. Figure is taken from the Addgene website. 
 
2.5.10 Cell culture experiments with Adhirons 
HeLa cells were obtained from ATCC. They were cultured in DMEM + GlutaMAX™-I 
medium (Thermo Fisher Scientific) supplemented with 100 unit/ml penicillin, 
100 µg/ml streptomycin and 10% v/v FBS. Cells were grown as adherent cell culture 
at 37 ºC and 5% CO2. To passage the cells usually after 3 days, when confluency 
reached approximately 75%, the growth medium was removed from the cells and 
replaced with 1 ml TrypLE Express (Thermo Fisher Scientific) and incubated for 
3 minutes to dissociate the cells. Cells were monitored with a light microscope to 
check if they are rounding up and detaching from the surface. When this was 
complete, 9 ml medium was added and the cells were centrifuged at 1,000 g for 5 
minutes. The pelleted cells were resuspended to a density of 104 cells/ml in fresh 
medium. To freeze cells for long term storage, the cells were centrifuged and 
resuspended in medium containing 10% v/v DMSO up to a density of 106 cells/ml. 
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They were aliquoted in 2 ml cryo-tubes that were placed in the -80 º C freezer and 
after 3 days were transferred into the liquid nitrogen storage. 
For imaging, cells were plated onto 13 mm diameter glass coverslips, that were 
cleaned by washing with hydrochloric acid, rinsing with H2O ten times and then with 
70% v/v ethanol. They were allowed to dry in the tissue culture hood and then placed 
one in each well of a 6-well plate. To prepare the cells for transfection with 
eGFP-tagged Adhirons, HeLa cells were passaged as described above and cells 
were diluted to a density of 105 cells/ml. 300 µl of the cell suspension was added to 
cleaned coverslips, and incubated at room temperature for 3 minutes. Then 2 ml of 
growth medium was added to the wells and the plate was incubated at 37 ºC and 5% 
CO2 for 24 hours. 
To transfect the cells 3 µl room temperature FuGENE® HD Transfection Reagent 
(Promega) was added to 97 µl DMEM and the mixture was incubated at room 
temperature for 5 minutes. Then 2 µg high quality (as described in section 2.5.9) 
DNA was added to the mixture and incubated at room temperature for 15 minutes. 
Finally, this mixture was pipetted onto the cells and the plate was incubated at 37 ºC 
and 5% v/v CO2 for 1-2 days before fixing and staining the cells. 
To fix the cells, the growth medium was aspirated from the wells and replaced with 
1 ml of 4% w/v paraformaldehyde (dissolved in PBS) at room temperature. After 
15 minutes incubation at room temperature, this solution was removed and the cells 
were washed 3x with 2 ml PBS. 1 ml of PBS was left in each well, the plates were 
sealed with Parafilm and the cells were stored at 4 ºC before staining. 
To stain the cells, the coverslips were removed from the 6-well plate and PBS + 
0.2% v/v Triton™ X-100 was added to permeabilise the cells. Alexa Fluor® 546 
labelled phalloidin and DAPI (both from Thermo Fisher Scientific) were diluted to  
66 nM and 2 µg/ml in PBS, respectively. 100 µl of this staining solution was pipetted 
onto the coverslips and allowed to incubate for 20 minutes at room temperature. 
Then the coverslip was washed 3x with PBS + 0.2% v/v Triton™ X-100 and then 3x 
with PBS. 3 µl ProLong® Diamond Antifade Mountant (Molecular Probes™) was 
pipetted onto a slide and the coverslip inverted onto the slide. The slide was 
incubated at room temperature for 1 hour to allow the mountant to set before 
imaging. Prepared slides were imaged using the DeltaVision deconvolution 
microscope. Cell culture experiments and imaging were performed with the help of 
Prof. Michelle Peckham. 
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To determine if any of the Adhirons bind to actin in non-transfected HeLa cells, 
biotinylated Cys-Adhirons were used. Cys-Adhirons were biotinylated as described 
(section 2.5.7). Fixed cells on 13 mm diameter glass coverslips were permeabilised 
with PBS containing 0.2% v/v Triton™ X-100 for 5 minutes. The Adhirons were 
diluted to 5 mg/ml in PBS, added to the cells, and incubated for 1 hour. The 
coverslips were washed 5x in PBS, and then Alexa Fluor® 647 labelled streptavidin 
in PBS, together with Alexa Fluor® 488 labelled phalloidin (1/50 dilution), and DAPI 
(1/500 dilution) was added and incubated for another hour. Coverslips were washed, 
mounted onto glass slides using Prolong antifade, and imaged with the DeltaVision 
deconvolution microscope.  
 
2.6 Assays of interaction between myosin and actin 
2.6.1 ATPase activity assay 
Actin-activated steady-state MgATPase activity of myosin-5 was measured using a 
continuous NADH-coupled assay (Figure 2.8). Usually 30 nM myosin-5 was mixed 
with a buffer comprising 20 mM MOPS pH 7.0, 3 mM MgCl2, 50 mM KCl, 1 mM DTT, 
0.05 mM EGTA, 40 units/ml lactate dehydrogenase, 200 units/ml pyruvate kinase, 
200 µM NADH, 1 mM PEP and 1 mM ATP in a total volume of 200 µl. To measure 
maximal velocity (Vmax) of the ATPase reaction, saturating concentrations (20 µM) of 
F-actin were used. The measurement was started by adding ATP to the reaction 
mixture. Oxidation of NADH, which indirectly shows the rate of the ATPase reaction, 
was measured by following the fall in absorbance at a wavelength of 340 nm using a 
Cary Spectrophotometer. The experiments were carried out at 25 °C. Since ADP 
produced by ATP hydrolysis is converted back to ATP by the pyruvate kinase, 
product inhibition by ADP will not occur. 
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Figure 2.8. Reactions in the NADH-coupled ATPase assay. Abbreviations are the 
following, PEP: phospho(enol)pyruvate, PYR: pyruvate, LAC: lactate. 
 
2.6.1.1 ATPase activity of Myo5-Avi 
ATPase activity assays were performed using 30 nM myosin-5 and 20 µM F-actin as 
described (section 2.6.1). Both biotinylated and non-biotinylated actin and myosin 
were used. Biotinylated myosin was kept in the biotinylation buffer, non-biotinylated 
myosin was kept in the dialysis buffer and 2.5-3 µl of the concentrated protein stock 
was added to 200 µl of reaction mix. To make up biotinylated F-actin, a mixture of 
actin monomers of which 5% were biotinylated (Cytoskeleton) were mixed and 
allowed to polymerise as described (section 2.3.4).  
Activities were corrected for the ATPase of Myo5-Avi (both biotinylated and 
non-biotinylated) measured in the absence of F-actin and also for the ATPase 
activity of F-actin (both biotinylated and non-biotinylated) measured in the absence 
of myosin. To test the effect of NeutrAvidin, the reaction was started with Myo5-Avi 
and F-actin. After obtaining a stable slope corresponding to constant ATPase rate, 
5 µl of 80 µM NeutrAvidin (Thermo Fisher Scientific, dissolved in H2O) was mixed 
into the 200 µl reaction mixture to obtain a final concentration of 2 µM. NeutrAvidin 
concentration is given in tetramers. 
 
2.6.1.2 Adhirons in the ATPase activity assay 
To determine the effect of the Adhirons on actin-activated MgATPase activity of 
Mus musculus myosin-5 S1, ATPase activity assays were performed as described 
(section 2.6.1). Stock F-actin, S1 and Adhiron were mixed to have a final 
concentration of 30 nM S1 and 1-40 µM Adhirons in a buffer containing 25 mM KCl 
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and all the additional components (section 2.6.1). A lower concentration of F-actin 
(4 µM, as compared to 20 µM) was used so that not all myosin heads will be bound 
to F-actin. At this actin concentration, ATPase activity will depend on the available 
concentration of actin in a quasilinear manner (Wang, Chen, et al., 2000). This way if 
Adhirons occupy the binding site of the myosin motor on F-actin, the observed 
reduction in ATPase activity would reflect the reduction of concentration of available 
actin. Three experiments were performed, and the data were averaged. The 
measured activities were corrected for S1 activity measured without F-actin. 
 
2.6.2 Motility assay 
The movement of myosin-5 on F-actin was visualised using total internal reflection 
fluorescence (TIRF) microscopy. Alexa Fluor® 647 labelled biotinylated F-actin was 
attached to the coverslip and the translocation of GFP-tagged myosin was tracked at 
room temperature (~23 °C) by imaging it using the green channel (emission 
wavelength of 488 nm) on the Nikon® Eclipse Ti microscope. The position of the 
F-actin filaments was imaged in the far-red channel (emission wavelength of 
640 nm). 100x oil TIRF objective was used, with a numerical aperture of 1.49 
(Nikon®). 
Biotinylated F-actin, where 20% of the monomers are biotinylated, was prepared as 
described in section 2.3.4. Alexa Fluor® 647 Phalloidin (Molecular Probes™) was 
dissolved in methanol and added to biotinylated F-actin (final methanol concentration 
was 5% v/v). The final concentration of the dye was double compared to F-actin to 
ensure full labelling that is important for imaging actin filaments. Labelled F-actin was 
left protected from light on ice for 2 hours before using it. 
To prepare the coverslips (22 x 30 mm), 3 µl of 0.1% w/v nitrocellulose (diluted in 
amyl acetate) was applied onto the surface and allowed to dry for 15 minutes at 
room temperature. To prepare the flow chamber, double-sided adhesive tape was 
attached to the long edges of a microscope slide and then coverslip was attached to 
the slide onto the tape, with the treated side facing down. The volume of the flow 
chamber was 20-30 µl as the channel between the tapes is 7-10 mm wide. Next, 
30 µl biotinylated BSA (1 mg/ml in H2O, Sigma-Aldrich®) was added into the 
chamber, and then incubated at room temperature for 2 minutes. The chamber was 
then washed with 200 µl motility buffer (MB: 20 mM MOPS pH 7.4, 5 mM MgCl2, 
0.1 mM EGTA). Filter paper was applied to suck the liquid from the opposite side of 
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the chamber as to the side where liquid was introduced to the chamber. 50 µl of 
NeutrAvidin (1 mg/ml, 16.7 µM in tetramers, in H2O) was then added into the 
chamber to bind to the biotinylated BSA, and incubated at room temperature for 
2 minutes, before washed again with 200 µl MB. 40 µl of Alexa 647 labelled 
biotinylated F-actin (50 nM in MB) was then added into the chamber to bind to 
NeutrAvidin, incubated for 1 minute at room temperature, then washed with 200 µl 
MB. The surface was then blocked by adding 100 µl BSA (1 mg/ml in MB), 
incubation at room temperature for 2 minutes and then the flow cell was washed with 
100 µl MB. The final myosin-containing mixture (100 µl) comprised 50 mM DTT, 
50 mM KCl, 1 mM ATP, 0.01 mg/ml BSA, 200 unit/ml glucose oxidase 
(Sigma-Aldrich®), 1150 unit/ml catalase (Roche), 20 mM glucose, and 5 nM 
Myo5-Avi in MB. After adding this mixture into the flow chamber, I started to image 
the slide. 
Frame rate was 0.21 sec-1 and pixel size was 0.13 µm/pixel. The software Fiji with 
plugin Trackmate v2.8.1 was used to analyse run length and speed of the single 
molecules (Tinevez et al., 2016). When analysing and identifying the tracks, no gaps 
were allowed, meaning that if a molecule disappeared for a frame and reappeared at 
the same place, it was considered as a separate track. Molecules that were visible 
for less than 4 frames and molecules that translocated less than 3 pixels (0.4 µm) 
from their initial site were omitted to have data only from processive movement 
(Sakamoto et al., 2008). Bin size was set 0.2 for both run length (µm) and for velocity 
(µm/sec). Run length distribution was fitted with a first order exponential decay 
function. Velocity distribution was fitted with a Gaussian function (Hodges et al., 
2007). Mean values show the fitted parameter and error of the fitting. 
 
2.6.2.1 Myo5-Avi motility assay 
To study the effect of NeutrAvidin on Myosin-5 motility, first the assay was set up 
using biotinylated GFP-tagged Myo5-Avi as described in section 2.6.2. After imaging 
the slide for 3 minutes, additional 30 µl of the following solution was introduced into 
the chamber, while being imaged continuously. This solution had the same 
composition as described in section 2.6.2, but it contained additional 16.7 µM 
NeutrAvidin tetramers. This way, myosin movement on the same filaments were 
tracked and additional myosin was added to the chamber to compensate for the 
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molecules that were washed away, when introducing the new mixture into the 
chamber. 
Acquisition time was 3 minutes for control assays and 6 minutes for NeutrAvidin 
assay. Velocity exhibited an unusual distribution after the addition of NeutrAvidin, 
therefore in that case average and standard deviation was calculated. 
 
2.6.2.2 Adhirons in the TIRF assay 
Adhirons were tested for the ability to fix actin to a glass surface and allow myosin 
movement in a TIRF assay. 0.5 or 5 µM Adhirons in motility buffer (MB) were added 
to the glass coverslips in the flow chamber (section 2.6.2), and incubated at room 
temperature for 5 minutes, before washing with 200 µl MB for 1 minute, and then 
adding Alexa Fluor® 647 labelled biotinylated F-actin. The remainder of the assay 
was performed as described (section 2.6.2). 
Anti-His antibodies (6x-His Epitope Tag Antibody, Thermo Fisher Scientific) were 
also tested for their ability to bind Adhirons and thus, actin to the surface. 
As Adhirons have a C-terminal His-tag, they could potentially be attached to the 
surface using these antibodies. 10 µg/ml antibodies were added to the flow chamber, 
then 1 mg/ml BSA (in MB) and then 5 µM Adhirons (in PBS), with wash steps in 
between and further steps as described above and in section 2.6.2. 
Run length distribution could not be fitted with a first order exponential decay 
function, therefore average and standard deviation was calculated. 
 
2.6.3 Negative stain electron microscopy 
First, myosin at a final concentration of 100 nM and 100 µM ATP was added to a 
buffer comprising 12.5 mM MOPS pH 7.2, 2 mM MgCl2, 0.1 mM EGTA and 100 mM 
KCl. Then, F-actin (final concentration of 1 µM, containing 50 nM biotinylated actin) 
was mixed with NeutrAvidin (final concentration of 80 nM). Next the mixture of 
biotinylated myosin (final concentration of 100 nM) and ATP (final concentration of 
1 µM) was added to the solution containing F-actin and NeutrAvidin, all diluted in the 
buffer described above. 30 seconds after mixing, 3 µl of the sample was applied to a 
carbon-filmed 200 mesh copper grid (Ted Pella), which had been UV treated for 
30 minutes prior. 
Grids were UV treated as a broad range of UV light wavelengths and ozone makes 
the surface of the grid more hydrophilic, and thus proteins will attach better to these 
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grids (Burgess et al., 2004). The grids were placed ~3 cm from the lamp 
(low pressure mercury vapour type R51, UV Products) in a cardboard box to retain 
the ozone that is generated in the air by the UV radiation. 
After applying protein to the grids, they were then stained with 1% w/v uranyl acetate 
by adding a few drops of the stain to the protein on the grid, and then blotting the 
excess liquid with filter paper (Whatman® grade 42).  
Micrographs were recorded at nominal magnification of 40,000 on a JEOL 1200EX II 
microscope with an AMT XR-60 CCD camera (2816x2528 pixels). Actual pixel size 
was calibrated by Dr. Neil Billington using the lattice spacing of bovine liver catalase 
crystals (Ted Pella) (Wrigley, 1968) and determined to be 0.46 nm/pixel. 
 
2.7 Data and figure analysis 
Data were plotted and analysed with OriginPro 7.5 (OriginLab Corp.). Figures were 
created using Photoshop CS6 (Adobe Systems Inc.). Microscope images and gel 
images were analysed by ImageJ. Protein structure images were created with Pymol 
(Schrödinger, LLC). T test were carried out using GraphPad (GraphPad Software 
Inc.). 
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3. Characterisation of actin-binding Adhirons 
3.1 Results 
3.1.1 Selection of Adhirons that bind to actin 
The phage ELISA assay showed that several clones bound to actin (Figure 3.1). 
Several wells showed high levels of absorbance, indicating binding of the phage to 
actin. None of the control wells, in which actin was not present, showed high 
absorbance levels and the absorbance for all control wells was less than 0.05. 
Phages with the ID numbers 2, 6, 10, 11, 13, 14, 15, 16, 19 and 24 gave absorbance 
levels of 0.2 or greater for wells containing actin. These clones were sequenced and 
four unique binders were identified. These were Adhiron2, Adhiron6, Adhiron14 and 
Adhiron24 according to their physical location on the 24-well plate. Adhiron2 was 
present in phages ID number 2, 13 and 15 and Adhiron6 in phages ID number 6, 11, 
16 and 19. Phage ID number 10 was not analysed as the sequencing results were of 
low quality for this clone. The amino acid sequence of the four potential actin-binding 
Adhirons is identical except for the two variable loops (Figure 3.2). Cys-Adhirons 
have the additional cysteine residue just preceding the His-tag. 
Amino acid sequence comparisons were performed on the variable loops using the 
BLAST webserver (Altschul et al., 1997) and the protein-protein BLAST algorithm 
with default parameter settings. No clear alignment with any known actin-binding 
domain was recognised. The sequence of loop1 of Adhiron6 and Adhiron14 are 
similar, therefore it is expected that they will have similar properties. No other 
sequence similarity was found in the loops. 
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Figure 3.1. Screening Adhiron clones for actin binding using ELISA. 24 clones were 
tested in wells coated with actin and in wells containing only buffer and absorbance 
of oxidised TMB at 620 nm was recorded. 
 
 
Figure 3.2. Sequence alignment of the actin-binding Adhirons, using the ClustalW 
webserver (Larkin et al., 2007). The amino acids in the variable loops lie between 
residue numbers 39–47 and 73–81, are denoted by the red boxes. 
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3.1.2 Expression and purification of Adhirons 
Adhiron sequences were cloned from the phagemid vector into a pET11a E. coli 
expression vector. All four Adhirons and also their Cys version were expressed and 
then purified using Ni-NTA resin, as they all bear a C-terminal His-tag (section 2.5.5). 
Typically, the purity of the Adhirons in the elution fractions was very high 
(Figure 3.3A). Occasionally (as shown in Figure 3.3A), there is Adhiron in the flow 
through suggesting that the amount of resin used in that purification was not enough 
to bind all of the Adhiron molecules or the resin incubation with the cell lysate was 
not performed appropriately. 
After expressing, purifying and dialysing all four Adhirons, their concentration was 
measured and they were analysed on an SDS gel (Figure 3.3B). This expression 
yielded concentrations of 33, 15, 56 and 39 µM for Adhiron2, 6, 14 and 24, 
respectively. Figure 3.3B shows that the preparations are clean, only Adhiron2 and 
14 contain small amount of contaminants. As expected all Adhirons have the same 
size according to the SDS gel. Band intensities correspond to the measured 
concentrations. 
Cys-Adhirons, which contain a single cysteine residue at the C-terminus of the 
protein, just preceding the His-tag can be specifically biotinylated on this residue. 
As the cysteine residue is solvent-exposed it is prone to oxidisation to cystine that 
dimerises the Cys-Adhirons via a disulphide bond. 
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Figure 3.3. Coomassie-stained SDS-PAGE gels of Cys-Adhiron14 purification steps 
and of the purified Adhirons. A) SDS-PAGE gel shows the steps of Cys-Adhiron14 
purification. Lanes are the following. Marker: BenchMark protein ladder, numbers 
denote molecular mass in kDa corresponding to the bands of the lane. Supernatant: 
taken after centrifuging the cell lysate. Pellet: taken after centrifuging the cell lysate. 
Flow through: taken after incubation with Ni-NTA resin. Wash: flow through taken 
after washing the Ni-NTA resin. Elution fractions: samples taken from each 1 ml 
elution fraction. B) SDS-PAGE gel of all four purified Adhirons. Lanes are the 
following. M: PageRuler Plus pre-stained protein ladder, numbers denote molecular 
mass in kDa corresponding to the bands of the lane. Ad2, Ad6, Ad14 and Ad24 
denote the four different Adhirons. Equal volumes of the purified protein were loaded 
in all wells. Arrows point out the Adhirons. 
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3.1.3 Measuring the binding of Adhirons to actin 
Phage ELISA results indicated that Adhiron2, 6, 14 and 24 bind to actin, however 
this has to be validated by direct measurement of the binding. As F-actin is a viscous 
polymer, standard biophysical methods for determining the binding constant 
(e.g. isothermal titration calorimetry), are not applicable. However, as the molecular 
weight of the F-actin polymer is high, it sediments in the ultracentrifuge, whereas 
Adhirons do not (Figure 3.4). Thus, we can exploit this property of actin to distinguish 
between free Adhiron and actin-bound Adhiron (Hertzog and Carlier, 2005). 
 
 
Figure 3.4. Coomassie-stained SDS gels showing results of centrifugation of F-actin 
and Adhirons alone. 2.5 µM concentrations were used for all proteins in the 
centrifugation and then equal volumes were loaded in all wells. Lanes are the 
following. M: BenchMark pre-stained protein ladder, numbers denote molecular 
mass in kDa corresponding to the bands of the lane. P: pellet after centrifugation. 
S: supernatant after centrifugation. Arrows point out actin and the Adhirons. 
 
To be able to quantify the information obtained from the spin down assays, I had to 
make sure that the intensity of the Adhiron bands on SDS gels is linearly related to 
the amount of protein loaded onto the gel in the concentration range used in the 
experiments (Figure 3.5). Band intensities from SDS gels of varying concentrations 
of Adhirons (Figure 3.5A) were quantified with ImageJ and plotted against the 
amount of protein loaded (Figure 3.5B). The data points could be fitted using a linear 
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function, which was only used as an initial check point, not as a calibration curve for 
subsequent assays. 
 
 
Figure 3.5. Calibration of Adhiron amount and band intensity on SDS gels. A) 
Coomassie-stained SDS gel showing increasing concentrations of Adhiron24. Lanes 
are the following. M: BenchMark pre-stained protein ladder, numbers denote 
molecular mass in kDa corresponding to the bands of the lane. 1, 2, 2.5, 5 and 7.5 
denote concentrations of Adhiron24 in µM. Adhiron samples were diluted in 2x 
Laemlli buffer and 30 µl mixture was loaded in each well. B) The intensities of the 
bands from gel A) were plotted versus the amount of protein loaded onto the SDS 
gel. Intensity is in arbitrary units. A linear function was fitted to the data with the 
following parameters: y = 5017x. 
 
SDS-PAGE gel of the Adhiron24 spin down assay shows that the ratio between actin 
in the pellet and in the supernatant did not change due to Adhiron binding, 
suggesting that Adhiron24 does not cause actin depolymerisation (Figure 3.6). 
The amount of Adhiron24 in the pellet appears to saturate, suggesting that the 
conditions used for the binding assay were appropriate. The amount of Adhiron24 in 
the supernatant increases above the saturating concentration, whereas its amount in 
the pellet is unchanged (Figure 3.6). 
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Figure 3.6. Coomassie-stained SDS gels of the result of a spin down assay using 
2.5 µM F-actin and Adhiron24. Lanes are the following. M: BenchMark protein 
ladder, numbers denote molecular mass in kDa corresponding to the bands of the 
lane. P: pellet after centrifugation. S: supernatant after centrifugation. Numbers 
above S and P denote concentration of Adhiron24 in that data point. Samples were 
diluted in 2x Laemlli buffer and 30 µl mixture was loaded in each well. Arrows point 
out actin and the Adhirons. 
 
Binding assays show that Adhiron6, Adhiron14 and Adhiron24 all bind to actin with a 
high affinity (Figure 3.7). Fits to the data points of Adhiron6, 14 and 24 gave values 
for the dissociation constants (Table 3.1) that were all close to 0.3 µM, indicating 
tight binding. In contrast, while Adhiron2 bound to actin, its binding curve did not 
show saturation for the concentration range used in this assay (Figure 3.7) and 
therefore the dissociation constant could not be determined. 
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Figure 3.7. Results of the actin spin down assay measured with all four Adhirons. 
Data points show mean of three independent measurements and error bars indicate 
the standard deviation. Quadratic curves were fitted to Adhiron6, 14 and 24. A linear 
function was fitted to the data points of Adhiron2 that could potentially fit the initial 
range of a quadratic data distribution. 
 
  Kd (µM) 
Adhiron6 0.31 ± 0.17  
Adhiron14 0.30 ± 0.05 
Adhiron24 0.38 ± 0.14  
Table 3.1. Dissociation constants of Adhirons binding to F-actin. Data were obtained 
from fitting the results of the actin spin down assays. Colours represent the same 
colours used in Figure 3.7. Numbers show mean of the fitting and confidence values. 
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3.1.4 Testing competition between Adhirons 
To test if the Adhirons bind to the same or overlapping binding sites on F-actin, 
further spin down assays were performed, using a mixture of two different Adhirons 
to determine if they can both bind, or if they interfere with binding of the second 
Adhiron. A mixture of three different Adhirons was also tested (Figure 3.8). 
 
 
Figure 3.8. Coomassie-stained SDS gel showing the results of one of the 
competition spin down assays performed. 2.5 µM F-actin and equimolar 
concentrations of 2.5 µM Adhirons were used in these experiments. The Adhiron 
concentrations used are well above the Kd, to ensure that the sites on F-actin for 
each Adhiron will be nearly saturated. Three independent sets of assays were 
performed including controls of single Adhiron binding the actin and also a mixture of 
three Adhirons and actin. Lanes are the following. M: BenchMark pre-stained protein 
ladder, numbers denote molecular mass in kDa corresponding to the bands of the 
lane. P: pellet after centrifugation. S: supernatant after centrifugation. Numbers 
above S and P denote the type of Adhiron that was added to the mixture in that data 
point. Samples were diluted in 2x Laemlli buffer and 15 µl mixture was loaded in 
each well. Arrows point out actin and the Adhirons. Band intensities were analysed 
and bound Adhiron concentrations are shown in Table 3.2. 
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Analysing the intensity of the bands for each of the competition assays shows that 
approximately 2.5 µM Adhiron is always found in the pellet for all experiments 
(single, double or triple Adhirons), which would be expected if these Adhirons 
compete for the same binding site (Table 3.2). Some of the values are however 
exceeding 2.5 µM, but are still far from the total Adhiron concentration, which would 
be expected if these Adhirons bind to independent binding sites on actin. These 
results suggest that the binding sites of Adhiron6, 14 and 24 on actin are either 
identical or at least these sites are overlapping. 
 
 
Total Adhiron 
concentration (µM) 
Bound Adhiron 
concentration (µM) 
Ad6 2.5 2.30 ± 0.09 
Ad14 2.5 2.35 ± 0.00 
Ad24 2.5 2.23 ± 0.20 
Ad6+Ad14 5.0 2.45 ± 0.44 
Ad6+Ad24 5.0 2.69 ± 0.54 
Ad14+Ad24 5.0 2.51 ± 0.52 
Ad6+Ad14+Ad24 7.5 3.14 ± 0.03 
Table 3.2. Results of the Adhiron competition spin down assays. Data shows 
average concentration of bound Adhirons with standard deviations. 
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3.1.5 Testing competition between Adhirons and myosin head in binding to 
actin 
To test if any of the Adhirons bind to the same or overlapping regions on actin to that 
of the motor domain of myosin, competition assays were performed using a mixture 
of Adhirons and myosin-5a subfragment 1, which contains the motor and the lever. 
Control experiments showed that under the conditions used, myosin-5a S1 only 
sediments in the presence of actin (Figure 3.9). Myosin-5a S1 binds to actin in the 
absence of ATP with a very high affinity (5 pM (De La Cruz et al., 1999)). Therefore, 
if Adhirons bind to the same site on F-actin, they will be displaced by myosin S1 as 
they bind with weaker affinity. Even though the data are scattered (Figure 3.10), all 
three Adhirons appear to be displaced from actin as the S1 concentration increases. 
This suggests that the binding site of these three Adhirons on actin may overlap with 
that of the motor domain of myosin-5. 
 
 
Figure 3.9. Coomassie-stained SDS gels showing myosin-5 S1 with bound 
calmodulins and the result of centrifugation of myosin-5 S1 alone and myosin-5 S1 
with actin. Myosin-5 S1 only sediments in the presence of actin. Lanes are the 
following. M: BenchMark pre-stained protein ladder, numbers denote molecular 
mass in kDa corresponding to the bands of the lane. P: pellet after centrifugation. 
S: supernatant after centrifugation. Samples were diluted in 2x Laemlli buffer and 
15 µl mixture was loaded in each well. Arrows point out actin, the heavy chain of S1 
and the calmodulin light chain. 
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Figure 3.10. SDS gel of a single experiment for the Adhiron6-S1 competition spin 
down assay and result of all of the experiments. A) Coomassie-stained SDS gel of 
the result of a single experiment for the Adhiron6-S1 competition spin down assay. 
2.5 µM actin was mixed with 2.5 µM Adhiron and increasing concentrations of S1 
(0-1 µM). Lanes are the following. M: BenchMark pre-stained protein ladder, 
numbers denote molecular mass in kDa corresponding to the bands of the lane. 
P: pellet after centrifugation. S: supernatant after centrifugation. Numbers above S 
and P denote concentration of S1 in that data point. Samples were diluted in 2x 
Laemlli buffer and 15 µl mixture was loaded in each well. Arrows point out the heavy 
chain of S1, calmodulin light chain, actin and Adhiron. B) Data points measured with 
Adhiron6 (B), Adhiron14 (C) and Adhiron24 (D) were plotted against total S1 
concentration. Only one set of experiments were carried out due to a limited supply 
of myosin-5 S1. The data points were fitted with a linear function. Deviations from the 
fit are also shown for each Adhiron. 
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3.1.6 Effect of the Adhirons on ATPase activity 
If Adhirons bind to the same site on actin as the motor domain of myosin their 
binding may inhibit myosin actin-activated ATPase activity. To test this, the actin-
activated ATPase activity of myosin-5 S1 was measured at increasing 
concentrations of Adhirons. The data shows that the ATPase activity of myosin-5 S1 
decreases upon addition of Adhiron6, 14 and 24 reducing to zero at equimolar 
concentration of actin and Adhiron (Figure 3.11). However, Adhiron2 has no effect 
on the ATPase activity over this concentration range suggesting that Adhiron2 does 
not bind to the same binding site on actin as the other three Adhirons. 
 
 
Figure 3.11. Results of the ATPase activity assay as a function of Adhiron 
concentration. 30 nM myosin-5a S1, 4 µM F-actin and 1-5 µM Adhirons were mixed 
and ATPase activity was measured. Data show the mean values and standard 
deviation for three measurements.  
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3.1.7 Using Adhirons to bind F-actin to coverslips 
As these Adhirons display binding to actin, they could potentially be used to attach 
actin to a coverslip for the TIRF single molecule in-vitro motility assay. As described 
above in section 1.4.3, the present methods to attach actin to the coverslip, involving 
biotinylated actin or NEM-treated myosin, have their drawbacks. Therefore Adhirons 
could yield an alternative, label-free way to attach actin to the surface. 
All four Adhirons were tested for their ability to bind F-actin to coverslips in in-vitro 
motility assays. After attaching the filaments, myosin-5 was also added to the flow 
chamber to test if Adhirons binding to actin interfere with single molecule myosin-5 
translocation. 
A concentration of 5 µM Adhiron firmly attached F-actin (50 nM) to the coverslip, and 
this was the case for all four Adhirons (Figure 3.12). A lower concentration of 0.5 µM 
Adhiron was however not sufficient to firmly attach the actin filaments as they were 
observed to be wiggling when imaged. Actin filaments that were attached to the 
coverslip surface by Adhiron2 appear shorter, than the actin filaments that were 
attached to the coverslip surface by either Adhiron6 or 14 and 24 (Figure 3.12). 
Alterations in the flow chamber, e.g. different flow speed or imaging the slide at the 
edge could result in the observed differences that are not due to the different nature 
of the binding proteins. 
Next, the ability of Myosin-5-Avi (described in section 1.3.5) to move along F-actin 
was investigated. GFP-tagged myosin-5-Avi was able to move along F-actin only 
when Adhiron2 was used to attach F-actin to the surface. Myosin-5-Avi had a 
characteristic run length of 1.05 ± 0.72 µm (mean ± s.d.) (Figure 3.13A) and the 
particles were observed to move with a velocity of 0.59 µm/sec (Figure 3.13B). 
Interestingly, a large number of immobile Myosin-5-Avi molecules were observed to 
be not co-localised with actin (Figure 3.12). These particles could possibly bind 
either to the surface of the coverslip or to the Adhirons, even though Adhirons were 
raised to bind actin. 
No myosin-5 movement was detected when F-actin was bound to the surface with 
either Adhiron6, 14 or 24, whereas 59 motile events were observed when Adhiron2 
was used. This could be due to the detachment of Adhirons from the surface, and 
rebinding to F-actin at sites that block movement of myosin-5a. Adhiron2 does not 
bind as tight as the other three Adhirons and it might also have a different binding 
site compared to that of the myosin motor domain, thus no inhibition effect is 
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apparent in this case.To try to overcome this problem, anti-His antibodies were first 
applied to the surface, followed by the Adhirons. This should ensure a more effective 
binding of Adhirons to the surface via the antibody, which should bind to the 
Adhirons through their C-terminal His-tag. Adhiron14 and 24 were both tested using 
this approach. However, while this promoted the binding of F-actin, myosin-5 
movement was still not detected. Most probably Adhirons still attach to the coverslip 
surface as they attached to it without the antibodies and then got washed off and 
reattached to actin. 
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Figure 3.12. TIRF microscope images of F-actin attached to the surface using 
Adhirons. Each row shows slides, where one Adhiron (Ad) was used to attach 
F-actin onto nitrocellulose coated coverslips and Myosin-5-Avi was also added to the 
flow chamber. GFP-tagged myosin-5 fluorescence and Alexa 647 phalloidin labelled 
F-actin fluorescence are shown in each row, together with the merged image in 
colour. In the merged image, myosin-5 is shown in green and F-actin is shown in 
red. Scale bar is 10 µm. 
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Figure 3.13. Run length (A) and velocity (B) distribution of Myo5-Avi on actin, when 
actin was fixed to the coverslip using Adhiron2. Run length distribution could not be 
fitted with a first order exponential decay function, therefore mean and standard 
deviation were calculated, yielding characteristic run length of 1.05 ± 0.72 µm. 
Velocity distribution was fitted with a Gaussian function, yielding average speed of 
0.59 ± 0.02 µm/sec, where numbers represent mean of the fitting and confidence 
values. Numbers of the observed molecules were 59. 
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3.1.8 Actin imaging in cells transfected with Adhirons 
GFP-tagged Adhiron constructs were cloned into a mammalian expression vector 
and HeLa cells were transfected. After incubation, they were fixed and co-stained 
with fluorescent phalloidin, which serves as an actin binding control. GFP is at the 
N-terminus of the Adhirons, whereas the target binding loops are in the middle of the 
molecule. Therefore change in the affinity of the Adhirons to actin is not expected 
when GFP-Adhirons are used. 
In four separate experiments 59, 85, 92 and 102 cells were imaged for Adhiron2, 6, 
14 and 24, respectively. GFP-Adhiron6, 14 and 24 localised to F-actin based 
structures, when expressed in the cells, whereas Adhiron2 did not (Figure 3.14). 
GFP-Adhiron6 and 14 both showed good co-localisation with F-actin structures that 
stained positively with fluorescent phalloidin. Analysis of the images using ImageJ 
showed that GFP-Adhiron6 and 14 exhibit 80% and 82% co-localisation with 
phalloidin, respectively. Adhiron6 additionally appeared to localise to vesicular 
structures, which were also co-stained for actin with fluorescent phalloidin. 
Adhiron24 showed a discrete localisation at the ends of actin bundles in structures 
that resemble focal adhesion. As this is only a small fraction of the phalloidin stained 
actin structures, Adhiron24 exhibits only 13% co-localisation with phalloidin. These 
differences in the observed localisation for GFP-Adhirons may reflect differences in 
their binding properties. 
Co-staining of the GFP-Adhiron expressing cells with fluorescent phalloidin, allows 
the assessment of the overall F-actin organisation, and whether it is disturbed by 
expressing the GFP-Adhirons. There did not appear to be any clear differences in 
actin organisation in GFP-Adhiron expressing cells, compared to adjacent 
non-transfected cells. However, it is also possible that the GFP-Adhirons do have 
minor effects on the organisation of F-actin. 
100 
 
 
Figure 3.14. Fluorescent images of HeLa cells transfected with GFP-tagged 
Adhirons. Each row shows HeLa cells that were transfected with one GFP-tagged 
Adhiron (Ad). GFP-Adhiron fluorescence and the staining for F-actin (using 
Alexa 546 phalloidin) are shown in each row, together with the merged image in 
colour. In the merged image, Adhiron staining is shown in green and phalloidin 
staining is shown in red. Arrows point to putative focal adhesions stained by 
Adhiron24. Images were taken using the DeltaVision deconvolution microscope. 
Scale bar is 15 µm. 
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3.1.9 Actin imaging in fixed cells using Adhirons 
Finally, we tested if any of the Adhirons were able to localise to F-actin in fixed cells, 
using biotinylated Adhirons and fluorescent streptavidin. Cells were co-stained with 
fluorescent phalloidin, to visualise the F-actin organisation. 
In two separate experiments 37, 14, 24 and 15 cells were imaged for Adhiron2, 6, 14 
and 24, respectively. In these experiments only Adhiron14 was able to label F-actin 
in HeLa cells (Figure 3.15) and it showed a similar staining pattern with 86% 
co-localisation to fluorescent phalloidin. Adhiron2, 6 and 24 did not localise to 
F-actin. In the example shown here, Adhiron6 appeared to show weak F-actin 
binding, and appeared to be localised to a membrane ruffle (arrows, Figure 3.15).  
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Figure 3.15. Fluorescent images of non-transfected HeLa cells stained with 
Adhirons and phalloidin. Each row shows HeLa cells stained with one fluorescent 
Adhiron (Ad). Biotinylated Adhiron staining (using Alexa 647 streptavidin) and 
staining for F-actin (using Alexa 488 phalloidin) are shown in each row, together with 
the merged image in colour. In the merged image, Adhiron staining is shown in red, 
phalloidin staining is shown in green and DAPI staining is shown in blue. Arrows 
point to membrane ruffle stained by Adhiron6. Images were taken using the 
DeltaVision deconvolution microscope. Scale bar is 5 µm. 
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3.2 Discussion 
Four potential actin-binding molecules were raised with phage display assay, named 
Adhiron2, 6, 14 and 24. These proteins are small and share the same core structure; 
they only differ in their two, 9 residues long variable loops. Adhiron6, 14 and 24 
showed submicromolar dissociation constant to actin and additional experiments 
suggest that they may share the same binding site with the myosin motor domain, as 
all three of these Adhirons inhibited myosin’s actin-activated ATPase activity. 
Adhiron2 showed much weaker binding to F-actin, and did not inhibit the ATPase 
activity. Adhiron2 was the only Adhiron that both bound F-actin to the coverslip 
surface, and allowed myosin-5 to walk along it in in-vitro motility TIRF assays. 
Adhiron14 stained F-actin in fixed, non-transfected HeLa cells. In contrast, GFP-
Adhiron6, 14 and 24 all bind to actin when expressed in HeLa cells, with each 
Adhiron showing a different localisation pattern. 
Adhiron6, 14 and 24 showed tight binding to actin and may share the same binding 
site with the myosin motor domain. One possible explanation is that these actin-
binding Adhirons occupy the potential binding sites on actin and therefore the weak 
initial binding of S1.ADP.Pi complex is inhibited and it cannot progress to Pi release. 
Even though Adhirons were raised to bind to actin, it cannot be ruled out that they 
bind non-specifically to the myosin motor domain, and therefore prevent either 
binding of ATP or binding of the myosin head to actin. This hypothesis however is 
challenging to be tested using ATPase activity assays, as myosin-5a S1 exhibits a 
low ATPase activity in the absence of actin (0.2 sec-1). Moreover, some experiments 
made by other groups at the University of Leeds using other, non-actin binding 
Adhirons suggest that Adhirons dimerise (Dr. Christian Tiede, personal 
communication). If these actin-binding Adhirons dimerise too, they could potentially 
bundle actin. If actin filaments are tightly bundled, binding sites for the myosin head 
sterically will not be available. 
There is an apparent contradiction in the S1-Adhiron competition spin down assay 
and in the actin-activated ATPase assay results as S1 displaced Adhirons off actin in 
the spin down assay, whereas Adhirons inhibited the actin-activated ATPase activity 
of S1. A possible explanation is that S1 has a very high affinity to actin in the 
absence of ATP (i.e. spin down assay conditions), whereas in the presence of the 
nucleotide S1 has a lower affinity to actin (i.e. ATPase assay conditions). Further 
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competition spin down assays, where ATP is also added to the mixture, could prove 
this explanation. 
Adhiron2 could be useful as an alternative method for binding F-actin to coverslips in 
in-vitro motility assays, in which myosin is visualised as it is walking along actin using 
TIRF microscopy. Adhiron2 could serve as a label-free actin attaching method that 
can be produced easily, thus it has advantages over both of the currently used 
methods involving biotinylation or NEM-myosin. It is unclear why Adhiron6, 14 and 
24 inhibit the movement of myosin-5 in TIRF assays, when they are applied to bind 
F-actin to the surface. It is possible that even though Adhirons are attached to the 
surface of the coverslip, they are washed off during the wash steps. After detaching 
from the surface, they might rebind elsewhere to F-actin and therefore block 
myosin-5 binding and movement. While Adhiron2 binds less tightly to F-actin 
compared to the other Adhirons it also does not appear to interfere with the actin-
activated ATPase activity of myosin-5 in solution. Therefore, even if Adhiron2 is 
similarly washed away from the surface in this assay, and rebinds to F-actin, it would 
not be expected to inhibit myosin-5 motility. 
Only Adhiron14 is useful for labelling F-actin in fixed cells, while GFP-Adhiron6, 14 
and 24 showed some localisation to the F-actin cytoskeleton when expressed in 
HeLa cells, although with differences. Adhiron6 appeared to have the least effect on 
actin organisation, with fewer actin bundles observed in transfected cells, compared 
to 14 or 24. Adhiron24 appeared to be excluded from F-actin bundles, and localised 
strongly to structures resembling focal adhesions. This suggests that Adhirons, while 
apparently having similar effects on myosin-5 ATPase activity, exhibit differences in 
their actin binding characteristics in live cells. 
Comparing Adhiron14 to previously described actin binding probes highlights the 
outstanding binding affinity of Adhiron14 to actin. Whereas F-tractin and Lifeact bind 
to F-actin with a Kd of ~2 µM (Schell et al., 2001; Riedl et al., 2008) and the 
CH domain of utrophin with a Kd of ~18 µM (Rybakova and Ervasti, 2005), Adhiron14 
has a Kd of ~0.3 µM in binding to F-actin. Even though the affinity of the GFP-tagged 
Adhirons have not been measured so far, the higher affinity of Adhiron14 compared 
to other actin-binding probes could potentially result in better recognition and 
localisation to F-actin structures. However, localisation of an actin binding probe to 
actin in live cell depends also on the size of the probe and also on the spatial 
availability of the actin filaments and the presence of other actin binding proteins. 
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Higher affinity could potentially result in perturbing the actin assembly or it might 
prevent binding of other actin-binding molecules as it inhibited the actin-activated 
ATPase activity of myosin-5. Further experiments are needed using various cell lines 
to explore if Adhiron14 could serve as a general actin-binding probe. 
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4. Characterisation of recombinant myosin-5 
constructs with actin-binding tail domains 
4.1 Results 
4.1.1 Myosin-5-Avi cloning 
Myosin-5-Avi construct was cloned as described (section 2.4.1). Both digested 
pFastBac and the PCR product of the coding sequence for the first 1,440 amino 
acids of mouse myosin-5a brain isoform were run on an agarose gel to check the 
efficiency of both the digestion and the amplification. The estimated sizes of the PCR 
product and the digested vector are 4.3 kb and 5.5 kb, respectively. Agarose gel 
electrophoresis confirmed the sizes of the vector and PCR product (Figure 4.1A).  
After ligation, an analysis of undigested plasmids purified from selected colonies, run 
on an agarose gel (Figure 4.1B) showed that only one out of ten colonies contained 
an insert. Subsequent sequencing verified that this plasmid has the correct 
sequence expected for Myo5-Avi (Supplementary Materials S2). 
PCR analysis of a bacmid purified from a white colony, obtained from a transposition 
of the Myo5-Avi (section 2.4.6) showed that transposition had been successful 
(Figure 4.1C). The size of the band obtained by PCR using the M13 forward and 
reverse primers was ~7 kb, consistent with the expected size of 7.4 kb (5.1 kb for the 
inserted DNA, plus an additional 2.3 kb from the bacmid backbone). A control PCR 
on a bacmid purified from a blue colony, which is not expected to contain an insert, 
generated a smaller sized band (2.3 kb), as expected (Figure 4.1C).  
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Figure 4.1. Agarose gels showing the steps of Myo5-Avi cloning. Ladder lanes stand 
for GeneRuler 1 kb DNA ladder, numbers denote size in kb corresponding to the 
bands of the lane. A) Result of the PCR amplification and digestion of the donor 
vector. Lanes are the following. PCR product: of amplifying the coding sequence for 
the first 1,440 amino acids of mouse myosin 5a. Digested vector: pFastBac vector, 
containing also the coding sequence of eGFP, digested by Stu I. B) Plasmid samples 
purified from 10 colonies. Lanes are the following. Screened colonies: purified 
pFastBac plasmid from 10 randomly picked colonies, plasmid from colony No. 4 has 
a significantly larger size compared to the other plasmids. Empty pFastBac: donor 
vector that was used for the cloning. C) Result of the M13 PCR amplification. Lanes 
are the following. M5-Avi: PCR product from a bacmid that was purified from a white 
colony. –control: PCR product from a bacmid that was purified from a blue colony. 
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4.1.2 Calmodulin baculovirus 
Western blotting of Sf9 cells infected with CaM baculovirus, together with control 
non-infected cells showed that CaM was successfully expressed from the new CaM 
virus (Figure 4.2). Anti-calmodulin antibody recognised a single band, with an 
approximate molecular weight of 17 kDa, in the cell lysate of infected cells, and in 
the positive control containing purified CaM protein. No band was detected for CaM 
in the lysate of control, uninfected cells. 
 
 
Figure 4.2. Anti-calmodulin Western blot of Sf9 cell lysate infected with calmodulin 
baculovirus and appropriate controls. Lanes are the following. Marker: PageRuler 
Plus pre-stained protein ladder, numbers denote size in kDa corresponding to the 
bands of the lane. – control cells: cell lysate of non-infected Sf9 cells. CaM cells: cell 
lysate of Sf9 cells infected with calmodulin baculovirus. + control CaM: 5 µM purified 
calmodulin protein. 20 µl was loaded to the wells from all three samples. 
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4.1.3 Myosin-5-Avi expression trials 
Myosin-5-Avi was co-expressed with calmodulin light chain in Sf9 insect cells and 
protein expression was followed by monitoring GFP fluorescence in Sf9 cells using 
fluorescence microscopy. Cells were harvested after 2-3 days, when 70-80% of the 
cells showed GFP fluorescence. Cell pellets were extracted and myosin-5 was 
purified on a Flag affinity resin.  
Myo5-Avi was successfully purified from the first protein expression trial run. A band 
of the expected molecular mass for Myo5-Avi was observed on an SDS-PAGE gel in 
each of the elution fractions (200 kDa; Figure 4.3A) together with a band of the 
expected size for calmodulin (17 kDa, Figure 4.3A). Two bands of the same size are 
also found in the purified, concentrated sample (Figure 4.3B). However, additional 
bands can also be observed.  
The protein yield for this purification was relatively low. The average yield was 
38 µg protein/litre of Sf9 cells from 5 expression runs. This value was calculated from 
measurements of absorbance at 280 nm, using the extinction coefficient for the full 
length construct with 6 calmodulins (Table 2.10). The additional bands observed in 
the concentrated protein sample suggest that the real protein yield may be even 
lower.  
Several expression and purification trials were carried out to improve the levels of 
expression and reduce the levels of additional bands, but without much success. 
Six calmodulin light chains bind to the lever of myosin-5a and therefore it is important 
to have enough calmodulin baculovirus during expression. As calmodulin is smaller 
than myosin-5a, it is expressed faster and thus, usually an identical MOI of myosin 
and calmodulin baculoviruses ensures that enough calmodulin is expressed. 
However, the exact myosin:calmodulin molecular ratio could potentially be assessed 
by densitometry using purified calmodulin as calibration or by mass spectrometry. 
I suspected that there could be an issue with the pFastBac plasmid used in cloning, 
as this DNA stock has been amplified, digested and cloned multiple times in the past 
it might have acquired mutations in the pFastBac backbone. Therefore I decided to 
re-clone the construct into a fresh pFastBac plasmid. 
  
110 
 
 
Figure 4.3. Coomassie-stained SDS-PAGE gels of Myosin-5-Avi purification. 
A) SDS-PAGE gel shows the steps of Myosin-5-Avi purification. Lanes are the 
following. Marker: BenchMark pre-stained protein ladder, numbers denote molecular 
mass in kDa corresponding to the bands of the lane. Total: cell lysate taken after 
extraction and sonication of the cell pellet and before centrifugation. Supernatant: 
taken after centrifuging the cell lysate. Flow through: supernatant taken after 
incubation with Flag resin. Wash: supernatant taken after washing the Flag resin. 
Elution fractions: samples taken from each 1 ml elution fraction. B) SDS-PAGE gel of 
the concentrated eluted sample. Arrows point out the full length construct and the 
calmodulin light chain. 
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4.1.4 Re-cloning the Myosin-5-Avi construct 
To overcome the problem of the poor expression yield, the Myosin-5-Avi construct 
was re-cloned into a fresh pFastBac plasmid as described (section 2.4.2). The PCR 
product of the coding sequence for the 1,721 amino acids of the entire construct was 
run on an agarose gel to check the efficiency of the amplification, and the size of the 
DNA generated. The PCR product was ~5 kb, consistent with the expected size of 
5.1 kb (Figure 4.4A). 
After cloning the PCR product into the backbone vector, 4 out of 6 colonies picked 
showed an increased size when analysed by agarose gel electrophoresis, 
suggesting that the PCR product had been successfully cloned into each of these 
plasmids (Figure 4.4B). Sequencing verified that colonies No. 3 and 4 contained 
inserts with the correct sequence. Successful transposition for plasmid No. 4 was 
verified by PCR amplification (Figure 4.4C), as described before. 
 
 
Figure 4.4. Agarose gels showing the steps of Myo5-Avi re-cloning. Ladder lanes 
stand for GeneRuler 1 kb DNA ladder, numbers denote size in kb corresponding to 
the bands of the lane. A) Result of the PCR amplification. Lanes are the following. 
PCR product: of amplifying the 1,721 amino acids of the entire construct. B) Plasmid 
samples purified from 6 colonies. Lanes are the following. Screened colonies: 
purified pFastBac plasmid from 6 randomly picked colonies, plasmid from colonies 
No. 1, 3, 4 and 6 have a significantly larger size compared to the other plasmids. 
C) Result of the M13 PCR amplification. Lanes are the following. M5-Avi: PCR 
product from bacmids that were purified from white colonies.  
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Expression using amplified virus from this new construct showed that higher levels of 
protein were produced than for the original construct (Figure 4.5A-B). The yields 
from two expression trials were 148 and 258 µg protein/litre of Sf9 cells. As the 
purified protein contained additional bands, the actual protein yield for the full length 
protein is likely to be lower than 203 µg protein/litre of Sf9 cells. In particular, there 
was a prominent band with an approximate size of 110 kDa. The protein preparation 
was purified on a Flag affinity column as it bears a Flag tag at the C-terminus, 
suggesting that this degraded construct had a cleavage at the motor domain and 
contains the coiled-coil tail. 
Co-expression of chaperones as reported (Bird et al., 2014) with the Myosin-5-Avi 
improved the expression yield still further. Unc45b together with Hsp90 were 
co-expressed at MOI of 5 with Myosin-5-Avi and calmodulin and protein was purified 
on Flag resin (Figure 4.5C-D). The level of purified Myosin-5-Avi was significantly 
higher than in the previous expression trials with the yields of 3.36 and 3.78 mg 
protein/litre of Sf9 cells from two expression runs. 
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Figure 4.5. Coomassie-stained SDS-PAGE gels showing the purification steps and 
concentrated eluted Myosin-5-Avi samples, that were expressed without (A and B) or 
with (C and D) Unc45b and Hsp90 chaperones. Lanes are the following. Marker: 
BenchMark pre-stained (A to C) and BenchMark unstained (D) protein ladders were 
used as marker, numbers denote size in kDa corresponding to the bands of the 
lanes. Total: cell lysate taken after extraction and sonication of the cell pellet and 
before centrifugation. Supernatant: taken after centrifuging the cell lysate. Pellet: 
taken after centrifuging the cell lysate and resuspending the pellet. Flow through: 
supernatant taken after incubation with Flag resin. Wash: supernatant taken after 
washing the Flag resin. Elution fractions: samples taken from each 1 ml elution 
fraction. Arrows indicate the full length construct and the calmodulin light chain. 
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4.1.5 Identifying the additional bands in the Myosin-5-Avi preparation 
While co-expressing chaperones with the myosin-5a construct markedly increased 
the yield, there were still additional bands on the SDS gel of the purified protein 
preparation. To identify these bands, Western blotting was performed using anti-
GFP, anti-Myo5a and anti-Flag antibodies (Figure 4.6). The anti-Myo5a antibody was 
raised against the amino acids 981-1070 of the human myosin-5a, which correspond 
to the same residue number in mouse myosin-5a, which is located at the first coiled-
coil section of the tail. 
The band with a molecular weight of approximately 200 kDa was recognised by all 
the antibodies, suggesting that this band is the full length construct as GFP is at the 
N-terminus, the Flag tag is at the C-terminus and the anti-Myo5a antibody 
recognises a region in the middle of the protein. 
The anti-Myo5a antibody also recognised a band with a molecular weight of 
~90 kDa. This band was apparently not recognised by either the anti-GFP or anti-
Flag antibody. However, the band for the full length construct on the anti-GFP blot 
was faint, and given the lower intensity of this band on the SDS gel, its levels may 
have been too low to have been detected by the anti-GFP antibody. The lack of 
reactivity with the anti-Flag antibody suggests that this band may contain a degraded 
construct that does not contain GFP, nor part of the tail, including the Flag tag. 
The third prominent band of approximately 70 kDa was only recognised by the 
anti-Flag antibody, suggesting this degraded protein no longer contains GFP, or the 
epitope recognised by the anti-Myo5a antibody (e.g. residues up to aa1070, wild 
type numbering). However, its size is larger than expected if this were the case. 
Two more bands approximately 55 and 30 kDa were recognised by the anti-Flag 
antibody that could correspond to tail fragments having cleavage at the first coiled-
coil section or at the distal section, respectively. This also suggests that the 55 kDa 
protein could have been recognised by the anti-Myo5a antibody too. However that 
blot is also faint and according to the SDS gel, the intensity of this band is much 
lower compared to the full-length construct, thus this band could have been 
recognised by the anti-Myo5a antibody, but is not visible on the blot. 
Note that the 198 and 98 kDa markers run slower on both the SDS gel and the blot 
(Figure 4.6) compared to the heavy chain of myosin-5 and to the first additional band 
seen on the gel that were identified to be approximately 200 and 110 kDa in the 
previous gels (Figure 4.5), respectively. In this case SeeBlue Plus2 protein ladder 
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was used that was expected to run at the appropriate speed. Reason for this 
anomaly is not known, however this means that exact size of the bands seen in the 
myosin-5 sample are uncertain. 
In summary the additional bands seen on the expression gels (Figure 4.6) are most 
probably degradation products of the Myosin-5-Avi construct, however results of the 
Western blots are inconclusive. 
 
 
Figure 4.6. Coomassie-stained SDS gel (A) and Western blots (B) showing the 
Myosin-5-Avi protein preparation. Marker lane shows SeeBlue Plus2 pre-stained 
protein ladder, numbers denote size in kDa corresponding to the bands of the lane. 
Equal volumes of Myosin-5-Avi were loaded to all wells. C) Schematic representation 
of Myosin-5-Avi. Labelling is the following. GFP: enhanced GFP; Motor: motor 
domain of myosin-5a; IQ: lever with the 6 IQ motifs; CC: 175 amino acids long 
coiled-coil; CC & loops: 350 amino acids long tail domain that contains predicted 
coiled-coil and loops.  
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4.1.6 Myosin-5-cc cloning 
Myosin-5-cc construct was cloned as described in section 2.4.3. Both digested 
pFastBac containing the Myosin-5-Avi sequence and the PCR product of the coding 
sequence for the 175 amino acids of coiled-coil were run on an agarose gel to check 
the efficiency of both the digestion and the amplification. Estimated size of the 
digested vector and the PCR product are 9.8 kb and 0.5 kb, respectively, which are 
verified by the result of the agarose gel electrophoresis (Figure 4.7A). 
Gel purified PCR product and digested vector were ligated using the 
GeneArt® Seamless cloning method, and then transformed into competent cells. 
Colonies were picked and colony PCR was performed, then PCR products were run 
on agarose gel to check for plasmids containing the coiled-coil insert (Figure 4.7B). 
The PCR product was expected to be 1,300 bp for the negative control 
(i.e. Myosin-5-Avi) and 1,800 bp if a colony contains the insert. Colonies No. 2, 3, 5, 
6, 9, 12 and 14 seemed to contain the insert. Sequencing confirmed that colony 
No. 14 indeed has the correct sequence. 
Bacmid DNA was generated as described in section 2.4.5. The pFastBac plasmid 
isolated from colony No. 14 was transposed into the bacmid and transposition was 
verified by PCR amplification using M13 primers as described in section 2.4.6. 
Bacmid was isolated from a white colony and PCR was run (Figure 4.7C). 
PCR product of this myosin-5 construct is expected to be 8 kb (5.7 kb for the 
construct, plus additional 2.3 kb from the bacmid backbone). Agarose gel verifies 
that the bacmid contains the insert of the expected size. 
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Figure 4.7. Agarose gels showing the steps of Myo5-cc cloning. Ladder lanes stand 
for GeneRuler 1 kb DNA ladder, numbers denote size in kb corresponding to the 
bands of the lane. A) Result of the digestion of the donor vector and the PCR 
amplification. Lanes are the following. Digested vector: pFastBac vector, containing 
the Myosin-5-Avi sequence digested by Afe I. PCR product: of amplifying the coding 
sequence for 175 amino acids of coiled-coil. B) Colony PCR results from 
15 colonies. Lanes are the following. Screened colonies: PCR product from 
15 randomly picked colonies. Control: PCR product from Myosin-5-Avi construct. 
PCR product from colonies No. 2, 3, 5, 6, 9, 12 and 14 are larger compared to the 
control PCR product. C) Result of the M13 PCR amplification. Lanes are the 
following. M5-cc: PCR product from a bacmid that was purified from a white colony. 
 
4.1.7 Myosin-5-cc expression trial 
SDS-PAGE gels of the purification steps and of the concentrated protein show 
multiple bands, but a band corresponding to the full length Myosin-5-cc construct is 
not visible (Figure 4.8). The concentration of protein in the purified sample was 
85 µg protein/litre of Sf9 cells, which was only calculated as estimation, using the 
extinction coefficient of the full length construct (Table 2.10). 
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Figure 4.8. Coomassie-stained SDS-PAGE gels of Myosin-5-cc purification. 
A) SDS-PAGE gel shows the steps of Myosin-5-cc purification. Lanes are the 
following. Marker: PageRuler Plus pre-stained protein ladder, numbers denote 
molecular mass in kDa corresponding to the bands of the lane. Before sonication: 
cell lysate taken after extraction and before sonication of the cell pellet. Total: cell 
lysate taken after sonication of the cell pellet and before centrifugation. Supernatant: 
taken after centrifuging the cell lysate. Flow through: supernatant taken after 
incubation with Flag resin. Wash: supernatant taken after washing the Flag resin. 
Elution fractions: samples taken from each 1 ml elution fraction. B) SDS-PAGE gel of 
the concentrated eluted sample. 
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4.1.8 Identifying the bands in the Myosin-5-cc expression 
The full length construct was not visible on the purification gel of Myosin-5-cc, 
however there are multiple bands approximately 60, 80, 100 and 110 kDa 
(Figure 4.8). Western blotting was performed using anti-GFP, anti-Myo5a and anti-
Flag antibodies to identify these bands (Figure 4.9). 
The highest molecular weight band on the anti-GFP blot is approximately 140 kDa. 
GFP is at the N-terminus of the protein, but the affinity tag, according to which the 
purification was carried out, is at the C-terminus. This protein fragment was purified 
on a Flag affinity column, therefore it could correspond to a protein that is full length 
in native conditions, but has a cleavage at the proximal part of the coiled-coil and 
thus, in the denaturing SDS-PAGE conditions it appears as a 140 kDa fragment. 
The second highest molecular weight band is approximately 100 kDa and is visible 
on both the anti-Myo5a and the anti-Flag blots. This corresponds to a degraded 
C-terminal protein that was cleaved at the lever. 
There are bands on all 3 blots approximately 80 kDa molecular weight, that could not 
all correspond to the same protein, as that would be the full length construct with 
220 kDa size. The 80 kDa band seen on the anti-GFP blot could be an N-terminal 
protein that was cleaved at the motor domain. The 80 kDa protein that is seen on the 
anti-Myo5a and anti-Flag blots could be an N-terminal protein fragment that had a 
cleavage at the proximal part of the coiled-coil. It is possible that this fragment is 
paired with the 140 kDa fragment seen on the anti-GFP blot in native conditions. 
There are more bands on the anti-GFP blot with ~70, ~50 and ~40 kDa size. 
That could all arise from cleavages within the motor domain. These proteins made it 
through the Flag-resin, therefore they could be full length protein in native conditions, 
but have cleavages various sites at the motor. 
There are ~50 and ~20 kDa molecular weight bands on the anti-Myo5a blot. These 
could be fragments that had cleavage both at the lever and at the distal part of the 
coiled-coil tail. 
There are ~60 and ~25 kDa molecular weight bands on the anti-Flag blot, that could 
correspond to N-terminal fragment that had cleavage at the doubled coiled-coil part 
(that is in the middle) or at the distal coiled-coil part. 
In summary, Western blotting identified the bands seen on the purification SDS gel 
of Myosin-5-cc. This prep was heavily degraded and the full length construct was not 
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visible. Expression optimisation is needed to get the full length Myosin-5-cc 
construct.  
 
 
Figure 4.9. A) Western blots showing the Myosin-5-cc protein preparation. Marker 
lane shows PageRuler Plus pre-stained protein ladder, numbers denote size in kDa 
corresponding to the bands of the lane. Equal volumes of Myosin-5-cc were loaded 
to all wells. B) Schematic representation of Myosin-5-cc. Labelling is the following. 
GFP: enhanced GFP; Motor: motor domain of myosin-5a; IQ: lever with the 6 IQ 
motifs; CC: 175 amino acids long coiled-coil; CC & loops: 350 amino acids long tail 
domain that contains predicted coiled-coil and loops. 
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4.1.9 Myosin-5-Ad cloning 
The recombinant Myosin-5-Ad construct was cloned into pFastBac plasmid by 
GenScript®. Bacmid DNA was generated from this pFastBac plasmid as described 
in section 2.4.5. Transposition into the bacmid was verified by PCR amplification 
using M13 primers as described in section 2.4.6. PCR was run on two colonies that 
were supposed to contain the Myosin-5-Ad construct (Figure 4.10). PCR product of 
this myosin-5 construct is expected to be 8.3 kb (6 kb for the construct, plus 
additional 2.3 kb from the bacmid backbone). Agarose gel verifies that the bacmid 
from colony No. 2 contains the insert of the expected size. 
 
 
Figure 4.10. Agarose gel showing the result of the M13 PCR amplification of the 
Myosin-5-Ad construct. Lanes are the following. Ladder: GeneRuler 1 kb DNA 
ladder, numbers denote size in kb corresponding to the bands of the lane. 
M5-Ad: PCR product from bacmids that were purified from white colonies. 
 
4.1.10 Myosin-5-Ad expression trials 
SDS-PAGE gel of the purification steps and of the concentrated protein sample show 
a small amount of protein that is approximately 120 kDa in size (Figure 4.11), 
inconsistent with the length of the full size protein construct. Either this is a degraded 
C-terminal cleavage product or a cleaved full length protein. However, no full length 
protein appears to be present. 
The yields from two expressions were 237 and 259 µg protein/litre of Sf9 cells, which 
was only calculated as estimation, using the extinction coefficient of the full length 
construct (Table 2.10). 
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Figure 4.11. Coomassie-stained SDS-PAGE gels of Myosin-5-Ad purification. 
A) SDS-PAGE gel shows the steps of Myosin-5-Ad purification. Lanes are the 
following. Marker: BenchMark pre-stained protein ladder, numbers denote size in 
kDa corresponding to the bands of the lane. Supernatant: taken after centrifuging the 
cell lysate. Pellet: taken after centrifuging the cell lysate. Flow through: supernatant 
taken after incubation with Flag resin. Wash: supernatant taken after washing the 
Flag resin. Elution fractions: samples taken from each 1 ml elution fraction. 
B) SDS-PAGE gel of the concentrated eluted sample. 
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4.1.11 Identifying the bands in the Myosin-5-Ad expression 
The full length construct was not visible on the purification gel of Myosin-5-Ad, 
however there are two bands approximately 120 and 50 kDa (Figure 4.11). Western 
blotting was performed using anti-Myo5a and anti-Flag antibodies to identify these 
bands (Figure 4.12). The anti-Myo5a antibody was raised against the amino acids 
981-1070 of the human myosin-5a, that corresponds to the same residue number in 
mouse myosin-5a. This section of the protein (i.e. 175 amino acids of the coiled-coil) 
was doubled in the current construct. 
There is only one major band recognised on the anti-Flag blot (Figure 4.12A), that is 
in the day1 sample and approximately 120 kDa. As the Flag tag is at the C-terminus 
of the construct, this could be an N-terminal fragment that had a cleavage at the 
lever. Interestingly this band is not visible on day2. There are some very faint bands 
appearing on day3 approximately 130, 120, 110, 60 and 40 kDa. Considering that 
these all have a Flag tag, these could be N-terminal fragments that had cleavage at 
the lever, two different sites at the proximal part of the coiled-coil, at the distal part of 
the coiled-coil and just before the GFP, respectively. The full length construct is not 
visible on the blot. 
The anti-Myo5a blot shows two bands in all samples approximately 60 and 30 kDa 
(Figure 4.12B). These could be coiled-coil fragments that have cleavages at the 
lever or at the motor and at the distal coiled-coil or at the loops that interrupt the 
predicted coiled-coil. The 130, 120 and 110 kDa bands that are visible in the day3 
sample on the anti-Flag blot, should have been recognised on the anti-Myo5a blot 
too, but they are not present there. 
The anti-Flag blot shows less protein on day2 and day3 compared to day1. 
The anti-Myo5a blot shows similar amounts of protein on day1 and day2, however 
less protein on day3. However, it is possible that either the cell extraction or the 
loading of the day3 sample into the well of the SDS gel was less efficient compared 
to the day1 and day2 samples. In summary, the protein sample looks degraded and 
the full length construct was not discovered. 
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Figure 4.12. Western blot showing the cell lysate of Sf9 cells expressing 
Myosin-5-Ad after 1, 2 and 3 days of infection. Anti-Flag (A) and anti-Myo5a (B) 
antibodies were used for blotting. Marker lane shows bands of PageRuler Plus 
pre-stained protein ladder, numbers denote size in kDa corresponding to the bands 
of the lane. 10 µl was loaded to the wells from all samples. C) Schematic 
representation of Myosin-5-Ad. Labelling is the following. Motor: motor domain of 
myosin-5a; IQ: lever with the 6 IQ motifs; CC: 175 amino acids long coiled-coil; 
CC & loops: 350 amino acids long tail domain that contains predicted coiled-coil and 
loops; GFP: enhanced GFP; Ad: Adhiron14. 
 
4.1.12 Biotinylation of the Myosin-5-Avi construct 
Western blotting of the purified Myosin-5-Avi after biotinylation confirmed that the 
myosin was biotinylated (Figure 4.13B). Full length Myosin-5-Avi construct and some 
of the additional bands seen also on the purification gel (Figure 4.5) were recognised 
by the anti-biotin antibody suggesting that these additional bands are degradation 
products of the myosin-5 construct that still contain the Avi-tag. The ~110 kDa band 
is not recognised by the anti-biotin antibody in agreement with the previous anti-Flag 
blot results (Figure 4.6). The ~70 kDa band is recognised by the anti-biotin antibody 
also in agreement with the previous anti-Flag blot results (Figure 4.6). An additional 
band with 35 kDa molecular weight was detected on the SDS gel in the biotinylated 
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Myosin-5-Avi sample that is not visible in the untreated sample (Figure 4.13A). This 
band was recognised by the anti-biotin antibody and most probably corresponds to 
the biotin ligase that is used for the biotinylation. Biotin ligase binds biotin, however 
covalent attachment is not supposed to happen, therefore this results is unexpected. 
None of the bands in the untreated sample were recognised. Biotinylated actin that 
was used as a positive control is recognised by the anti-biotin antibody at the 
approximate molecular weight of 42 kDa. 
Note that the 250 kDa marker runs faster on both the SDS gel and the blot 
(Figure 4.13) compared to the heavy chain of myosin-5 that is expected to be 
200 kDa. In this case, the PageRuler Plus protein ladder was used and this was 
expected to run at the appropriate speed. Reason for this anomaly is not known, 
however this means that exact size of the bands seen in the biotinylated myosin-5 
sample are uncertain. 
 
 
Figure 4.13. SDS gel (A) and anti-biotin Western blot (B) showing biotinylated 
Myosin-5-Avi and appropriate controls. Lanes are the following. Biotinylated myosin: 
1 µM Myosin-5-Avi treated with biotin ligase. Marker: PageRuler Plus pre-stained 
protein ladder, numbers denote size in kDa corresponding to the bands of the lane. 
– control myosin: 1.25 µM untreated Myosin-5-Avi. + control biotinylated actin: 3 µM 
biotinylated actin (Cytoskeleton). 8 µl was loaded to the wells from all samples. Note 
that the 70 kDa and 25 kDa marker bands are only showing up on the SDS gel (A). 
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4.1.13 Checking biotinylation with mass spectrometry 
As western blotting does not yield quantitative information on the efficiency of the 
biotinylation, mass spectrometry has been applied to analyse the protein 
preparation. The Myosin-5-Avi construct was incubated with the biotin ligase enzyme 
two different ways. In method 1, the construct was incubated with the ligase mixture 
at a temperature of 30 °C for 45 minutes according to the manufacturer’s protocol 
and in method 2 the construct was incubated on ice for 16–18 hours. As a control, 
similar incubation reactions were set up in the biotinylation buffer using the 
Myosin-5-Avi construct, but without adding the biotin ligase. All samples were 
analysed by mass spectrometry.  
Accurate mass determination for big molecules like myosin-5 is a challenge, 
however the obtained mass of the non-biotinylated myosin-5 construct (202,922.9 
and 202,923.4 Da for non-biotinylated myosin-5 controls using method 1 and 2, 
respectively) is only 1.5% different from the mass expected (199,539.4 Da) 
(Table 4.1). Post-translational modifications and artefacts arising from the ionisation 
method used in the mass spectrometer could account for the difference between the 
two values, which appears to be systematic for all samples.  
Molecular masses of the biotinylated myosin-5 increased by 679.1 Da (method 1) 
and by 441.5 Da (method 2) compared to non-biotinylated myosin-5 (Table 4.1). 
When a single molecule of biotin is covalently attached to a molecule, the mass of 
the molecule is expected to increase by 226 Da. Thus method 1 adds three biotins 
per myosin-5 heavy chain, whereas method 2 adds two. That is unexpected as the 
myosin heavy chain was only expected to be biotinylated at the Avi-tag. This mass 
spectrometry analysis does not show where the biotins get attached to. However 
protein fragmentation and subsequently performed mass spectrometry could analyse 
the sequence of the protein and therefore could potentially identify the additional 
residues that got biotinylated using method 1 or method 2. Site directed mutagenesis 
targeting these additional biotinylated residues could eliminate them from the 
sequence and thus, could avoid that additional biotinylation occur. As the extent of 
biotinylation is sufficient with method 2, which is expected to be gentler than method 
1, this method was used for the remainder of this study. 
The biotinylation levels of the commercially available biotinylated G-actin 
(Cytoskeleton) were also checked using mass spectrometry. The expected mass of 
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rabbit skeletal α-actin is 41,785 Da (Elzinga et al., 1973). The measured mass of 
control non-biotinylated G-actin, prepared from rabbit skeletal muscle had a mass of 
41,872.8 Da, close to that expected. The biotinylated G-actin sample had multiple 
peaks with ~452.6 Da differences in mass (Table 4.2). Cytoskeleton Inc. used the 
compound Biotin-XX, SE (Thermo Fisher Scientific) for biotinylation that adds 
452.6 Da mass per biotin to the protein mass. Therefore, these results suggest that 
the sample contains actin monomers with either 0, 1, 2, 3, 4 or 5 biotin molecules 
with prevalence rates of 7%, 17%, 29%, 30%, 15% and 1%, respectively, according 
to a peak area analysis (Table 4.2). This gives an average of 2.3 biotins per actin 
monomer that is generally in agreement with that reported by the technical support of 
Cytoskeleton Inc. (i.e. ~1 biotin per actin monomer). In this case, biotin attaches to 
surface lysine residues of G-actin, in a random manner. If adding 2 to 5 biotin 
molecules does not interfere with polymerisation of G-actin to F-actin, then the 
resulting filament will contain more biotins than 1 biotin/subunit. 
 
Sample  myo30 myo0 bmyo30 bmyo0 
Mass (Da) 202,922.9 202,923.4 203,602.0 203,364.4 
  
 
  Difference in mass (Da) 679.1 441.5 
Number of biotins (226 Da) 3.00 1.95 
Table 4.1. Molecular mass results from mass spectrometry of the non-biotinylated 
and biotinylated Myosin-5-Avi. Samples were treated at 30 °C for 45 minutes (myo30 
and bmyo30) or incubated on ice for 16–18 hours (myo0 and bmyo0). 
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Peak 
No. 
Measured 
masses (Da) 
Difference 
in masses 
(Da) 
Number of 
biotins 
(calculated) 
Number 
of biotins 
Proportion 
(%) 
1 41,873.8  0 0 7.4 
2 42,325.7 451.9 0.99845 1 17.1 
3 42,778.4 904.6 1.99867 2 29.1 
4 43,230.9 1357.1 2.99845 3 30.2 
5 43,684.2 1810.4 4.00000 4 14.8 
6 44,137.2 2263.4 5.00088 5 1.4 
Table 4.2. Analysis of the mass spectrometry results of biotinylated actin. Multiple 
peaks observed on the mass spec deconvolution graph are associated with G-actin 
having 0 to 5 biotin molecules. The column ‘Number of biotins (calculated)’ shows 
the mass difference value divided by 452.6 Da. Calculating the area of the peaks 
suggests the prevalence rates of the compounds shown in the last column. 
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4.1.14 ATPase activity of the Myosin-5-Avi construct 
In the absence of NeutrAvidin, ATPase assays showed that biotinylation of myosin 
affected the actin-activated ATPase activity (Figure 4.14A). The ATPase activity of 
the biotinylated myosin-5 construct was significantly reduced by about 50% 
compared to the non-biotinylated protein (p=0.0001), when the ATPase assays are 
performed with non-biotinylated actin (Table 4.3). Similarly, a decrease of about 40% 
in the ATPase activity for biotinylated myosin compared to non-biotinylated protein 
was also observed when biotinylated actin was used (p=0.0011). It is possible that 
either the biotinylation treatment or the biotinylation buffer conditions decreased the 
activity of the biotinylated myosin. The measured ATPase rates were somewhat 
similar for non-biotinylated myosin when either actin or biotinylated actin was used. 
However interestingly there was a significant (p=0.0001) 30% increase in the rate of 
biotinylated myosin with biotinylated actin compared to non-biotinylated actin. 
The reason underlying this is not understood. It is also notable that the activity of this 
construct (1.1 sec-1) is lower than 3.8 sec-1 that was reported for mouse myosin-5 
HMM at 25 ºC (Wang, Chen, et al., 2000). The presented construct, however, 
contains an additional N-terminal GFP that could potentially result in decreased 
activity, especially considering that the GFP is close to the motor domain. 
Adding NeutrAvidin in each of these four conditions showed that the largest 
decrease in the ATPase activity of Myosin-5-Avi was when both biotinylated myosin 
and biotinyated actin was used (Figure 4.14B) (Table 4.4). This reduced the rate 
compared to non-biotinylated myosin and actin ATPase valued to 40% (p=0.0001). 
Smaller, but significant reductions were seen when either myosin and biotinylated 
actin (p=0.0477) or biotinyated myosin and actin (p=0.0001) were used. NeutrAvidin 
had no effect on the ATPase activity when non-biotinylated myosin and actin were 
used. The inhibitory effect of NeutrAvidin on biotinylated myosin and biotinylated 
actin is greater than the sum of the effects measured with the controls. This indicates 
that crosslinking the tail to actin via the avidin linkage may affect the ATPase rates of 
acto-myosin. 
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Figure 4.14. Bar graphs showing the results of the actin-activated ATPase activity of 
Myosin-5-Avi. Abbreviations are the followings. AM: non-biotinylated actin with 
non-biotinylated myosin. BAM: biotinylated actin with non-biotinylated myosin. 
ABM: non-biotinylated actin with biotinylated myosin. BABM: biotinylated actin with 
biotinylated myosin. 20 µM F-actin was used in the measurements, biotinylated 
F-actin had 5% of the actin subunits biotinylated. Bars show average and standard 
deviation of three measurements. P values showing significance are presented on 
the graphs. 
Panel A shows results of the actin-activated ATPase activity in sec-1 myosin head-1. 
Values corresponding to the graph are presented in Table 4.3. Panel B shows 
results of the actin-activated ATPase activity after addition of NeutrAvidin compared 
to the activity measured before NeutrAvidin addition, in percentage. Values 
corresponding to the graph are presented in Table 4.4. 
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Actin Biotinylated actin 
Myosin 1.10 ± 0.01 1.19 ± 0.10 
Biotinylated myosin 0.54 ± 0.01 0.70 ± 0.01 
Table 4.3. Values of the actin-activated ATPase activity of Myosin-5-Avi in 
sec-1 myosin head-1. 20 µM F-actin was used in the measurements, biotinylated 
F-actin had 5% of the actin subunits biotinylated. Numbers show average and 
standard deviation of three measurements. 
 
 
Actin Biotinylated actin 
Myosin 100 ± 2 71 ± 16 
Biotinylated myosin 87 ± 3 40 ± 5 
Table 4.4. Percentage of the actin-activated ATPase activity of Myosin-5-Avi after 
addition of NeutrAvidin compared to the activity measured before NeutrAvidin 
addition. Actual values are 1*1.1=1.1; 0.71*1.19=0.84; 0.87*0.54=0.47 and 
0.4*0.7=0.28. 20 µM F-actin was used in the measurements, biotinylated F-actin had 
5% of the actin subunits biotinylated. Numbers show average and standard deviation 
of three measurements. 
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4.1.15 Electron microscopy images of Myosin-5-Avi on actin 
Negative stain electron micrographs of non-biotinylated Myosin-5-Avi, in the 
presence of ATP and in the absence of NeutrAvidin, showed molecules in which the 
motor domain, lever and coiled-coil tail of the molecule were visible (Figure 4.15). 
Negative stain electron micrographs of biotinylated actin mixed with NeutrAvidin to 
which biotinylated Myosin-5-Avi was then added together with ATP showed the 
attachment of Myosin-5-Avi to actin filaments via its motor domains (Figure 4.16). 
However, the tail of the myosin construct was almost never seen to be attached to 
actin. There was only one single molecule, where both the motor domains and the 
tail were attached to actin. However, in this case, the tail was not attached to the 
same actin filament as the motor domains, but to an adjacent filament. 
 
 
Figure 4.15. Negative stain electron microscope images of the Myosin-5-Avi 
construct. 50 nM myosin-5 dimer molecules with 100 µM ATP was mixed and 
applied to the carbon coated grids. Arrows point to show lever arm and motor 
domain of Myosin-5-Avi and also to show the coiled-coil tail. Scale bar corresponds 
to 50 nm. 
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Figure 4.16. Negative stain electron microscope images show biotinylated 
Myosin-5-Avi construct on biotinylated actin. 50 nM biotinylated Myosin-5-Avi with 
1 µM ATP was mixed with 1 µM biotinylated actin (50 nM biotinylated actin subunits 
as 5% of the subunits are biotinylated) and 80 nM NeutrAvidin tetramers. Arrows 
point to show lever arm and motor domain of Myosin-5-Avi and also to show the 
coiled-coil tail. Scale bar corresponds to 50 nm. 
 
4.1.16 Single molecule motility assay 
In the absence of NeutrAvidin the non-biotinylated and biotinylated Myosin-5-Avi 
constructs moved along fluorescent biotinylated actin in TIRF microscopy based 
in-vitro motility assays with similar characteristic run length of 0.61 ± 0.14 µm 
(Figure 4.17A) and 0.55 ± 0.06 µm (Figure 4.17C), respectively. The average speed 
of the observed Myo5-Avi particles were 0.88 ± 0.01 µm/sec (Figure 4.17B) and 
0.83 ± 0.01 µm/sec (Figure 4.17D) for non-biotinylated and biotinylated Myo5-Avi, 
respectively. Numbers represent mean of the fitting and confidence values. Numbers 
of the observed molecules were 183 and 1,001 for non-biotinylated and biotinylated 
Myo5-Avi, respectively. These numbers were compared to literature data measured 
using mouse myosin-5 HMM constructs by different laboratories and by different 
methods (Table 4.5). Even though it is not straightforward to compare results that 
were measured at different temperature using different salt concentrations, 
interestingly results suggest that the characteristic run lengths are shorter, whereas 
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velocity values are faster compared to literature data (Sakamoto et al., 2003; Baker 
et al., 2004; Hodges et al., 2007; Ortega Arroyo et al., 2014). 
 
 
Figure 4.17. Run length and velocity distribution of the Myo5-Avi construct on actin 
without NeutrAvidin. Panels A and B show data of the non-biotinylated Myo5-Avi, 
whereas panels C and D show data of the biotinylated Myo5-Avi. Run length 
distributions were fitted with a first order exponential decay function, yielding 
characteristic run lengths of 0.61 ± 0.14 µm (A) and 0.55 ± 0.06 µm (C). Velocity 
distributions were fitted with a Gaussian function, yielding average speed of 
0.88 ± 0.01 µm/sec (B) and 0.83 ± 0.01 (D). Numbers represent mean of the fitting 
and confidence values. Numbers of the observed molecules were 183 and 1,001 for 
non-biotinylated and biotinylated Myo5-Avi, respectively. 
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Study 
Temperature 
(ºC) 
KCl 
(mM) 
Run length 
(µm) 
Velocity 
(µm/sec) 
Number 
of tracked 
molecules 
(Sakamoto et 
al., 2003) 30 25 1.81 0.3 ± 0.1* ~153** 
(Baker et al., 
2004) 25 25 1.3 ± 0.2 0.38 ± 0.04 >72 
(Baker et al., 
2004) 25 100 0.8 ± 0.2 0.55 ± 0.04 >54 
(Hodges et al., 
2007) 30 50 1.8 ± 0.2 0.94 ± 0.32 ~117*** 
(Ortega Arroyo 
et al., 2014) 23 40 0.86 ± 0.35 0.43 ± 0.15 91 
This thesis 23 50 0.61 ± 0.14 0.88 ± 0.01 183 
Table 4.5. Run length and velocity data taken from the literature, measured using 
mouse myosin-5 HMM constructs and data on the non-biotinylated Myosin-5-Avi 
construct presented above in Figure 4.17. 
*Velocity value is not stated in the paper. Estimated values are given here according 
to Figure 6 in (Sakamoto et al., 2003). 
**Number of observed molecules is not stated in the paper. An estimate number is 
given here according to Figure 5 in (Sakamoto et al., 2003). 
***Number of observed molecules is not stated in the paper. An estimate number is 
given here according to Figure 4 in (Hodges et al., 2007). 
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There is an apparent controversy in the data of the steady state ATPase activity and 
the single molecule motility assay. Steady state ATPase assay showed that the 
activity is decreased compared to the literature data (Wang, Chen, et al., 2000) and 
it also showed decreased activity for the biotinylated myosin compared to the 
non-biotinylated myosin. Whereas in the single molecule motility assay velocity of 
the non-biotinylated and biotinylated myosin were similar and it was also similar or 
even higher compared to the literature data (Sakamoto et al., 2003; Baker et al., 
2004; Hodges et al., 2007; Ortega Arroyo et al., 2014). This could be explained that 
some fraction of the myosin molecules is not active in the preparation and that the 
biotinylation method even decreased the number of the active molecules. The steady 
state activity describes a population average activity, therefore if only 30% of the 
molecules are active, the steady state activity will be 30% of that expected. However, 
in the single molecule motility assay, the inactive molecules are not taken into 
account and only those molecules are analysed that are actually moving. Therefore 
this assay could potentially give an activity that is much higher than the steady state 
activity. 
The effect of NeutrAvidin on the motility of biotinylated Myo5-Avi was also tested. 
The distribution of both the run length and the velocity of the single particles altered 
after the addition of NeutrAvidin (Figure 4.18), even though the average did not 
change significantly. Characteristic run length was found to be 0.55 ± 0.03 µm 
(Figure 4.18A) without NeutrAvidin and 0.51 ± 0.11 µm (Figure 4.18C) after 
NeutrAvidin addition. Numbers represent mean of the fitting and confidence values. 
Velocity distribution after NeutrAvidin addition could not be fitted with a Gaussian 
curve, therefore average was calculated and was found to be 0.92 ± 0.46 µm/sec 
(mean ± s.d.) (Figure 4.18B) without NeutrAvidin and it was 0.97 ± 0.57 µm/sec 
(mean ± s.d.) (Figure 4.18D) after addition of NeutrAvidin. Numbers of the observed 
molecules were 336 and 261 for without NeutrAvidin and after NeutrAvidin addition, 
respectively. 
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Figure 4.18. Run length and velocity distribution of biotinylated Myo5-Avi before and 
after NeutrAvidin addition. Panels A and B show data before, whereas panels C and 
D show data after NeutrAvidin addition. Run length distributions were fitted with a 
first order exponential decay function, yielding characteristic run lengths of 
0.55 ± 0.03 µm (A) and 0.51 ± 0.13 µm (C). Velocity distribution without NeutrAvidin 
was fitted with a Gaussian function, yielding average velocity of 0.78 ± 0.01 µm (B). 
Numbers represent mean of the fitting and confidence values. Numbers of tracked 
molecules were 338 and 261 for without NeutrAvidin and after NeutrAvidin addition, 
respectively. 
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Results show that NeutrAvidin addition had some effect on biotinylated Myo5-Avi. 
Run length distribution (Figure 4.18C) could not be fitted properly with a single 
exponential decay function as there were no molecules observed with run length 
above 2 µm. However, proportionally more molecules had shorter run length 
compared to the molecules observed before NeutrAvidin addition (Figure 4.18A). 
The Gaussian distribution (Figure 4.18B) of the velocity changed after NeutrAvidin 
addition and similar number of molecules were observed with velocities 
0.3 to 1.3 µm/sec (Figure 4.18D). NeutrAvidin was in a large excess (16.7 µM) 
compared to Myo5-Avi (5 nM) and biotinylated actin subunits (10 nM), therefore most 
probably every biotinylated molecule had NeutrAvidin bound to them. NeutrAvidin 
molecules bound to actin could act as obstacles that myosin-5 either i) has to bypass 
or ii) it dissociates from actin. Increased ratio of slower velocities and short run 
lengths could be explained by i) and ii), respectively. 
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4.2 Discussion 
A myosin-5 construct that contains the whole coiled-coil tail of the full length 
myosin-5a molecule, but missing the C-terminal globular tail domain, was designed, 
cloned, expressed and purified. Yield and purity of the expression was low, thus 
chaperones were employed that helped to achieve higher yield and also less 
impurity in the protein preparation. Biotinylation of the myosin decreased the 
acto-myosin ATPase activity by ~50% in the absence of NeutrAvidin, suggesting that 
the process of biotinylation may affect myosin ATPase. Crosslinking of biotinylated 
myosin to actin using NeutrAvidin further decreased the ATPase activity. However, 
electron micrographs did not show the presence of molecules in which the motor and 
the tail domain were attached to the same actin filament. Moreover, single molecule 
motility of the individual biotinylated myosin-5 molecules were not affected by the 
addition of NeutrAvidin. 
This study is the first to employ chaperones to help with expression of myosin-5. 
Previously, myosin-5 has been shown to express well even in the absence of 
chaperones. This includes full length constructs (Krementsov et al., 2004; Wu et al., 
2006) as well as the myosin-5 HMM construct that is more typically expressed 
(Andrecka et al., 2015; Zimmermann et al., 2015; Iwaki et al., 2015). 
The chaperones are thought to bind to and interact with the motor domain to 
promote folding (Barral et al., 2002; Liu et al., 2008), and have been shown to 
improve expression levels of other myosin isoforms including myosin-14 and 
myosin-15 (Bookwalter et al., 2014; Bird et al., 2014). In the case of Myosin-5-Avi 
construct, chaperones increased yield of expression by one order of magnitude and 
they also helped to reduce the intensity of the additional bands seen on the SDS gel 
of myosin-5 preparation. Therefore applying chaperones to express this and further 
myosin-5 constructs is beneficial to get good quality protein for downstream 
biochemical and biophysical studies. 
The reduced ATPase activity following myosin biotinylation suggests that the 
process of biotinylation may affect myosin. In previous reports, the Avi-tag was 
added to the N-terminus of myosin-5, and decrease in the actin-activated ATPase 
was not reported after biotinylation of the myosin (Hodges et al., 2007; Nelson et al., 
2009; Andrecka et al., 2015). It is unlikely that this is due to the positioning of the tag, 
or the smaller size of the myosin-5 constructs used in those experiments (Hodges et 
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al., 2007; Nelson et al., 2009; Andrecka et al., 2015). An N-terminal biotinylation is 
close to the motor, where the ATP hydrolysis takes place, therefore could interfere 
with that, whereas a C-terminal biotinylation is spatially far from the active site. 
However, mass spectrometry analysis showed that the Myo5-Avi construct gets 
biotinylated at 2 or 3 sites depending on the incubation circumstances. If the motor 
gets non-specifically biotinylated, that could decrease ATPase activity explaining the 
observed results. 
Moreover, the measured actin-activated ATPase activity is ~3 fold lower than 
previously reported (Wang, Chen, et al., 2000). It is possible that the active fraction 
of the molecules is only ~30% and therefore the steady state activity is 30% 
compared to what was observed before. That could be tested with active site titration 
using a stopped flow instrument. However the observed difference might also be due 
to the fact that this construct is 350 residues longer than an HMM. Overestimation of 
the protein concentration due to the additional bands seen on the SDS gel might also 
lead to lower activity. Exact protein concentration could be measured using mass 
spectrometry, however inaccurate protein concentration cannot account for 70% of 
the activity loss compared to the literature results.  
NeutrAvidin decreased the ATPase activity of biotinylated myosin-5 on biotinylated 
actin, suggesting that the tail of myosin-5 might be bound to actin. However, electron 
microscope images did not show the hypothesised myosin-actin conformation, in 
which the motor and the tail are tethered to the same actin filament (Figure 1.13). 
In the one example where Myosin-5-Avi was attached to F-actin by both of its motor 
domains and via its tail, the motors were on a different filament to that to which the 
tail was bound. Different experimental setup might explain the difference observed in 
the ATPase assay and the EM images. Moreover EM images are 2D projections of 
the molecules present in solution, which limits the number and variety of molecules 
and structures to be observed. 
Single molecule motility experiments showed that Myo5-Avi construct moves with 
similar or even higher speed compared to previous literature data on mouse 
myosin-5 HMM. This was unexpected as steady state activity of the molecules was 
found to be lower than that of previously reported. However as explained above, it is 
possible that a huge fraction of the Myo5-Avi molecules are inactive, therefore their 
population average (i.e. steady state) activity is low. Whereas in single molecule 
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experiments individual, motile molecules are analysed and inactive molecules that 
do not move are filtered out. 
Single molecule experiments also revealed that non-biotinylated and biotinylated 
Myo5-Avi molecules display similar run length and velocity. It is however still 
possible that the biotinylation process affects some Myo5-Avi molecules and renders 
them inactive. But it might be more likely that the biotinylation buffer affected the 
steady state ATPase activity measurement as there was ~1% v/v biotinylation buffer 
in the final reaction mixture. In the single molecule experiments there is only 
0.1% v/v biotinylation buffer in the final reaction mixture. 
Considering that the tail of myosin-5 was never observed to be tethered to the same 
actin filament as it is walking on, and that NeutrAvidin did not affect the single 
molecule motility of biotinylation Myo5-Avi, it is possible that lever and the coiled-coil 
junction is not flexible enough to allow that attachment. If the predicted coiled-coil 
sections of the myosin-5 tail indeed form coiled-coil, that would add up to a 
54 nm (26+13+15 nm (Chothia et al., 1981; Baboolal et al., 2009)) long tail. 
Assuming that the loops are not extending, this coiled-coil tail would be able to 
attach to the actin filament if the tail is able to meet at a ~27º to the lever and then 
the N-terminal end of the tail would be bound 30 nm away from the trailing motor 
(Figure 4.19). If the loops are able to extend, both the angle and the distance would 
be larger. If the tail is only able to make a wider angle to the lever, we either need a 
construct with a longer tail or a construct with some flexible regions in the tail. Even 
though the loops that interrupt the predicted coiled-coil structure were thought to be 
flexible, this flexibility is apparently not sufficient for our study. 
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Figure 4.19. Calculating distances and angles in the schematic myosin-5 structure 
bound to actin. Blue arrows indicate the steps of the calculations. Distances are in 
nm. Step size (36 nm) (Walker et al., 2000), length of the head domain (31 nm) 
(Cheney et al., 1993) and length of the coiled-coil tail (54 nm) (Chothia et al., 1981) 
are taken from the literature. Numbers denoted with red were calculated using 
simple algebra in the given step. Final step shows that the tail meets at a 27º angle 
with the trailing head to attach to actin. 
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Results suggest that the present Myosin-5-Avi construct is not appropriate to study 
the elasticity of the tail domain as hypothesised (Figure 1.13). Therefore two new 
constructs, Myosin-5-cc and Myosin-5-Ad, were designed that have a longer coiled-
coil tail. 175 amino acids of the coiled-coil were doubled in these constructs, making 
the tail 26 nm longer compared to Myosin-5-Avi. In the previous chapter a new 
method, Adhirons, were explored that could substitute the biotin-avidin interaction, 
thus avoid the biotinylation process. The sequence of an actin binding Adhiron 
molecule was added to the C-terminus of the Myosin-5-Ad construct, whereas 
Myosin-5-cc contains a C-terminal Avi-tag such as Myosin-5-Avi. 
The expression trials of neither Myosin-5-cc, nor Myosin-5-Ad were successful as 
the full length constructs were not obtained. The DNA sequence of the constructs 
was correct as checked by sequencing. Western blots confirmed that the protein 
bands seen in the protein purification prep were fragments of the full length protein. 
It is possible that the extended coiled-coil of 350 amino acids (doubling the 
175 amino acids) is prone to cleavage by proteases. Furthermore, it is also possible 
that the Adhiron at the C-terminus of the Myosin-5-Ad construct binds to actin in 
Sf9 cells that makes it prone to cleavage by proteases. Due to these or due to other 
reasons the molecules can get cleaved during expression in the insect cells. Further 
expression optimisation is needed to obtain the full length protein constructs. 
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5. Concluding remarks 
5.1 Characterisation of actin-binding Adhirons 
5.1.1 Summary 
Four new actin-binding molecules were raised with phage display assay. These new 
proteins are small, easy to express and bind tightly to actin, making them potentially 
useful in wide variety of applications. These molecules are named Adhiron2, 
Adhiron6, Adhiron14 and Adhiron24. Adhiron14 binds with a submicromolar affinity 
to actin and, when labelled with a fluorophore, can be used to label actin in live cells 
or in fixed cells. Adhiron2 binds with a micromolar affinity to actin and could 
potentially be used to attach actin to the coverslip in TIRF single molecule motility 
assay. 
 
5.1.2 Future directions 
Future experiments will explore the exact binding affinity of Adhiron2 to actin using 
further spin down assays. The potential difference in binding due to biotinylation of 
the Adhirons will also be studied using similar spin down assays. 
The presented results suggest that Adhiron6, Adhiron14 and Adhiron24 bind to the 
same or overlapping sites on actin. This will be further studied using competition spin 
down assays of pairs of Adhirons, where one Adhiron is biotin labelled and the other 
Adhiron is non-labelled. Western blotting will be performed and using an anti-biotin 
antibody, the amount of one of the Adhirons in the pellet and in the supernatant will 
specifically be determined. 
Competition between the myosin motor domain and the Adhirons will also be further 
studied using competition spin down assays. It will also be tested if S1 competes 
Adhirons off actin in the presence of ATP. 
The properties of Adhiron2 in attaching actin to the coverslips will also be further 
studied. Myosin movement on actin attached to the surface by Adhiron2 and by 
NeutrAvidin will be compared, run length and velocity distribution will be analysed. 
The application of Adhiron14 in cell staining will be further studied using more, 
different cell lines. On and off rates of Adhiron will be measured and these properties 
along with Adhiron distribution in binding to various actin structures will be compared 
with present methods used for actin staining. Adhiron24 was implied to stain focal 
adhesions when expressed in HeLa cells, which will be tested using anti-vinculin or 
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anti-paxillin antibodies. Exact nature of Adhiron24 binding to actin will be determined, 
as the reason behind targeting to focal adhesions remains to be resolved. 
The potential actin bundling properties of Adhirons will be studied by electron 
microscopy. The use of Adhirons will be explored in optical trapping and also in 
iSCAT systems. 
A mutational analysis on the Adhirons could be performed to discover which 
residues in the variable loops are responsible for binding to actin. These residues 
could be selectively mutated, then the mutant Adhirons expressed and studied in 
spin down assays. 
Structure prediction of the Adhirons could be performed using homology modelling, 
then Adhirons could be docked to the structure of F-actin to discover potential 
binding site of Adhirons on F-actin. 
 
5.2 Characterisation of recombinant myosin-5 constructs with 
actin-binding tail domains 
5.2.1 Summary 
Multiple myosin-5 constructs were designed and cloned that contain an actin-binding 
motif at their C-termini. Myosin-5-Avi that contains the entire predicted coiled-coil 
motif was expressed and purified successfully. Even though steady state 
actin-activated ATPase activity indicated low activity of this construct, single 
molecule motility assay results showed that individual molecules move along actin 
with a faster speed than was reported earlier. The presented experiments did not 
show that the tail of this construct is able to bind to the same actin filament as the 
motors are walking on. Expression of Myosin-5-cc and Myosin-5-Ad constructs, 
where the coiled-coil tail of myosin-5 is longer to allow attachment of the tail to actin, 
only proceeded successfully as far as the creation of baculoviruses and expression 
trials are currently in progress. 
 
5.2.2 Future directions 
Expression optimisation will be performed to get full length constructs of Myosin-5-cc 
and Myosin-5-Ad and study if their tail is able to bind to the same actin filament as 
the heads are bound to. Negative staining electron microscopy will be used to image 
the motor domains and levers of stalled myosin-5 and their structures will be 
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compared to those of myosin-5 molecules moving under unloaded conditions. 
It is likely that the predicted coiled-coil tail of myosin-5 is elastic and might extend 
under these conditions, which will be measured. In addition, a fluorescent-analogue 
of ATP will be applied to determine how strain affects the kinetics of the two heads of 
myosin under stalled conditions. 
Future experiments will also explore further properties of Myosin-5-Avi. 
Adding NeutrAvidin to the single molecule motility assay did not change the average 
velocity and run length of biotinylated Myosin-5-Avi, even though the distribution of 
the velocities and run lengths of the single molecules altered. Control experiment 
using non-biotinylated Myosin-5-Avi could clarify whether the distribution change was 
due to the binding of NeutrAvidin to the biotinylated myosin or due to NeutrAvidin 
attachment to biotinylated actin. Adhiron2 will also be explored to attach actin to 
coverslips and to study the difference between using biotinylated or non-biotinylated 
actin in Myosin-5-Avi motility assays. 
Detailed analyses of electron micrographs can show the length of the first coiled-coil 
part of the tail, as loop motifs following this segment are usually not visible in 
negative stain EM. The angle between the tail and the lever will also be measured 
that could suggest if there is enough flexibility at the head-tail junction to allow the 
attachment of the tail to the same actin filament as the heads are bound to. 
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Supplementary Materials 
S1. Amino acid sequences of the GFP-Adhiron constructs 
legend: 
GFP 
Adhiron 
linker 
 
GFP-Adhiron2 
        10         20         30         40         50         60  
MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT  
 
        70         80         90        100        110        120  
LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL  
 
       130        140        150        160        170        180  
VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA  
 
       190        200        210        220        230        240  
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYKS  
 
       250        260        270        280        290        300  
GLRSRAQASN SASNSLEIEE LARFAVDEHN KKENALLEFV RVVKAKEQWI YIHPRKVTMY  
 
       310        320        330        340        350  
YLTLEAKDGG KKKLYEAKVW VKTHKYQNMS DNFKELQEFK PVGDAAGSTG SR  
 
GFP-Adhiron6 
        10         20         30         40         50         60  
MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT  
 
        70         80         90        100        110        120  
LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL  
 
       130        140        150        160        170        180  
VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA  
 
       190        200        210        220        230        240  
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYKS  
 
       250        260        270        280        290        300  
GLRSRAQASN SASNSLEIEE LARFAVDEHN KKENALLEFV RVVKAKEQSS VPHWWWTTMY  
 
       310        320        330        340        350  
YLTLEAKDGG KKKLYEAKVW VKRDPNMIFK INFKELQEFK PVGDAAGSTG SR 
 
GFP-Adhiron14 
        10         20         30         40         50         60  
MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT  
 
        70         80         90        100        110        120  
LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL  
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       130        140        150        160        170        180  
VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA  
 
       190        200        210        220        230        240  
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYKS  
 
       250        260        270        280        290        300  
GLRSRAQASN SASNSLEIEE LARFAVDEHN KKENALLEFV RVVKAKEQSD TPHWWWTTMY  
 
       310        320        330        340        350  
YLTLEAKDGG KKKLYEAKVW VKESPVHPKR LNFKDLQEFK PVGDAAGSTG SR  
 
GFP-Adhiron24 
        10         20         30         40         50         60  
MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY GKLTLKFICT TGKLPVPWPT  
 
        70         80         90        100        110        120  
LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL  
 
       130        140        150        160        170        180  
VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA  
 
       190        200        210        220        230        240  
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYKS  
 
       250        260        270        280        290        300  
GLRSRAQASN SASNSLEIEE LARFAVDEHN KKENALLEFV RVVKAKEQMD MIGEYVSTMY  
 
       310        320        330        340        350  
YLTLEAKDGG KKKLYEAKVW VKGWMPLYSR QNFKELQEFK PVGDAAGSTG SR  
 
S2. Amino acid sequence of Myosin-5-Avi construct 
Sequence alignment was performed using the ClustalW webserver (Larkin et al., 
2007). First line shows the DNA sequence of the brain isoform of mouse myosin-5a 
(NCBI Reference Sequence: XM_006510832.3). Second line shows the DNA 
sequence of the Myosin-5-Avi construct. Third line shows the amino acid sequence 
corresponding to the Myosin-5-Avi construct. Colouring of the amino acid sequence 
represents the distinct domains and motifs of the protein according to the legend. 
Numbers at the end of the lines represent the number of nucleic acids or amino 
acids up to that point in the sequence. 
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Legend: 
GFP 
Restriction sites: BssH II, EcoR I and Stu I 
Mouse myosin-5a brain isoform with the whole coiled-coil domain, 1440 aa 
Avi-tag 
Restriction sites: Stu I, Sal I, Sst I, Spe I and Not I 
Flag tag 
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC 60 
           M  V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  20                                                                       
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    GGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC 120 
           G  D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  40                                                                   
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC 180 
           G  K  L  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T  60                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG 240 
           L  V  T  T  L  T  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K  80                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC 300 
           Q  H  D  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F  100                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG 360 
           F  K  D  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L  120                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC 420 
           V  N  R  I  E  L  K  G  I  D  F  K  E  D  G  N  I  L  G  H  140                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC 480 
           K  L  E  Y  N  Y  N  S  H  N  V  Y  I  M  A  D  K  Q  K  N  160                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC 540 
           G  I  K  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  A  180                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC 600 
           D  H  Y  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  200                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC 660 
           Y  L  S  T  Q  S  A  L  S  K  D  P  N  E  K  R  D  H  M  V  220                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-Avi    CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGCG 720 
           L  L  E  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K  A  240                                                                    
 
XM_00651  ------------------ATGGCCGCGTCCGAGCTCTACACCAAGTTTGCCAGGGTTTGG 42 
M5-Avi    CGCGGAATTCAAAGGCCTATGGCCGCGTCCGAGCTCTACACCAAGTTTGCCAGGGTTTGG 780 
           R  G  I  Q  R  P  M  A  A  S  E  L  Y  T  K  F  A  R  V  W  260                
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XM_00651  ATCCCTGATCCTGAGGAAGTGTGGAAATCGGCAGAGTTGCTCAAGGATTATAAGCCTGGA 102 
M5-Avi    ATCCCTGATCCTGAGGAAGTGTGGAAATCGGCAGAGTTGCTCAAGGATTATAAGCCTGGA 840 
           I  P  D  P  E  E  V  W  K  S  A  E  L  L  K  D  Y  K  P  G  280 
 
XM_00651  GATAAAGTGCTCCTGCTTCACCTCGAGGAAGGGAAGGATTTGGAATACCGTCTAGACCCA 162 
M5-Avi    GATAAAGTGCTCCTGCTTCACCTCGAGGAAGGGAAGGATTTGGAATACCGTCTAGACCCA 900 
           D  K  V  L  L  L  H  L  E  E  G  K  D  L  E  Y  R  L  D  P  300 
 
XM_00651  AAGACCGGTGAGCTCCCTCACTTACGGAACCCTGACATACTTGTTGGAGAAAATGACCTC 222 
M5-Avi    AAGACCGGTGAGCTCCCTCACTTACGGAACCCTGACATACTTGTTGGAGAAAATGACCTC 960 
           K  T  G  E  L  P  H  L  R  N  P  D  I  L  V  G  E  N  D  L  320 
 
XM_00651  ACAGCCCTCAGCTACCTTCACGAGCCCGCTGTGCTACATAATCTCCGAGTTCGCTTCATC 282 
M5-Avi    ACAGCCCTCAGCTACCTTCACGAGCCCGCTGTGCTACATAATCTCCGAGTTCGCTTCATC 1020 
           T  A  L  S  Y  L  H  E  P  A  V  L  H  N  L  R  V  R  F  I  340 
 
XM_00651  GATTCCAAACTTATTTATACGTATTGTGGAATAGTTCTGGTAGCTATAAATCCCTATGAG 342 
M5-Avi    GATTCCAAACTTATTTATACGTATTGTGGAATAGTTCTGGTAGCTATAAATCCCTATGAG 1080 
           D  S  K  L  I  Y  T  Y  C  G  I  V  L  V  A  I  N  P  Y  E  360 
 
XM_00651  CAGCTGCCTATTTATGGAGAAGATATTATTAATGCCTACAGTGGCCAGAACATGGGTGAC 402 
M5-Avi    CAGCTGCCTATTTATGGAGAAGATATTATTAATGCCTACAGTGGCCAGAACATGGGTGAC 1140 
           Q  L  P  I  Y  G  E  D  I  I  N  A  Y  S  G  Q  N  M  G  D  380 
 
XM_00651  ATGGATCCTCACATCTTCGCAGTAGCTGAAGAGGCTTACAAGCAAATGGCAAGGGATGAA 462 
M5-Avi    ATGGATCCTCACATCTTCGCAGTAGCTGAAGAGGCTTACAAGCAAATGGCAAGGGATGAA 1200 
           M  D  P  H  I  F  A  V  A  E  E  A  Y  K  Q  M  A  R  D  E  400 
 
XM_00651  CGAAATCAGTCCATCATTGTAAGTGGAGAGTCAGGCGCAGGGAAGACGGTCTCTGCTAAG 522 
M5-Avi    CGAAATCAGTCCATCATTGTAAGTGGAGAGTCAGGCGCAGGGAAGACGGTCTCTGCTAAG 1260 
           R  N  Q  S  I  I  V  S  G  E  S  G  A  G  K  T  V  S  A  K  420 
 
XM_00651  TATGCCATGCGGTACTTCGCAACTGTAAGTGGCTCTGCCAGTGAGGCCAATGTTGAGGAA 582 
M5-Avi    TATGCCATGCGGTACTTCGCAACTGTAAGTGGCTCTGCCAGTGAGGCCAATGTTGAGGAA 1320 
           Y  A  M  R  Y  F  A  T  V  S  G  S  A  S  E  A  N  V  E  E  440 
 
XM_00651  AAGGTCTTGGCCTCCAACCCCATCATGGAGTCAATTGGAAATGCCAAAACAACCAGGAAT 642 
M5-Avi    AAGGTCTTGGCCTCCAACCCCATCATGGAGTCAATTGGAAATGCCAAAACAACCAGGAAT 1380 
           K  V  L  A  S  N  P  I  M  E  S  I  G  N  A  K  T  T  R  N  460 
 
XM_00651  GATAATAGCAGCCGGTTTGGAAAATATATTGAAATTGGTTTTGACAAGAGGTACAGAATC 702 
M5-Avi    GATAATAGCAGCCGGTTTGGAAAATATATTGAAATTGGTTTTGACAAGAGGTACAGAATC 1440 
           D  N  S  S  R  F  G  K  Y  I  E  I  G  F  D  K  R  Y  R  I  480 
 
XM_00651  ATCGGTGCCAATATGAGAACTTACCTTTTAGAGAAATCCAGAGTGGTGTTCCAGGCAGAA 762 
M5-Avi    ATCGGTGCCAATATGAGAACTTACCTTTTAGAGAAATCCAGAGTGGTGTTCCAGGCAGAA 1500 
           I  G  A  N  M  R  T  Y  L  L  E  K  S  R  V  V  F  Q  A  E  500 
 
XM_00651  GAGGAGAGAAACTACCATATCTTCTATCAGCTCTGTGCTTCGGCAAAGTTACCTGAGTTT 822 
M5-Avi    GAGGAGAGAAACTACCATATCTTCTATCAGCTCTGTGCTTCGGCAAAGTTACCTGAGTTT 1560 
           E  E  R  N  Y  H  I  F  Y  Q  L  C  A  S  A  K  L  P  E  F  520 
 
XM_00651  AAAATGCTGCGGTTAGGAAATGCAGATAGTTTTCATTACACGAAGCAAGGAGGCAGCCCT 882 
M5-Avi    AAAATGCTGCGGTTAGGAAATGCAGATAGTTTTCATTACACGAAGCAAGGAGGCAGCCCT 1620 
           K  M  L  R  L  G  N  A  D  S  F  H  Y  T  K  Q  G  G  S  P  540 
 
XM_00651  ATGATAGAAGGAGTAGATGATGCGAAGGAGATGGCGCACACCAGGCAGGCCTGCACTCTG 942 
M5-Avi    ATGATAGAAGGAGTAGATGATGCGAAGGAGATGGCGCACACCAGGCAGGCCTGCACTCTG 1680 
           M  I  E  G  V  D  D  A  K  E  M  A  H  T  R  Q  A  C  T  L  560 
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XM_00651  CTGGGAATTAGTGAATCTTACCAAATGGGAATTTTTCGAATACTTGCTGGCATTCTTCAC 1002 
M5-Avi    CTGGGAATTAGTGAATCTTACCAAATGGGAATTTTTCGAATACTTGCTGGCATTCTTCAC 1740 
           L  G  I  S  E  S  Y  Q  M  G  I  F  R  I  L  A  G  I  L  H  580 
 
XM_00651  TTAGGCAATGTTGGATTTGCATCTCGGGATTCAGACAGCTGCACAATACCTCCCAAGCAC 1062 
M5-Avi    TTAGGCAATGTTGGATTTGCATCTCGGGATTCAGACAGCTGCACAATACCTCCCAAGCAC 1800 
           L  G  N  V  G  F  A  S  R  D  S  D  S  C  T  I  P  P  K  H  600 
 
XM_00651  GAACCTCTTACCATCTTCTGTGACCTTATGGGTGTGGATTATGAAGAGATGTGTCACTGG 1122 
M5-Avi    GAACCTCTTACCATCTTCTGTGACCTTATGGGTGTGGATTATGAAGAGATGTGTCACTGG 1860 
           E  P  L  T  I  F  C  D  L  M  G  V  D  Y  E  E  M  C  H  W  620 
 
XM_00651  CTCTGCCACCGAAAGCTGGCTACTGCCACAGAGACATACATCAAGCCCATCTCCAAGCTG 1182 
M5-Avi    CTCTGCCACCGAAAGCTGGCTACTGCCACAGAGACATACATCAAGCCCATCTCCAAGCTG 1920 
           L  C  H  R  K  L  A  T  A  T  E  T  Y  I  K  P  I  S  K  L  640 
 
XM_00651  CAGGCCACAAATGCCCGAGATGCTTTAGCAAAGCACATCTATGCAAAGCTCTTTAACTGG 1242 
M5-Avi    CAGGCCACAAATGCCCGAGATGCTTTAGCAAAGCACATCTATGCAAAGCTCTTTAACTGG 1980 
           Q  A  T  N  A  R  D  A  L  A  K  H  I  Y  A  K  L  F  N  W  660 
 
XM_00651  ATTGTTGACCACGTCAATCAGGCTCTCCATTCTGCTGTCAAGCAGCACTCTTTCATCGGC 1302 
M5-Avi    ATTGTTGACCACGTCAATCAGGCTCTCCATTCTGCTGTCAAGCAGCACTCTTTCATCGGC 2040 
           I  V  D  H  V  N  Q  A  L  H  S  A  V  K  Q  H  S  F  I  G  680 
 
XM_00651  GTGCTGGACATCTATGGATTTGAAACATTTGAAATAAATAGTTTTGAACAGTTCTGCATA 1362 
M5-Avi    GTGCTGGACATCTATGGATTTGAAACATTTGAAATAAATAGTTTTGAACAGTTCTGCATA 2100 
           V  L  D  I  Y  G  F  E  T  F  E  I  N  S  F  E  Q  F  C  I  700 
 
XM_00651  AATTATGCAAATGAAAAACTACAACAACAATTCAACATGCATGTCTTCAAATTGGAACAG 1422 
M5-Avi    AATTATGCAAATGAAAAACTACAACAACAATTCAACATGCATGTCTTCAAATTGGAACAG 2160 
           N  Y  A  N  E  K  L  Q  Q  Q  F  N  M  H  V  F  K  L  E  Q  720  
 
XM_00651  GAGGAATATATGAAGGAACAGATTCCATGGACACTTATAGATTTCTATGATAATCAGCCT 1482 
M5-Avi    GAGGAATATATGAAGGAACAGATTCCATGGACACTTATAGATTTCTATGATAATCAGCCT 2220 
           E  E  Y  M  K  E  Q  I  P  W  T  L  I  D  F  Y  D  N  Q  P  740 
 
XM_00651  TGTATCAATCTTATAGAATCTAAACTGGGAATTCTCGATTTGCTGGATGAGGAATGTAAG 1542 
M5-Avi    TGTATCAATCTTATAGAATCTAAACTGGGAATTCTCGATTTGCTGGATGAGGAATGTAAG 2280 
           C  I  N  L  I  E  S  K  L  G  I  L  D  L  L  D  E  E  C  K  760 
 
XM_00651  ATGCCTAAAGGCACAGATGACACATGGGCCCAAAAACTGTACAACACACATTTGAACAAA 1602 
M5-Avi    ATGCCTAAAGGCACAGATGACACATGGGCCCAAAAACTGTACAACACACATTTGAACAAA 2340 
           M  P  K  G  T  D  D  T  W  A  Q  K  L  Y  N  T  H  L  N  K  780 
 
XM_00651  TGTGCCCTCTTTGAGAAGCCCCGCATGTCAAACAAAGCTTTCATCATCAAACATTTTGCT 1662 
M5-Avi    TGTGCCCTCTTTGAGAAGCCCCGCATGTCAAACAAAGCTTTCATCATCAAACATTTTGCT 2400 
           C  A  L  F  E  K  P  R  M  S  N  K  A  F  I  I  K  H  F  A  800 
 
XM_00651  GACAAAGTGGAGTACCAGTGTGAAGGTTTTCTTGAAAAGAATAAAGATACTGTTTTTGAA 1722 
M5-Avi    GACAAAGTGGAGTACCAGTGTGAAGGTTTTCTTGAAAAGAATAAAGATACTGTTTTTGAA 2460 
           D  K  V  E  Y  Q  C  E  G  F  L  E  K  N  K  D  T  V  F  E  820 
 
XM_00651  GAACAAATTAAAGTCCTTAAGTCAAGCAAGTTTAAGATGCTACCAGAGCTATTTCAAGAT 1782 
M5-Avi    GAACAAATTAAAGTCCTTAAGTCAAGCAAGTTTAAGATGCTACCAGAGCTATTTCAAGAT 2520 
           E  Q  I  K  V  L  K  S  S  K  F  K  M  L  P  E  L  F  Q  D  840 
 
XM_00651  GATGAGAAGGCCATCAGTCCCACCTCTGCCACCTCCTCAGGGCGCACTCCTCTCACTCGA 1842 
M5-Avi    GATGAGAAGGCCATCAGTCCCACCTCTGCCACCTCCTCAGGGCGCACTCCTCTCACTCGA 2580 
           D  E  K  A  I  S  P  T  S  A  T  S  S  G  R  T  P  L  T  R  860 
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XM_00651  GTTCCTGTAAAGCCCACCAAGGGCCGACCTGGCCAGACTGCCAAAGAGCACAAGAAGACA 1902 
M5-Avi    GTTCCTGTAAAGCCCACCAAGGGCCGACCTGGCCAGACTGCCAAAGAGCACAAGAAGACA 2640 
           V  P  V  K  P  T  K  G  R  P  G  Q  T  A  K  E  H  K  K  T  880 
 
XM_00651  GTGGGACATCAGTTTCGAAACTCCCTTCACCTGCTTATGGAAACCCTTAATGCCACTACT 1962 
M5-Avi    GTGGGACATCAGTTTCGAAACTCCCTTCACCTGCTTATGGAAACCCTTAATGCCACTACT 2700 
           V  G  H  Q  F  R  N  S  L  H  L  L  M  E  T  L  N  A  T  T  900 
 
XM_00651  CCTCACTATGTACGCTGTATTAAGCCTAATGATTTCAAGTTTCCATTCACATTTGATGAG 2022 
M5-Avi    CCTCACTATGTACGCTGTATTAAGCCTAATGATTTCAAGTTTCCATTCACATTTGATGAG 2760 
           P  H  Y  V  R  C  I  K  P  N  D  F  K  F  P  F  T  F  D  E  920 
 
XM_00651  AAGAGGGCAGTGCAGCAGCTAAGAGCATGTGGTGTCCTGGAGACCATCCGGATCAGCGCA 2082 
M5-Avi    AAGAGGGCAGTGCAGCAGCTAAGAGCATGTGGTGTCCTGGAGACCATCCGGATCAGCGCA 2820 
           K  R  A  V  Q  Q  L  R  A  C  G  V  L  E  T  I  R  I  S  A  940 
 
XM_00651  GCAGGGTTTCCCTCACGGTGGACTTACCAAGAGTTTTTCAGCCGGTACCGGGTCCTAATG 2142 
M5-Avi    GCAGGGTTTCCCTCACGGTGGACTTACCAAGAGTTTTTCAGCCGGTACCGGGTCCTAATG 2880 
           A  G  F  P  S  R  W  T  Y  Q  E  F  F  S  R  Y  R  V  L  M  960 
 
XM_00651  AAGCAAAAAGATGTGCTGGGAGATAGAAAGCAAACGTGCAAGAATGTATTAGAGAAACTA 2202 
M5-Avi    AAGCAAAAAGATGTGCTGGGAGATAGAAAGCAAACGTGCAAGAATGTATTAGAGAAACTA 2940 
           K  Q  K  D  V  L  G  D  R  K  Q  T  C  K  N  V  L  E  K  L  980 
 
XM_00651  ATATTGGACAAGGATAAATACCAGTTTGGTAAGACAAAGATCTTTTTCCGTGCTGGTCAA 2262 
M5-Avi    ATATTGGACAAGGATAAATACCAGTTTGGTAAGACAAAGATCTTTTTCCGTGCTGGTCAA 3000 
           I  L  D  K  D  K  Y  Q  F  G  K  T  K  I  F  F  R  A  G  Q  1000 
 
XM_00651  GTGGCCTATCTTGAAAAATTGAGGGCTGACAAACTTCGGGCTGCCTGCATCCGGATCCAG 2322 
M5-Avi    GTGGCCTATCTTGAAAAATTGAGGGCTGACAAACTTCGGGCTGCCTGCATCCGGATCCAG 3060 
           V  A  Y  L  E  K  L  R  A  D  K  L  R  A  A  C  I  R  I  Q  1020 
 
XM_00651  AAGACCATTCGTGGGTGGCTTCTAAGGAAGAGATACCTGTGTATGCAGAGGGCAGCCATC 2382 
M5-Avi    AAGACCATTCGTGGGTGGCTTCTAAGGAAGAGATACCTGTGTATGCAGAGGGCAGCCATC 3120 
           K  T  I  R  G  W  L  L  R  K  R  Y  L  C  M  Q  R  A  A  I  1040 
 
XM_00651  ACAGTGCAGCGATACGTGCGGGGCTATCAGGCTCGATGCTATGCTAAGTTTCTGCGCAGA 2442 
M5-Avi    ACAGTGCAGCGATACGTGCGGGGCTATCAGGCTCGATGCTATGCTAAGTTTCTGCGCAGA 3180 
           T  V  Q  R  Y  V  R  G  Y  Q  A  R  C  Y  A  K  F  L  R  R  1060 
 
XM_00651  ACCAAGGCAGCAACCACCATTCAAAAGTACTGGCGCATGTATGTGGTCCGCAGGAGGTAC 2502 
M5-Avi    ACCAAGGCAGCAACCACCATTCAAAAGTACTGGCGCATGTATGTGGTCCGCAGGAGGTAC 3240 
           T  K  A  A  T  T  I  Q  K  Y  W  R  M  Y  V  V  R  R  R  Y  1080 
 
XM_00651  AAGATTAGACGAGCTGCCACGATTGTTATTCAGTCTTACTTGAGAGGCTACTTGACAAGA 2562 
M5-Avi    AAGATTAGACGAGCTGCCACGATTGTTATTCAGTCTTACTTGAGAGGCTACTTGACAAGA 3300 
           K  I  R  R  A  A  T  I  V  I  Q  S  Y  L  R  G  Y  L  T  R  1100 
 
XM_00651  AATAGGTATCGCAAGATACTCCGTGAATACAAAGCAGTCATCATTCAGAAACGTGTCCGT 2622 
M5-Avi    AATAGGTATCGCAAGATACTCCGTGAATACAAAGCAGTCATCATTCAGAAACGTGTCCGT 3360 
           N  R  Y  R  K  I  L  R  E  Y  K  A  V  I  I  Q  K  R  V  R  1120 
 
XM_00651  GGCTGGCTGGCCCGTACACATTATAAGAGGACCATGAAAGCCATCGTCTACCTTCAGTGC 2682 
M5-Avi    GGCTGGCTGGCCCGTACACATTATAAGAGGACCATGAAAGCCATCGTCTACCTTCAGTGC 3420 
           G  W  L  A  R  T  H  Y  K  R  T  M  K  A  I  V  Y  L  Q  C  1140 
 
XM_00651  TGCTTCCGGCGGATGATGGCCAAGCGTGAGCTGAAGAAACTCAAAATTGAGGCTCGCTCT 2742 
M5-Avi    TGCTTCCGGCGGATGATGGCCAAGCGTGAGCTGAAGAAACTCAAAATTGAGGCTCGCTCT 3480 
           C  F  R  R  M  M  A  K  R  E  L  K  K  L  K  I  E  A  R  S  1160 
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XM_00651  GTGGAACGCTACAAGAAGCTCCATATTGGCATGGAGAACAAGATTATGCAGCTGCAGCGC 2802 
M5-Avi    GTGGAACGCTACAAGAAGCTCCATATTGGCATGGAGAACAAGATTATGCAGCTGCAGCGC 3540 
           V  E  R  Y  K  K  L  H  I  G  M  E  N  K  I  M  Q  L  Q  R  1180 
 
XM_00651  AAAGTGGATGAGCAGAATAAAGACTACAAATGCCTCATGGAGAAACTGACCAATCTGGAA 2862 
M5-Avi    AAAGTGGATGAGCAGAATAAAGACTACAAATGCCTCATGGAGAAACTGACCAATCTGGAA 3600 
           K  V  D  E  Q  N  K  D  Y  K  C  L  M  E  K  L  T  N  L  E  1200 
 
XM_00651  GGAGTATACAACTCTGAGACTGAAAAACTACGAAATGATGTAGAACGTCTTCAGCTAAGT 2922 
M5-Avi    GGAGTATACAACTCTGAGACTGAAAAACTACGAAATGATGTAGAACGTCTTCAGCTAAGT 3660 
           G  V  Y  N  S  E  T  E  K  L  R  N  D  V  E  R  L  Q  L  S  1220 
 
XM_00651  GAAGAGGAAGCTAAGGTTGCCACTGGGCGGGTCCTTAGTCTGCAGGAAGAAATTGCAAAA 2982 
M5-Avi    GAAGAGGAAGCTAAGGTTGCCACTGGGCGGGTCCTTAGTCTGCAGGAAGAAATTGCAAAA 3720 
           E  E  E  A  K  V  A  T  G  R  V  L  S  L  Q  E  E  I  A  K  1240 
 
XM_00651  CTCCGAAAAGACCTGGAACAAACTCGATCAGAGAAAAAGTCTATTGAAGAAAGAGCAGAT 3042 
M5-Avi    CTCCGAAAAGACCTGGAACAAACTCGATCAGAGAAAAAGTCTATTGAAGAAAGAGCAGAT 3780 
           L  R  K  D  L  E  Q  T  R  S  E  K  K  S  I  E  E  R  A  D  1260 
 
XM_00651  AAATACAAACAAGAAACTGACCAGCTGGTGTCAAACTTGAAGGAAGAAAATACTTTGCTG 3102 
M5-Avi    AAATACAAACAAGAAACTGACCAGCTGGTGTCAAACTTGAAGGAAGAAAATACTTTGCTG 3840 
           K  Y  K  Q  E  T  D  Q  L  V  S  N  L  K  E  E  N  T  L  L  1280 
 
XM_00651  AAGCAGGAAAAGGAGACCCTCAACCACCGCATTGTGGAGCAGGCGAAGGAGATGACAGAA 3162 
M5-Avi    AAGCAGGAAAAGGAGACCCTCAACCACCGCATTGTGGAGCAGGCGAAGGAGATGACAGAA 3900 
           K  Q  E  K  E  T  L  N  H  R  I  V  E  Q  A  K  E  M  T  E  1300 
 
XM_00651  ACTATGGAGAGGAAGTTAGTAGAAGAGACAAAACAACTGGAGCTTGACCTGAATGATGAG 3222 
M5-Avi    ACTATGGAGAGGAAGTTAGTAGAAGAGACAAAACAACTGGAGCTTGACCTGAATGATGAG 3960 
           T  M  E  R  K  L  V  E  E  T  K  Q  L  E  L  D  L  N  D  E  1320 
 
XM_00651  AGGCTGAGGTATCAGAACCTTCTGAATGAGTTCAGTCGCCTGGAGGAGCGCTATGATGAC 3282 
M5-Avi    AGGCTGAGGTATCAGAACCTTCTGAATGAGTTCAGTCGCCTGGAGGAGCGCTATGATGAC 4020 
           R  L  R  Y  Q  N  L  L  N  E  F  S  R  L  E  E  R  Y  D  D  1340 
 
XM_00651  CTCAAGGAAGAGATGACCCTGATGCTGAATGTGCCTAAGCCAGGACACAAGAGAACAGAC 3342 
M5-Avi    CTCAAGGAAGAGATGACCCTGATGCTGAATGTGCCTAAGCCAGGACACAAGAGAACAGAC 4080 
           L  K  E  E  M  T  L  M  L  N  V  P  K  P  G  H  K  R  T  D  1360 
 
XM_00651  TCTACCCACAGCAGTAATGAGTCTGAATACACCTTCAGCTCTGAGTTTGCAGAAACTGAA 3402 
M5-Avi    TCTACCCACAGCAGTAATGAGTCTGAATACACCTTCAGCTCTGAGTTTGCAGAAACTGAA 4140 
           S  T  H  S  S  N  E  S  E  Y  T  F  S  S  E  F  A  E  T  E  1380 
 
XM_00651  GACATTGCACCAAGAACAGAGGAGCCAATTGAGAAGAAGGTGCCTCTGGATATGTCACTA 3462 
M5-Avi    GACATTGCACCAAGAACAGAGGAGCCAATTGAGAAGAAGGTGCCTCTGGATATGTCACTA 4200 
           D  I  A  P  R  T  E  E  P  I  E  K  K  V  P  L  D  M  S  L  1400 
 
XM_00651  TTCCTTAAGCTCCAGAAGCGTGTCACAGAGCTGGAACAGGAGAAGCAGCTGATGCAGGAT 3522 
M5-Avi    TTCCTTAAGCTCCAGAAGCGTGTCACAGAGCTGGAACAGGAGAAGCAGCTGATGCAGGAT 4260 
           F  L  K  L  Q  K  R  V  T  E  L  E  Q  E  K  Q  L  M  Q  D  1420 
 
XM_00651  GAGCTGGACCGCAAGGAGGAGCAGGTGTTCCGCAGCAAGGCAAAGGAAGAAGAAAGGCCA 3582 
M5-Avi    GAGCTGGACCGCAAGGAGGAGCAGGTGTTCCGCAGCAAGGCAAAGGAAGAAGAAAGGCCA 4320 
           E  L  D  R  K  E  E  Q  V  F  R  S  K  A  K  E  E  E  R  P  1440 
 
XM_00651  CAGATAAGAGGAGCTGAACTAGAGTATGAGTCTCTCAAGCGTCAAGAACTGGAGTCAGAA 3642 
M5-Avi    CAGATAAGAGGAGCTGAACTAGAGTATGAGTCTCTCAAGCGTCAAGAACTGGAGTCAGAA 4380 
           Q  I  R  G  A  E  L  E  Y  E  S  L  K  R  Q  E  L  E  S  E  1460 
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XM_00651  AACAAAAAACTGAAAAACGAGCTGAATGAGTTGCGCAAAGCCCTCAGTGAGAAAAGTGCC 3702 
M5-Avi    AACAAAAAACTGAAAAACGAGCTGAATGAGTTGCGCAAAGCCCTCAGTGAGAAAAGTGCC 4440 
           N  K  K  L  K  N  E  L  N  E  L  R  K  A  L  S  E  K  S  A  1480 
 
XM_00651  CCAGAAGTGACTGCGCCAGGTGCGCCTGCTTACCGAGTCCTCATGGAACAGCTGACCTCC 3762 
M5-Avi    CCAGAAGTGACTGCGCCAGGTGCGCCTGCTTACCGAGTCCTCATGGAACAGCTGACCTCC 4500 
           P  E  V  T  A  P  G  A  P  A  Y  R  V  L  M  E  Q  L  T  S  1500 
 
XM_00651  GTGAGCGAGGAGCTCGACGTGCGCAAGGAGGAAGTCCTCATCTTGAGGTCGCAGCTGGTG 3822 
M5-Avi    GTGAGCGAGGAGCTCGACGTGCGCAAGGAGGAAGTCCTCATCTTGAGGTCGCAGCTGGTG 4560 
           V  S  E  E  L  D  V  R  K  E  E  V  L  I  L  R  S  Q  L  V  1520 
 
XM_00651  AGCCAAAAAGAAGCCATCCAACCCAAGGATGACAAGAATACAATGACAGATTCCACAATT 3882 
M5-Avi    AGCCAAAAAGAAGCCATCCAACCCAAGGATGACAAGAATACAATGACAGATTCCACAATT 4620 
           S  Q  K  E  A  I  Q  P  K  D  D  K  N  T  M  T  D  S  T  I  1540 
 
XM_00651  CTTTTAGAAGATGTACAGAAAATGAAAGACAAAGGTGAAATAGCACAAGCATATATTGGT 3942 
M5-Avi    CTTTTAGAAGATGTACAGAAAATGAAAGACAAAGGTGAAATAGCACAAGCATATATTGGT 4680 
           L  L  E  D  V  Q  K  M  K  D  K  G  E  I  A  Q  A  Y  I  G  1560 
 
XM_00651  TTGAAAGAAACAAACAGGCTCTTAGAATCCCAGCTACAGTCACAGAAAAGAAGCCATGAG 4002 
M5-Avi    TTGAAAGAAACAAACAGGCTCTTAGAATCCCAGCTACAGTCACAGAAAAGAAGCCATGAG 4740 
           L  K  E  T  N  R  L  L  E  S  Q  L  Q  S  Q  K  R  S  H  E  1580 
 
XM_00651  AATGAGGCTGAGGCCCTCCGTGGGGAGATCCAGAGCCTAAAGGAAGAAAACAACCGGCAA 4062 
M5-Avi    AATGAGGCTGAGGCCCTCCGTGGGGAGATCCAGAGCCTAAAGGAAGAAAACAACCGGCAA 4800 
           N  E  A  E  A  L  R  G  E  I  Q  S  L  K  E  E  N  N  R  Q  1600 
 
XM_00651  CAGCAGCTGCTGGCCCAGAACCTGCAGCTGCCCCCTGAGGCCCGCATTGAGGCCAGCCTG 4122 
M5-Avi    CAGCAGCTGCTGGCCCAGAACCTGCAGCTGCCCCCTGAGGCCCGCATTGAGGCCAGCCTG 4860 
           Q  Q  L  L  A  Q  N  L  Q  L  P  P  E  A  R  I  E  A  S  L  1620 
 
XM_00651  CAGCATGAGATCACCCGGCTGACCAATGAAAACCTGGATCTGATGGAACAACTTGAAAAG 4182 
M5-Avi    CAGCATGAGATCACCCGGCTGACCAATGAAAACCTGGATCTGATGGAACAACTTGAAAAG 4920 
           Q  H  E  I  T  R  L  T  N  E  N  L  D  L  M  E  Q  L  E  K  1640 
 
XM_00651  CAGGATAAAACTGTCCGGAAACTGAAGAAACAACTGAAAGTCTTTGCCAAAAAAATTGGT 4242 
M5-Avi    CAGGATAAAACTGTCCGGAAACTGAAGAAACAACTGAAAGTCTTTGCCAAAAAAATTGGT 4980 
           Q  D  K  T  V  R  K  L  K  K  Q  L  K  V  F  A  K  K  I  G  1660 
 
XM_00651  GAACTAGAAGTGGGGCAGATGGAGAACATATCTCCAGGACAGATCATCGATGAGCCTATC 4302 
M5-Avi    GAACTAGAAGTGGGGCAGATGGAGAACATATCTCCAGGACAGATCATCGATGAGCCTATC 5040 
           E  L  E  V  G  Q  M  E  N  I  S  P  G  Q  I  I  D  E  P  I  1680 
 
XM_00651  CGGCCAGTCAACATTCCC------------------------------------------ 4320 
M5-Avi    CGGCCAGTCAACATTCCCGGCCTGAATGATATTTTTGAAGCGCAGAAAATTGAATGGCAT 5100 
           R  P  V  N  I  P  G  L  N  D  I  F  E  A  Q  K  I  E  W  H  1700                      
 
XM_00651  ------------------------------------------------------------  
M5-Avi    GAAAGGCCTACGTCGACGAGCTCACTAGTCGCGGCCGCAGACTACAAGGACGACGATGAT 5160 
           E  R  P  T  S  T  S  S  L  V  A  A  A  D  Y  K  D  D  D  D  1720                             
 
XM_00651  ------ 
M5-Avi    AAGTAG 5166 
           K  X  1721 
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S3. Amino acid sequence of Myosin-5-cc construct 
Sequence alignment was performed using the ClustalW webserver (Larkin et al., 
2007). First line shows the DNA sequence of the brain isoform of mouse myosin-5a 
(NCBI Reference Sequence: XM_006510832.3). Second line shows the DNA 
sequence of the Myosin-5-cc construct. Third line shows the amino acid sequence 
corresponding to the Myosin-5-cc construct. Colouring of the amino acid sequence 
represents the distinct domains and motifs of the protein according to the legend. 
Numbers at the end of the lines represent the number of nucleic acids or amino 
acids up to that point in the sequence. 
 
Legend: 
GFP 
Restriction sites: BssH II, EcoR I and Stu I 
Mouse myosin-5a brain isoform with the whole coiled-coil domain, with additional 
175 amino acid coiled-coil 
Avi-tag 
Restriction sites: Stu I, Sal I, Sst I, Spe I and Not I 
Flag tag 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGAC 60 
           M  V  S  K  G  E  E  L  F  T  G  V  V  P  I  L  V  E  L  D  20                                                                       
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTAC 120 
           G  D  V  N  G  H  K  F  S  V  S  G  E  G  E  G  D  A  T  Y  40                                                                   
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACC 180 
           G  K  L  T  L  K  F  I  C  T  T  G  K  L  P  V  P  W  P  T  60                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     CTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAG 240 
           L  V  T  T  L  T  Y  G  V  Q  C  F  S  R  Y  P  D  H  M  K  80                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     CAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTC 300 
           Q  H  D  F  F  K  S  A  M  P  E  G  Y  V  Q  E  R  T  I  F  100                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     TTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTG 360 
           F  K  D  D  G  N  Y  K  T  R  A  E  V  K  F  E  G  D  T  L  120                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCAC 420 
           V  N  R  I  E  L  K  G  I  D  F  K  E  D  G  N  I  L  G  H  140                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     AAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAAC 480 
           K  L  E  Y  N  Y  N  S  H  N  V  Y  I  M  A  D  K  Q  K  N  160                                                                    
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XM_00651  ------------------------------------------------------------ 
M5-cc     GGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCC 540 
           G  I  K  V  N  F  K  I  R  H  N  I  E  D  G  S  V  Q  L  A  180                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCAC 600 
           D  H  Y  Q  Q  N  T  P  I  G  D  G  P  V  L  L  P  D  N  H  200                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     TACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTC 660 
           Y  L  S  T  Q  S  A  L  S  K  D  P  N  E  K  R  D  H  M  V  220                                                                    
 
XM_00651  ------------------------------------------------------------ 
M5-cc     CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGGCG 720 
           L  L  E  F  V  T  A  A  G  I  T  L  G  M  D  E  L  Y  K  A  240                                                                    
 
XM_00651  ------------------ATGGCCGCGTCCGAGCTCTACACCAAGTTTGCCAGGGTTTGG 42 
M5-cc     CGCGGAATTCAAAGGCCTATGGCCGCGTCCGAGCTCTACACCAAGTTTGCCAGGGTTTGG 780 
           R  G  I  Q  R  P  M  A  A  S  E  L  Y  T  K  F  A  R  V  W  260                
 
XM_00651  ATCCCTGATCCTGAGGAAGTGTGGAAATCGGCAGAGTTGCTCAAGGATTATAAGCCTGGA 102 
M5-cc     ATCCCTGATCCTGAGGAAGTGTGGAAATCGGCAGAGTTGCTCAAGGATTATAAGCCTGGA 840 
           I  P  D  P  E  E  V  W  K  S  A  E  L  L  K  D  Y  K  P  G  280 
 
XM_00651  GATAAAGTGCTCCTGCTTCACCTCGAGGAAGGGAAGGATTTGGAATACCGTCTAGACCCA 162 
M5-cc     GATAAAGTGCTCCTGCTTCACCTCGAGGAAGGGAAGGATTTGGAATACCGTCTAGACCCA 900 
           D  K  V  L  L  L  H  L  E  E  G  K  D  L  E  Y  R  L  D  P  300 
 
XM_00651  AAGACCGGTGAGCTCCCTCACTTACGGAACCCTGACATACTTGTTGGAGAAAATGACCTC 222 
M5-cc     AAGACCGGTGAGCTCCCTCACTTACGGAACCCTGACATACTTGTTGGAGAAAATGACCTC 960 
           K  T  G  E  L  P  H  L  R  N  P  D  I  L  V  G  E  N  D  L  320 
 
XM_00651  ACAGCCCTCAGCTACCTTCACGAGCCCGCTGTGCTACATAATCTCCGAGTTCGCTTCATC 282 
M5-cc     ACAGCCCTCAGCTACCTTCACGAGCCCGCTGTGCTACATAATCTCCGAGTTCGCTTCATC 1020 
           T  A  L  S  Y  L  H  E  P  A  V  L  H  N  L  R  V  R  F  I  340 
 
XM_00651  GATTCCAAACTTATTTATACGTATTGTGGAATAGTTCTGGTAGCTATAAATCCCTATGAG 342 
M5-cc     GATTCCAAACTTATTTATACGTATTGTGGAATAGTTCTGGTAGCTATAAATCCCTATGAG 1080 
           D  S  K  L  I  Y  T  Y  C  G  I  V  L  V  A  I  N  P  Y  E  360 
 
XM_00651  CAGCTGCCTATTTATGGAGAAGATATTATTAATGCCTACAGTGGCCAGAACATGGGTGAC 402 
M5-cc     CAGCTGCCTATTTATGGAGAAGATATTATTAATGCCTACAGTGGCCAGAACATGGGTGAC 1140 
           Q  L  P  I  Y  G  E  D  I  I  N  A  Y  S  G  Q  N  M  G  D  380 
 
XM_00651  ATGGATCCTCACATCTTCGCAGTAGCTGAAGAGGCTTACAAGCAAATGGCAAGGGATGAA 462 
M5-cc     ATGGATCCTCACATCTTCGCAGTAGCTGAAGAGGCTTACAAGCAAATGGCAAGGGATGAA 1200 
           M  D  P  H  I  F  A  V  A  E  E  A  Y  K  Q  M  A  R  D  E  400 
 
XM_00651  CGAAATCAGTCCATCATTGTAAGTGGAGAGTCAGGCGCAGGGAAGACGGTCTCTGCTAAG 522 
M5-cc     CGAAATCAGTCCATCATTGTAAGTGGAGAGTCAGGCGCAGGGAAGACGGTCTCTGCTAAG 1260 
           R  N  Q  S  I  I  V  S  G  E  S  G  A  G  K  T  V  S  A  K  420 
 
XM_00651  TATGCCATGCGGTACTTCGCAACTGTAAGTGGCTCTGCCAGTGAGGCCAATGTTGAGGAA 582 
M5-cc     TATGCCATGCGGTACTTCGCAACTGTAAGTGGCTCTGCCAGTGAGGCCAATGTTGAGGAA 1320 
           Y  A  M  R  Y  F  A  T  V  S  G  S  A  S  E  A  N  V  E  E  440 
 
XM_00651  AAGGTCTTGGCCTCCAACCCCATCATGGAGTCAATTGGAAATGCCAAAACAACCAGGAAT 642 
M5-cc     AAGGTCTTGGCCTCCAACCCCATCATGGAGTCAATTGGAAATGCCAAAACAACCAGGAAT 1380 
           K  V  L  A  S  N  P  I  M  E  S  I  G  N  A  K  T  T  R  N  460 
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XM_00651  GATAATAGCAGCCGGTTTGGAAAATATATTGAAATTGGTTTTGACAAGAGGTACAGAATC 702 
M5-cc     GATAATAGCAGCCGGTTTGGAAAATATATTGAAATTGGTTTTGACAAGAGGTACAGAATC 1440 
           D  N  S  S  R  F  G  K  Y  I  E  I  G  F  D  K  R  Y  R  I  480 
 
XM_00651  ATCGGTGCCAATATGAGAACTTACCTTTTAGAGAAATCCAGAGTGGTGTTCCAGGCAGAA 762 
M5-cc     ATCGGTGCCAATATGAGAACTTACCTTTTAGAGAAATCCAGAGTGGTGTTCCAGGCAGAA 1500 
           I  G  A  N  M  R  T  Y  L  L  E  K  S  R  V  V  F  Q  A  E  500 
 
XM_00651  GAGGAGAGAAACTACCATATCTTCTATCAGCTCTGTGCTTCGGCAAAGTTACCTGAGTTT 822 
M5-cc     GAGGAGAGAAACTACCATATCTTCTATCAGCTCTGTGCTTCGGCAAAGTTACCTGAGTTT 1560 
           E  E  R  N  Y  H  I  F  Y  Q  L  C  A  S  A  K  L  P  E  F  520 
 
XM_00651  AAAATGCTGCGGTTAGGAAATGCAGATAGTTTTCATTACACGAAGCAAGGAGGCAGCCCT 882 
M5-cc     AAAATGCTGCGGTTAGGAAATGCAGATAGTTTTCATTACACGAAGCAAGGAGGCAGCCCT 1620 
           K  M  L  R  L  G  N  A  D  S  F  H  Y  T  K  Q  G  G  S  P  540 
 
XM_00651  ATGATAGAAGGAGTAGATGATGCGAAGGAGATGGCGCACACCAGGCAGGCCTGCACTCTG 942 
M5-cc     ATGATAGAAGGAGTAGATGATGCGAAGGAGATGGCGCACACCAGGCAGGCCTGCACTCTG 1680 
           M  I  E  G  V  D  D  A  K  E  M  A  H  T  R  Q  A  C  T  L  560 
 
XM_00651  CTGGGAATTAGTGAATCTTACCAAATGGGAATTTTTCGAATACTTGCTGGCATTCTTCAC 1002 
M5-cc     CTGGGAATTAGTGAATCTTACCAAATGGGAATTTTTCGAATACTTGCTGGCATTCTTCAC 1740 
           L  G  I  S  E  S  Y  Q  M  G  I  F  R  I  L  A  G  I  L  H  580 
 
XM_00651  TTAGGCAATGTTGGATTTGCATCTCGGGATTCAGACAGCTGCACAATACCTCCCAAGCAC 1062 
M5-cc     TTAGGCAATGTTGGATTTGCATCTCGGGATTCAGACAGCTGCACAATACCTCCCAAGCAC 1800 
           L  G  N  V  G  F  A  S  R  D  S  D  S  C  T  I  P  P  K  H  600 
 
XM_00651  GAACCTCTTACCATCTTCTGTGACCTTATGGGTGTGGATTATGAAGAGATGTGTCACTGG 1122 
M5-cc     GAACCTCTTACCATCTTCTGTGACCTTATGGGTGTGGATTATGAAGAGATGTGTCACTGG 1860 
           E  P  L  T  I  F  C  D  L  M  G  V  D  Y  E  E  M  C  H  W  620 
 
XM_00651  CTCTGCCACCGAAAGCTGGCTACTGCCACAGAGACATACATCAAGCCCATCTCCAAGCTG 1182 
M5-cc     CTCTGCCACCGAAAGCTGGCTACTGCCACAGAGACATACATCAAGCCCATCTCCAAGCTG 1920 
           L  C  H  R  K  L  A  T  A  T  E  T  Y  I  K  P  I  S  K  L  640 
 
XM_00651  CAGGCCACAAATGCCCGAGATGCTTTAGCAAAGCACATCTATGCAAAGCTCTTTAACTGG 1242 
M5-cc     CAGGCCACAAATGCCCGAGATGCTTTAGCAAAGCACATCTATGCAAAGCTCTTTAACTGG 1980 
           Q  A  T  N  A  R  D  A  L  A  K  H  I  Y  A  K  L  F  N  W  660 
 
XM_00651  ATTGTTGACCACGTCAATCAGGCTCTCCATTCTGCTGTCAAGCAGCACTCTTTCATCGGC 1302 
M5-cc     ATTGTTGACCACGTCAATCAGGCTCTCCATTCTGCTGTCAAGCAGCACTCTTTCATCGGC 2040 
           I  V  D  H  V  N  Q  A  L  H  S  A  V  K  Q  H  S  F  I  G  680 
 
XM_00651  GTGCTGGACATCTATGGATTTGAAACATTTGAAATAAATAGTTTTGAACAGTTCTGCATA 1362 
M5-cc     GTGCTGGACATCTATGGATTTGAAACATTTGAAATAAATAGTTTTGAACAGTTCTGCATA 2100 
           V  L  D  I  Y  G  F  E  T  F  E  I  N  S  F  E  Q  F  C  I  700 
 
XM_00651  AATTATGCAAATGAAAAACTACAACAACAATTCAACATGCATGTCTTCAAATTGGAACAG 1422 
M5-cc     AATTATGCAAATGAAAAACTACAACAACAATTCAACATGCATGTCTTCAAATTGGAACAG 2160 
           N  Y  A  N  E  K  L  Q  Q  Q  F  N  M  H  V  F  K  L  E  Q  720  
 
XM_00651  GAGGAATATATGAAGGAACAGATTCCATGGACACTTATAGATTTCTATGATAATCAGCCT 1482 
M5-cc     GAGGAATATATGAAGGAACAGATTCCATGGACACTTATAGATTTCTATGATAATCAGCCT 2220 
           E  E  Y  M  K  E  Q  I  P  W  T  L  I  D  F  Y  D  N  Q  P  740 
 
XM_00651  TGTATCAATCTTATAGAATCTAAACTGGGAATTCTCGATTTGCTGGATGAGGAATGTAAG 1542 
M5-cc     TGTATCAATCTTATAGAATCTAAACTGGGAATTCTCGATTTGCTGGATGAGGAATGTAAG 2280 
           C  I  N  L  I  E  S  K  L  G  I  L  D  L  L  D  E  E  C  K  760 
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XM_00651  ATGCCTAAAGGCACAGATGACACATGGGCCCAAAAACTGTACAACACACATTTGAACAAA 1602 
M5-cc     ATGCCTAAAGGCACAGATGACACATGGGCCCAAAAACTGTACAACACACATTTGAACAAA 2340 
           M  P  K  G  T  D  D  T  W  A  Q  K  L  Y  N  T  H  L  N  K  780 
 
XM_00651  TGTGCCCTCTTTGAGAAGCCCCGCATGTCAAACAAAGCTTTCATCATCAAACATTTTGCT 1662 
M5-cc     TGTGCCCTCTTTGAGAAGCCCCGCATGTCAAACAAAGCTTTCATCATCAAACATTTTGCT 2400 
           C  A  L  F  E  K  P  R  M  S  N  K  A  F  I  I  K  H  F  A  800 
 
XM_00651  GACAAAGTGGAGTACCAGTGTGAAGGTTTTCTTGAAAAGAATAAAGATACTGTTTTTGAA 1722 
M5-cc     GACAAAGTGGAGTACCAGTGTGAAGGTTTTCTTGAAAAGAATAAAGATACTGTTTTTGAA 2460 
           D  K  V  E  Y  Q  C  E  G  F  L  E  K  N  K  D  T  V  F  E  820 
 
XM_00651  GAACAAATTAAAGTCCTTAAGTCAAGCAAGTTTAAGATGCTACCAGAGCTATTTCAAGAT 1782 
M5-cc     GAACAAATTAAAGTCCTTAAGTCAAGCAAGTTTAAGATGCTACCAGAGCTATTTCAAGAT 2520 
           E  Q  I  K  V  L  K  S  S  K  F  K  M  L  P  E  L  F  Q  D  840 
 
XM_00651  GATGAGAAGGCCATCAGTCCCACCTCTGCCACCTCCTCAGGGCGCACTCCTCTCACTCGA 1842 
M5-cc     GATGAGAAGGCCATCAGTCCCACCTCTGCCACCTCCTCAGGGCGCACTCCTCTCACTCGA 2580 
           D  E  K  A  I  S  P  T  S  A  T  S  S  G  R  T  P  L  T  R  860 
 
XM_00651  GTTCCTGTAAAGCCCACCAAGGGCCGACCTGGCCAGACTGCCAAAGAGCACAAGAAGACA 1902 
M5-cc     GTTCCTGTAAAGCCCACCAAGGGCCGACCTGGCCAGACTGCCAAAGAGCACAAGAAGACA 2640 
           V  P  V  K  P  T  K  G  R  P  G  Q  T  A  K  E  H  K  K  T  880 
 
XM_00651  GTGGGACATCAGTTTCGAAACTCCCTTCACCTGCTTATGGAAACCCTTAATGCCACTACT 1962 
M5-cc     GTGGGACATCAGTTTCGAAACTCCCTTCACCTGCTTATGGAAACCCTTAATGCCACTACT 2700 
           V  G  H  Q  F  R  N  S  L  H  L  L  M  E  T  L  N  A  T  T  900 
 
XM_00651  CCTCACTATGTACGCTGTATTAAGCCTAATGATTTCAAGTTTCCATTCACATTTGATGAG 2022 
M5-cc     CCTCACTATGTACGCTGTATTAAGCCTAATGATTTCAAGTTTCCATTCACATTTGATGAG 2760 
           P  H  Y  V  R  C  I  K  P  N  D  F  K  F  P  F  T  F  D  E  920 
 
XM_00651  AAGAGGGCAGTGCAGCAGCTAAGAGCATGTGGTGTCCTGGAGACCATCCGGATCAGCGCA 2082 
M5-cc     AAGAGGGCAGTGCAGCAGCTAAGAGCATGTGGTGTCCTGGAGACCATCCGGATCAGCGCA 2820 
           K  R  A  V  Q  Q  L  R  A  C  G  V  L  E  T  I  R  I  S  A  940 
 
XM_00651  GCAGGGTTTCCCTCACGGTGGACTTACCAAGAGTTTTTCAGCCGGTACCGGGTCCTAATG 2142 
M5-cc     GCAGGGTTTCCCTCACGGTGGACTTACCAAGAGTTTTTCAGCCGGTACCGGGTCCTAATG 2880 
           A  G  F  P  S  R  W  T  Y  Q  E  F  F  S  R  Y  R  V  L  M  960 
 
XM_00651  AAGCAAAAAGATGTGCTGGGAGATAGAAAGCAAACGTGCAAGAATGTATTAGAGAAACTA 2202 
M5-cc     AAGCAAAAAGATGTGCTGGGAGATAGAAAGCAAACGTGCAAGAATGTATTAGAGAAACTA 2940 
           K  Q  K  D  V  L  G  D  R  K  Q  T  C  K  N  V  L  E  K  L  980 
 
XM_00651  ATATTGGACAAGGATAAATACCAGTTTGGTAAGACAAAGATCTTTTTCCGTGCTGGTCAA 2262 
M5-cc     ATATTGGACAAGGATAAATACCAGTTTGGTAAGACAAAGATCTTTTTCCGTGCTGGTCAA 3000 
           I  L  D  K  D  K  Y  Q  F  G  K  T  K  I  F  F  R  A  G  Q  1000 
 
XM_00651  GTGGCCTATCTTGAAAAATTGAGGGCTGACAAACTTCGGGCTGCCTGCATCCGGATCCAG 2322 
M5-cc     GTGGCCTATCTTGAAAAATTGAGGGCTGACAAACTTCGGGCTGCCTGCATCCGGATCCAG 3060 
           V  A  Y  L  E  K  L  R  A  D  K  L  R  A  A  C  I  R  I  Q  1020 
 
XM_00651  AAGACCATTCGTGGGTGGCTTCTAAGGAAGAGATACCTGTGTATGCAGAGGGCAGCCATC 2382 
M5-cc     AAGACCATTCGTGGGTGGCTTCTAAGGAAGAGATACCTGTGTATGCAGAGGGCAGCCATC 3120 
           K  T  I  R  G  W  L  L  R  K  R  Y  L  C  M  Q  R  A  A  I  1040 
 
XM_00651  ACAGTGCAGCGATACGTGCGGGGCTATCAGGCTCGATGCTATGCTAAGTTTCTGCGCAGA 2442 
M5-cc     ACAGTGCAGCGATACGTGCGGGGCTATCAGGCTCGATGCTATGCTAAGTTTCTGCGCAGA 3180 
           T  V  Q  R  Y  V  R  G  Y  Q  A  R  C  Y  A  K  F  L  R  R  1060 
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XM_00651  ACCAAGGCAGCAACCACCATTCAAAAGTACTGGCGCATGTATGTGGTCCGCAGGAGGTAC 2502 
M5-cc     ACCAAGGCAGCAACCACCATTCAAAAGTACTGGCGCATGTATGTGGTCCGCAGGAGGTAC 3240 
           T  K  A  A  T  T  I  Q  K  Y  W  R  M  Y  V  V  R  R  R  Y  1080 
 
XM_00651  AAGATTAGACGAGCTGCCACGATTGTTATTCAGTCTTACTTGAGAGGCTACTTGACAAGA 2562 
M5-cc     AAGATTAGACGAGCTGCCACGATTGTTATTCAGTCTTACTTGAGAGGCTACTTGACAAGA 3300 
           K  I  R  R  A  A  T  I  V  I  Q  S  Y  L  R  G  Y  L  T  R  1100 
 
XM_00651  AATAGGTATCGCAAGATACTCCGTGAATACAAAGCAGTCATCATTCAGAAACGTGTCCGT 2622 
M5-cc     AATAGGTATCGCAAGATACTCCGTGAATACAAAGCAGTCATCATTCAGAAACGTGTCCGT 3360 
           N  R  Y  R  K  I  L  R  E  Y  K  A  V  I  I  Q  K  R  V  R  1120 
 
XM_00651  GGCTGGCTGGCCCGTACACATTATAAGAGGACCATGAAAGCCATCGTCTACCTTCAGTGC 2682 
M5-cc     GGCTGGCTGGCCCGTACACATTATAAGAGGACCATGAAAGCCATCGTCTACCTTCAGTGC 3420 
           G  W  L  A  R  T  H  Y  K  R  T  M  K  A  I  V  Y  L  Q  C  1140 
 
XM_00651  TGCTTCCGGCGGATGATGGCCAAGCGTGAGCTGAAGAAACTCAAAATTGAGGCTCGCTCT 2742 
M5-cc     TGCTTCCGGCGGATGATGGCCAAGCGTGAGCTGAAGAAACTCAAAATTGAGGCTCGCTCT 3480 
           C  F  R  R  M  M  A  K  R  E  L  K  K  L  K  I  E  A  R  S  1160 
 
XM_00651  GTGGAACGCTACAAGAAGCTCCATATTGGCATGGAGAACAAGATTATGCAGCTGCAGCGC 2802 
M5-cc     GTGGAACGCTACAAGAAGCTCCATATTGGCATGGAGAACAAGATTATGCAGCTGCAGCGC 3540 
           V  E  R  Y  K  K  L  H  I  G  M  E  N  K  I  M  Q  L  Q  R  1180 
 
XM_00651  AAAGTGGATGAGCAGAATAAAGACTACAAATGCCTCATGGAGAAACTGACCAATCTGGAA 2862 
M5-cc     AAAGTGGATGAGCAGAATAAAGACTACAAATGCCTCATGGAGAAACTGACCAATCTGGAA 3600 
           K  V  D  E  Q  N  K  D  Y  K  C  L  M  E  K  L  T  N  L  E  1200 
 
XM_00651  GGAGTATACAACTCTGAGACTGAAAAACTACGAAATGATGTAGAACGTCTTCAGCTAAGT 2922 
M5-cc     GGAGTATACAACTCTGAGACTGAAAAACTACGAAATGATGTAGAACGTCTTCAGCTAAGT 3660 
           G  V  Y  N  S  E  T  E  K  L  R  N  D  V  E  R  L  Q  L  S  1220 
 
XM_00651  GAAGAGGAAGCTAAGGTTGCCACTGGGCGGGTCCTTAGTCTGCAGGAAGAAATTGCAAAA 2982 
M5-cc     GAAGAGGAAGCTAAGGTTGCCACTGGGCGGGTCCTTAGTCTGCAGGAAGAAATTGCAAAA 3720 
           E  E  E  A  K  V  A  T  G  R  V  L  S  L  Q  E  E  I  A  K  1240 
 
XM_00651  CTCCGAAAAGACCTGGAACAAACTCGATCAGAGAAAAAGTCTATTGAAGAAAGAGCAGAT 3042 
M5-cc     CTCCGAAAAGACCTGGAACAAACTCGATCAGAGAAAAAGTCTATTGAAGAAAGAGCAGAT 3780 
           L  R  K  D  L  E  Q  T  R  S  E  K  K  S  I  E  E  R  A  D  1260 
 
XM_00651  AAATACAAACAAGAAACTGACCAGCTGGTGTCAAACTTGAAGGAAGAAAATACTTTGCTG 3102 
M5-cc     AAATACAAACAAGAAACTGACCAGCTGGTGTCAAACTTGAAGGAAGAAAATACTTTGCTG 3840 
           K  Y  K  Q  E  T  D  Q  L  V  S  N  L  K  E  E  N  T  L  L  1280 
 
XM_00651  AAGCAGGAAAAGGAGACCCTCAACCACCGCATTGTGGAGCAGGCGAAGGAGATGACAGAA 3162 
M5-cc     AAGCAGGAAAAGGAGACCCTCAACCACCGCATTGTGGAGCAGGCGAAGGAGATGACAGAA 3900 
           K  Q  E  K  E  T  L  N  H  R  I  V  E  Q  A  K  E  M  T  E  1300 
 
XM_00651  ACTATGGAGAGGAAGTTAGTAGAAGAGACAAAACAACTGGAGCTTGACCTGAATGATGAG 3222 
M5-cc     ACTATGGAGAGGAAGTTAGTAGAAGAGACAAAACAACTGGAGCTTGACCTGAATGATGAG 3960 
           T  M  E  R  K  L  V  E  E  T  K  Q  L  E  L  D  L  N  D  E  1320 
 
XM_00651  AGGCTGAGGTATCAGAACCTTCTGAATGAGTTCAGTCGCCTGGAGGAGCGC--------- 3273 
M5-cc     AGGCTGAGGTATCAGAACCTTCTGAATGAGTTCAGTCGCCTGGAGGAGCGCCGCTACAAG 4020 
           R  L  R  Y  Q  N  L  L  N  E  F  S  R  L  E  E  R  R  Y  K  1340 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     AAGCTCCATATTGGCATGGAGAACAAGATTATGCAGCTGCAGCGCAAAGTGGATGAGCAG 4080 
           K  L  H  I  G  M  E  N  K  I  M  Q  L  Q  R  K  V  D  E  Q  1360 
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XM_00651  ------------------------------------------------------------ 
M5-cc     AATAAAGACTACAAATGCCTCATGGAGAAACTGACCAATCTGGAAGGAGTATACAACTCT 4140 
           N  K  D  Y  K  C  L  M  E  K  L  T  N  L  E  G  V  Y  N  S  1380 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GAGACTGAAAAACTACGAAATGATGTAGAACGTCTTCAGCTAAGTGAAGAGGAAGCTAAG 4200 
           E  T  E  K  L  R  N  D  V  E  R  L  Q  L  S  E  E  E  A  K  1400 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GTTGCCACTGGGCGGGTCCTTAGTCTGCAGGAAGAAATTGCAAAACTCCGAAAAGACCTG 4260 
           V  A  T  G  R  V  L  S  L  Q  E  E  I  A  K  L  R  K  D  L  1420 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     GAACAAACTCGATCAGAGAAAAAGTCTATTGAAGAAAGAGCAGATAAATACAAACAAGAA 4320 
           E  Q  T  R  S  E  K  K  S  I  E  E  R  A  D  K  Y  K  Q  E  1440 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     ACTGACCAGCTGGTGTCAAACTTGAAGGAAGAAAATACTTTGCTGAAGCAGGAAAAGGAG 4380 
           T  D  Q  L  V  S  N  L  K  E  E  N  T  L  L  K  Q  E  K  E  1460 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     ACCCTCAACCACCGCATTGTGGAGCAGGCGAAGGAGATGACAGAAACTATGGAGAGGAAG 4440 
           T  L  N  H  R  I  V  E  Q  A  K  E  M  T  E  T  M  E  R  K  1480 
 
XM_00651  ------------------------------------------------------------ 
M5-cc     TTAGTAGAAGAGACAAAACAACTGGAGCTTGACCTGAATGATGAGAGGCTGAGGTATCAG 4500 
           L  V  E  E  T  K  Q  L  E  L  D  L  N  D  E  R  L  R  Y  Q  1500 
 
XM_00651  ------------------------------------TATGATGACCTCAAGGAAGAGATG 3297 
M5-cc     AACCTTCTGAATGAGTTCAGTCGCCTGGAGGAGCGCTATGATGACCTCAAGGAAGAGATG 4560 
           N  L  L  N  E  F  S  R  L  E  E  R  Y  D  D  L  K  E  E  M  1520 
 
XM_00651  ACCCTGATGCTGAATGTGCCTAAGCCAGGACACAAGAGAACAGACTCTACCCACAGCAGT 3357 
M5-cc     ACCCTGATGCTGAATGTGCCTAAGCCAGGACACAAGAGAACAGACTCTACCCACAGCAGT 4620 
           T  L  M  L  N  V  P  K  P  G  H  K  R  T  D  S  T  H  S  S  1540 
 
XM_00651  AATGAGTCTGAATACACCTTCAGCTCTGAGTTTGCAGAAACTGAAGACATTGCACCAAGA 3417 
M5-cc     AATGAGTCTGAATACACCTTCAGCTCTGAGTTTGCAGAAACTGAAGACATTGCACCAAGA 4680 
           N  E  S  E  Y  T  F  S  S  E  F  A  E  T  E  D  I  A  P  R  1560 
 
XM_00651  ACAGAGGAGCCAATTGAGAAGAAGGTGCCTCTGGATATGTCACTATTCCTTAAGCTCCAG 3477 
M5-cc     ACAGAGGAGCCAATTGAGAAGAAGGTGCCTCTGGATATGTCACTATTCCTTAAGCTCCAG 4740 
           T  E  E  P  I  E  K  K  V  P  L  D  M  S  L  F  L  K  L  Q  1580 
 
XM_00651  AAGCGTGTCACAGAGCTGGAACAGGAGAAGCAGCTGATGCAGGATGAGCTGGACCGCAAG 3537 
M5-cc     AAGCGTGTCACAGAGCTGGAACAGGAGAAGCAGCTGATGCAGGATGAGCTGGACCGCAAG 4800 
           K  R  V  T  E  L  E  Q  E  K  Q  L  M  Q  D  E  L  D  R  K  1600 
 
XM_00651  GAGGAGCAGGTGTTCCGCAGCAAGGCAAAGGAAGAAGAAAGGCCACAGATAAGAGGAGCT 3597 
M5-cc     GAGGAGCAGGTGTTCCGCAGCAAGGCAAAGGAAGAAGAAAGGCCACAGATAAGAGGAGCT 4860 
           E  E  Q  V  F  R  S  K  A  K  E  E  E  R  P  Q  I  R  G  A  1620 
 
XM_00651  GAACTAGAGTATGAGTCTCTCAAGCGTCAAGAACTGGAGTCAGAAAACAAAAAACTGAAA 3657 
M5-cc     GAACTAGAGTATGAGTCTCTCAAGCGTCAAGAACTGGAGTCAGAAAACAAAAAACTGAAA 4920 
           E  L  E  Y  E  S  L  K  R  Q  E  L  E  S  E  N  K  K  L  K  1640 
 
XM_00651  AACGAGCTGAATGAGTTGCGCAAAGCCCTCAGTGAGAAAAGTGCCCCAGAAGTGACTGCG 3717 
M5-cc     AACGAGCTGAATGAGTTGCGCAAAGCCCTCAGTGAGAAAAGTGCCCCAGAAGTGACTGCG 4980 
           N  E  L  N  E  L  R  K  A  L  S  E  K  S  A  P  E  V  T  A  1660 
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XM_00651  CCAGGTGCGCCTGCTTACCGAGTCCTCATGGAACAGCTGACCTCCGTGAGCGAGGAGCTC 3777 
M5-cc     CCAGGTGCGCCTGCTTACCGAGTCCTCATGGAACAGCTGACCTCCGTGAGCGAGGAGCTC 5040 
           P  G  A  P  A  Y  R  V  L  M  E  Q  L  T  S  V  S  E  E  L  1680 
 
XM_00651  GACGTGCGCAAGGAGGAAGTCCTCATCTTGAGGTCGCAGCTGGTGAGCCAAAAAGAAGCC 3837 
M5-cc     GACGTGCGCAAGGAGGAAGTCCTCATCTTGAGGTCGCAGCTGGTGAGCCAAAAAGAAGCC 5100 
           D  V  R  K  E  E  V  L  I  L  R  S  Q  L  V  S  Q  K  E  A  1700 
 
XM_00651  ATCCAACCCAAGGATGACAAGAATACAATGACAGATTCCACAATTCTTTTAGAAGATGTA 3897 
M5-cc     ATCCAACCCAAGGATGACAAGAATACAATGACAGATTCCACAATTCTTTTAGAAGATGTA 5160 
           I  Q  P  K  D  D  K  N  T  M  T  D  S  T  I  L  L  E  D  V  1720 
 
XM_00651  CAGAAAATGAAAGACAAAGGTGAAATAGCACAAGCATATATTGGTTTGAAAGAAACAAAC 3957 
M5-cc     CAGAAAATGAAAGACAAAGGTGAAATAGCACAAGCATATATTGGTTTGAAAGAAACAAAC 5220 
           Q  K  M  K  D  K  G  E  I  A  Q  A  Y  I  G  L  K  E  T  N  1740 
 
XM_00651  AGGCTCTTAGAATCCCAGCTACAGTCACAGAAAAGAAGCCATGAGAATGAGGCTGAGGCC 4017 
M5-cc     AGGCTCTTAGAATCCCAGCTACAGTCACAGAAAAGAAGCCATGAGAATGAGGCTGAGGCC 5280 
           R  L  L  E  S  Q  L  Q  S  Q  K  R  S  H  E  N  E  A  E  A  1760 
 
XM_00651  CTCCGTGGGGAGATCCAGAGCCTAAAGGAAGAAAACAACCGGCAACAGCAGCTGCTGGCC 4077 
M5-cc     CTCCGTGGGGAGATCCAGAGCCTAAAGGAAGAAAACAACCGGCAACAGCAGCTGCTGGCC 5340 
           L  R  G  E  I  Q  S  L  K  E  E  N  N  R  Q  Q  Q  L  L  A  1780 
      
XM_00651  CAGAACCTGCAGCTGCCCCCTGAGGCCCGCATTGAGGCCAGCCTGCAGCATGAGATCACC 4137 
M5-cc     CAGAACCTGCAGCTGCCCCCTGAGGCCCGCATTGAGGCCAGCCTGCAGCATGAGATCACC 5400 
           Q  N  L  Q  L  P  P  E  A  R  I  E  A  S  L  Q  H  E  I  T  1800 
 
XM_00651  CGGCTGACCAATGAAAACCTGGATCTGATGGAACAACTTGAAAAGCAGGATAAAACTGTC 4197 
M5-cc     CGGCTGACCAATGAAAACCTGGATCTGATGGAACAACTTGAAAAGCAGGATAAAACTGTC 5460 
           R  L  T  N  E  N  L  D  L  M  E  Q  L  E  K  Q  D  K  T  V  1820 
      
XM_00651  CGGAAACTGAAGAAACAACTGAAAGTCTTTGCCAAAAAAATTGGTGAACTAGAAGTGGGG 4257 
M5-cc     CGGAAACTGAAGAAACAACTGAAAGTCTTTGCCAAAAAAATTGGTGAACTAGAAGTGGGG 5520 
           R  K  L  K  K  Q  L  K  V  F  A  K  K  I  G  E  L  E  V  G  1840 
 
XM_00651  CAGATGGAGAACATATCTCCAGGACAGATCATCGATGAGCCTATCCGGCCAGTCAACATT 4317 
M5-cc     CAGATGGAGAACATATCTCCAGGACAGATCATCGATGAGCCTATCCGGCCAGTCAACATT 5580 
           Q  M  E  N  I  S  P  G  Q  I  I  D  E  P  I  R  P  V  N  I  1860 
 
XM_00651  CCC--------------------------------------------------------- 4320 
M5-cc     CCCGGCCTGAATGATATTTTTGAAGCGCAGAAAATTGAATGGCATGAAAGGCCTACGTCG 5640 
           P  G  L  N  D  I  F  E  A  Q  K  I  E  W  H  E  R  P  T  S  1880 
      
XM_00651  ---------------------------------------------------  
M5-cc     ACGAGCTCACTAGTCGCGGCCGCAGACTACAAGGACGACGATGATAAGTAG 5691 
           T  S  S  L  V  A  A  A  D  Y  K  D  D  D  D  K  X  1896 
 
S4. Amino acid sequence of Myosin-5-Ad construct 
Amino acid sequence is shown with colouring that represents the distinct domains 
and motifs of the protein according to the legend. Numbers at the end of the lines 
represent the number of amino acids up to that point in the sequence. 
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Legend: 
Avi-tag 
Mouse myosin-5a brain isoform HMM with 175 aa of coiled-coil 
175 aa of the coiled-coil from HMM again 
Sal I site 
350 aa coiled-coil motif interrupted by loops 
Sal I site 
GFP 
Precision protease site 
Nhe I site 
Adhiron14 
Nhe I site 
Flag tag 
 
M G L N D I F E A Q K I E W H E M A A S E L Y T K F A R     28 
V W I P D P E E V W K S A E L L K D Y K P G D K V L L L     56 
H L E E G K D L E Y R L D P K T G E L P H L R N P D I L     84 
V G E N D L T A L S Y L H E P A V L H N L R V R F I D S    112 
K L I Y T Y C G I V L V A I N P Y E Q L P I Y G E D I I    140 
N A Y S G Q N M G D M D P H I F A V A E E A Y K Q M A R    168 
D E R N Q S I I V S G E S G A G K T V S A K Y A M R Y F    196 
A T V S G S A S E A N V E E K V L A S N P I M E S I G N    224 
A K T T R N D N S S R F G K Y I E I G F D K R Y R I I G    252 
A N M R T Y L L E K S R V V F Q A E E E R N Y H I F Y Q    280 
L C A S A K L P E F K M L R L G N A D S F H Y T K Q G G    308 
S P M I E G V D D A K E M A H T R Q A C T L L G I S E S    336 
Y Q M G I F R I L A G I L H L G N V G F A S R D S D S C    364 
T I P P K H E P L T I F C D L M G V D Y E E M C H W L C    392 
H R K L A T A T E T Y I K P I S K L Q A T N A R D A L A    420 
K H I Y A K L F N W I V D H V N Q A L H S A V K Q H S F    448 
I G V L D I Y G F E T F E I N S F E Q F C I N Y A N E K    476 
L Q Q Q F N M H V F K L E Q E E Y M K E Q I P W T L I D    504 
F Y D N Q P C I N L I E S K L G I L D L L D E E C K M P    532 
K G T D D T W A Q K L Y N T H L N K C A L F E K P R M S    560 
N K A F I I K H F A D K V E Y Q C E G F L E K N K D T V    588 
F E E Q I K V L K S S K F K M L P E L F Q D D E K A I S    616 
P T S A T S S G R T P L T R V P V K P T K G R P G Q T A    644 
K E H K K T V G H Q F R N S L H L L M E T L N A T T P H    672 
Y V R C I K P N D F K F P F T F D E K R A V Q Q L R A C    700 
G V L E T I R I S A A G F P S R W T Y Q E F F S R Y R V    728 
L M K Q K D V L G D R K Q T C K N V L E K L I L D K D K    756 
Y Q F G K T K I F F R A G Q V A Y L E K L R A D K L R A    784 
A C I R I Q K T I R G W L L R K R Y L C M Q R A A I T V    812 
Q R Y V R G Y Q A R C Y A K F L R R T K A A T T I Q K Y    840 
W R M Y V V R R R Y K I R R A A T I V I Q S Y L R G Y L    868 
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T R N R Y R K I L R E Y K A V I I Q K R V R G W L A R T    896 
H Y K R T M K A I V Y L Q C C F R R M M A K R E L K K L    924 
K I E A R S V E R Y K K L H I G M E N K I M Q L Q R K V    952 
D E Q N K D Y K C L M E K L T N L E G V Y N S E T E K L    980 
R N D V E R L Q L S E E E A K V A T G R V L S L Q E E I   1008 
A K L R K D L E Q T R S E K K S I E E R A D K Y K Q E T   1036 
D Q L V S N L K E E N T L L K Q E K E T L N H R I V E Q   1064 
A K E M T E T M E R K L V E E T K Q L E L D L N D E R L   1092 
R Y Q N L L N E F S R L E E R R Y K K L H I G M E N K I   1120 
M Q L Q R K V D E Q N K D Y K C L M E K L T N L E G V Y   1148 
N S E T E K L R N D V E R L Q L S E E E A K V A T G R V   1176 
L S L Q E E I A K L R K D L E Q T R S E K K S I E E R A   1204 
D K Y K Q E T D Q L V S N L K E E N T L L K Q E K E T L   1232 
N H R I V E Q A K E M T E T M E R K L V E E T K Q L E L   1260 
D L N D E R L R Y Q N L L N E F S R L E E R V D Y D D L   1288 
K E E M T L M L N V P K P G H K R T D S T H S S N E S E   1316 
Y T F S S E F A E T E D I A P R T E E P I E K K V P L D   1344 
M S L F L K L Q K R V T E L E Q E K Q L M Q D E L D R K   1372 
E E Q V F R S K A K E E E R P Q I R G A E L E Y E S L K   1400 
R Q E L E S E N K K L K N E L N E L R K A L S E K S A P   1428 
E V T A P G A P A Y R V L M E Q L T S V S E E L D V R K   1456 
E E V L I L R S Q L V S Q K E A I Q P K D D K N T M T D   1484 
S T I L L E D V Q K M K D K G E I A Q A Y I G L K E T N   1512 
R L L E S Q L Q S Q K R S H E N E A E A L R G E I Q S L   1540 
K E E N N R Q Q Q L L A Q N L Q L P P E A R I E A S L Q   1568 
H E I T R L T N E N L D L M E Q L E K Q D K T V R K L K   1596 
K Q L K V F A K K I G E L E V G Q M E N I S P G Q I I D   1624 
E P I R P V N I P V D M V S K G E E L F T G V V P I L V   1652 
E L D G D V N G H K F S V S G E G E G D A T Y G K L T L   1680 
K F I C T T G K L P V P W P T L V T T L T Y G V Q C F S   1708 
R Y P D H M K Q H D F F K S A M P E G Y V Q E R T I F F   1736 
K D D G N Y K T R A E V K F E G D T L V N R I E L K G I   1764 
D F K E D G N I L G H K L E Y N Y N S H N V Y I M A D K   1792 
Q K N G I K V N F K I R H N I E D G S V Q L A D H Y Q Q   1820 
N T P I G D G P V L L P D N H Y L S T Q S A L S K D P N   1848 
E K R D H M V L L E F V T A A G I T L G M D E L Y K S L   1876 
E V L F Q G P A S M A S N S L E I E E L A R F A V D E H   1904 
N K K E N A L L E F V R V V K A K E Q S D T P H W W W T   1932 
T M Y Y L T L E A K D G G K K K L Y E A K V W V K E S P   1960 
V H P K R L N F K D L Q E F K P V G D A A A A A S D Y K   1988 
D D D D K                                                 1993 
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